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Abstract
Non-invasive prenatal testing (NIPT) is a prenatal test that has experienced unprecedented
commercial development and transformed prenatal care. The Ontario Ministry of Health
presently funds NIPT as a first-tier prenatal screening option for high-risk singleton
pregnancies and all twin pregnancies. Individuals who do not qualify for public funding or
would like to screen for additional conditions can pay for NIPT privately, starting at
approximately $495-$550 (CA) for baseline panels. Prenatal care providers such as family
physicians, maternal-fetal-medicine specialists, obstetrician-gynaecologists, residents,
midwives and registered nurses have an increasingly important role in offering NIPT in
Ontario. Although these healthcare professionals do not have a specific genetic focus to their
practice, little research exists exploring their experience of being at the forefront of
counselling for this technology. This dissertation explores how these prenatal care providers
in Ontario provide counselling for NIPT within their clinical practice.
Charmaz’s constructivist grounded theory methodology was used to explore how prenatal
care providers have enacted the process of prenatal pre-test counselling since the introduction
of NIPT in Ontario. A total of 19 providers who encounter NIPT professionally in the
Ontario cities of London, Hamilton, Toronto and Kingston participated in this study. The
resulting theoretical model describes how providers experience pre-test counselling
considerations for NIPT, including challenges, ethical considerations, and patient
engagement in decision-making. To address these issues and effectively counsel patients
about this expanding technology requires ongoing education, support and resources.
Findings suggest practical, educational, and ethical inequalities between current NIPT panel
options and prenatal care providers’ comfort and ability to provide pre-test counselling.
Prenatal care providers require ongoing guidance and support as their role in prenatal
screening is shifting to involve more complex counselling for NIPT. It is also essential to be
proactive and develop supportive strategies to help providers navigate this technology's rapid
expansion in the future.
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Summary for Lay Audience
Non-invasive prenatal testing (NIPT) is an optional screening test that can tell a pregnant
person if they have a high or low chance of having a baby with certain chromosome
differences, including trisomy 21 (Down syndrome), trisomy 18, trisomy 13 and Turner
syndrome. These chromosomal differences involve changes in a fetus's genetic material,
which can lead to serious physical and developmental challenges. NIPT involves a maternal
blood draw at 9-10 weeks of pregnancy and is funded in Ontario for all pregnant individuals
who meet specific Ministry of Health criteria. Individuals can also pay for this test if they do
not qualify for public funding.
Pre-test counselling involves giving information about the benefits and limitations of testing
and addressing any potential medical, reproductive, and psychosocial implications of genetic
test results. When NIPT in Ontario became publicly funded in 2014, healthcare professionals
trained in genetics, such as genetic counsellors, provided counselling to facilitate a patient’s
decision to undergo NIPT. Since then, many prenatal care providers not specialized in
genetics, including family physicians, maternal-fetal-medicine specialists, obstetriciangynaecologists, midwives and registered nurses, discuss NIPT during a prenatal care visit.
However, there is concern that patients are not receiving adequate counselling due to barriers
such as time constraints and a provider’s lack of knowledge about this technology. In
addition, NIPT counselling is becoming more complex as screening expands to include more
conditions and is used for non-medical purposes such as sex identification.
This research explores how prenatal care providers in Ontario provide pre-test counselling
for NIPT within their clinical practice. I interviewed 19 providers from the Ontario cities of
London, Hamilton, Toronto, and Kingston in 2016. From these interviews, I used the
methodology “constructivist grounded theory” (as described by Kathy Charmaz) to generate
a theoretical model. This model describes the practical, educational, and ethical issues
between current NIPT panel options and these prenatal care providers' comfort and ability to
provide pre-test counselling. These providers require ongoing guidance and support as their
role in prenatal screening is shifting to involve more complex counselling for NIPT.
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Glossary of Terms
Accuracy:

The overall percentage of correct test results. This includes true
positives and true negatives (Maxim et al., 2014).

Aneuploidy:

Describes the condition where trisomy or monosomy occurs due
to an error in meiosis or mitosis (cell division). The incidence of
fetal aneuploidy increases with maternal age (Rink & Norton,
2016).

Autosome

Refers to any of the 22 (numbered) chromosomes, not a sex
chromosome (X or Y) (Nussbaum et al., 2007).

Cell-free DNA

Extracellular DNA that exists in the bloodstream of all individuals

(cfDNA)

(Lo et al., 1997).

Cell-free fetal DNA

Extracellular DNA of fetal origin that exists in the bloodstream of
pregnant individuals. Used in NIPT screening (Lo et al., 1997).

(cff-DNA)
Chorionic villus

An invasive procedure of obtaining a small piece of placental

sampling (CVS):

tissue. This tissue contains fetal cells that can be used for
diagnostic testing purposes, such as a karyotype. This procedure
has a risk of pregnancy loss of about 1% or less (Akolekar et al.,
2015).

Chromosome:

Biological structures that are comprised of DNA and proteins and
carry genetic information in the cells of living organisms
(Nussbaum et al., 2007).

xiv

Clinical utility:

To what extent a test improves health outcomes compared to the
current alternative (which could be another form of testing or no
testing at all) (Lesko et al., 2010).

Clinical validity:

How well the test performs: this is dependent on the test’s
sensitivity, specificity, positive predictive value, and negative
predictive value (Burke, 2014).

Congenital:

Present from birth (Nussbaum et al., 2007).

Deoxyribonucleic

Deoxyribonucleic acid (DNA) is a chemical that contains within

acid (DNA):

its structure the genetic information needed to specify all aspects
of the formation and development of a human (Nussbaum et al.,
2007).

Diagnostic test:

Either a test which has 100% sensitivity and 100% specificity, or
a test whose performance characteristics are high enough to allow
a conclusive diagnosis without causing serious concern for a
clinical error (Benn et al., 2012).

Disorders of sex

Congenital conditions associated with abnormal development of

determination:

internal and external genital structures (Nussbaum et al., 2007).

Enhanced first-

A prenatal screening test which involves measurements from

trimester screen

maternal, fetal, and placental analytes (hormones or proteins) in a

((e)FTS):

pregnant individual’s blood and a first-trimester NT ultrasound.
Performed between 11 weeks 2 days to 13 weeks 3 days gestation
pregnancy, results of this blood work, ultrasound and individual’s
age at delivery (or the age of the egg donor) provides a risk
estimate of having a fetus with trisomy 21 and trisomy 18
(Nussbaum et al., 2007).
xv

False-negative:

When an individual with the disease is misclassified as not having
the disease (Maxim et al., 2014).

False-negative rate

The proportion of affective individuals with a negative result

(FNR):

(Nussbaum et al., 2007).

False-positive:

When an individual without the disease is misclassified as having
the disease (Maxim et al., 2014).

False-positive rate

The proportion of unaffected individuals who have a positive

(FPR):

result (Nussbaum et al., 2007).

Genes:

Functional units of genetic information. Genes are made up of
DNA. (Nussbaum et al., 2007).

Gonads:

The reproductive gland that produces an organism's gametes and
sex hormones, such as the ovary in females or the testicles in
males (Nussbaum et al., 2007).

In vitro fertilization A patient's eggs (oocytes) are surgically removed from the ovaries
(IVF) with

and fertilized in a laboratory through the injection of live sperm

intracytoplasmic

into the oocyte (Nussbaum et al., 2007).

sperm injection:
Integrated Prenatal A prenatal screening test which was available in Ontario in 2016.
Screening (IPS):

It involved measurements from maternal, fetal, and placental
analytes (hormones or proteins) in a pregnant individual’s blood
and a first-trimester NT ultrasound. IPS required two separate
blood tests. Blood was drawn between 11-14 weeks in the first
trimester and at 15-20 weeks in the second. IPS results were not
released until the second trimester blood draw was analyzed at 16 xvi

21 weeks (Mt. Sinai Hospital, 2007). In 2018, (e)FTS replaced IPS
in Ontario.
Karyotype:

A procedure which produces an image of an individual’s
chromosomes (Nussbaum et al., 2007).

Maternal serum

A prenatal screening test which analyzes maternal, fetal, and

screen:

placental analytes (hormones or proteins) in a pregnant
individual’s blood. Performed between 14 and 20 weeks six days
of pregnancy, results of this blood work combined with the
individual’s age at delivery (or the age of the egg donor) can
provide a risk estimate of having a fetus with trisomy 21 and
trisomy 18 (Nussbaum et al., 2007).

Microdeletion:

Smaller deletions in DNA that are 1-3 million base pairs in size
(the chemical building blocks of genetic material) (Nussbaum et
al., 2007).

Monosomy:

The loss of one member of a pair of chromosomes (Nussbaum et
al., 2007).

xvii

Multiple marker

Overall term to describe prenatal screening test. These tests

Screening:

measure maternal, fetal, and placental analytes (hormones or
proteins) in a pregnant individual’s blood and, if the individual is
undergoing (e)FTS, an NT ultrasound. Results of this screening,
combined with the individual’s age at delivery (or the age of the
egg donor) can provide a risk estimate of having a fetus with
trisomy 21 and trisomy 18. The two maternal serum screening tests
available in Ontario are the enhanced first trimester screen
((e)FTS) and maternal serum screen. At the time of this study
(e)FTS was not available, and the integrated prenatal screen (IPS)
was offered (Nussbaum et al., 2007).

Mutation:

A change in the sequence of DNA (Nussbaum et al., 2007).

Negative predictive

The probability that subjects with a low-risk/negative screening

value (NPV):

result truly do not have the disease (Mennuti et al., 2013).

Neural tube defects: Birth defects of the brain, spine or spinal cord (Nussbaum et al.,
2007)
Non-invasive

Prenatal screening method that detects the cell-free DNA in the

prenatal testing

blood of pregnant individuals to determine the risk that a fetus will

(NIPT):

be born with certain genetic abnormalities (Lo et al., 1997).

Prenatal Care

Professionals who do not specialize in genetics, and have not

Providers

received advanced training in this field. For this particular study,
these professionals are referring to family physicians, maternal
fetal medicine specialists, obstetrician- gynaecologists, residents,
midwives and a registered nurse.

xviii

Nuchal

A measurement of fluid accumulation between the skin and soft

translucency (NT):

tissue of the fetal neck. An increased nuchal translucency can be
correlated with a greater chance of having a fetus with trisomy 21,
trisomy 18 or another chromosomal abnormality. Healthy
pregnancies can also have increased NT (Nussbaum et al., 2007).
The prenatal screening test, (e)FTS, includes the analysis of
nuchal translucency (NT).

Penetrance:

The probability that a particular mutation will have any
phenotypic expression at all. When there is reduced penetrance, a
proportion of individuals who carry a mutation will not exhibit a
characteristic phenotype (Nussbaum et al., 2007).

Phenotype:

The observable expression of a person’s genetic information in the
form of morphological or clinical traits (Nussbaum et al., 2007).

Plasma:

Component of blood that does not contain cells. It contains
elements such as water, proteins, clotting factors and nutrients
(Nussbaum et al., 2007).

Positive predictive

Probability that subjects with a high-risk/positive screening result

value (PPV):

truly have the disease (Mennuti et al., 2013).

Prevalence:

The proportion of the population that have a specific disease
and/or characteristic in a given time period (Nussbaum et al.,
2007).

Screening test:

A medical test or procedure performed on a defined asymptomatic
population (or population subgroup) to assess the likelihood that
these members have a particular disease (Maxim et al., 2014).

xix

Sensitivity

A test’s ability to correctly identify an individual with a disease as

(detection rate):

positive. If a test is highly sensitive, there are few false-negative
results, and therefore it will rarely miss subjects with the disease
(Maxim et al., 2014).

Serum:

The clear to yellowish coloured fluid in the blood that does not
contain white or red blood cells, but does contains substances such
as electrolytes, antibodies and hormones (Nussbaum et al., 2007).

Sex-limited

Mutations in genes that are not on the sex chromosomes, but

disorders:

whose presentation is influenced by the sex of the individual
(Shawky, 2014).

Specificity:

A test’s ability to correctly identify an individual who doesn’t have
a disease as negative. High specificity tests have few falsepositive results (Maxim et al., 2014).

Trisomy:

The addition of an extra chromosome (Nussbaum et al., 2007).

True negative:

When the individual with the disease is properly classified as
having the disease (Maxim, Niebo, & Utell, 2014).
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Chapter 1

1

Introduction

Clinical practice guidelines by the Society of Obstetricians and Gynaecologists of Canada
and the Canadian College of Medical Genetics (SOGC-CCMG) recommend that all
pregnant people in Canada should be offered, through an informed pre-test counselling
process, the option of prenatal screening for common fetal aneuploidies (Audibert et al.,
2017). Guidelines recommend that this aneuploidy screening is discussed early in
pregnancy (ACOG-SMFM, 2020; Audibert et al., 2017). Therefore, patients usually first
discuss prenatal genetic screening with their prenatal care provider. These providers can
include obstetricians, midwives, family physicians or other primary obstetrical care
providers (Minkoff & Berkowitz, 2014; Farrell, Nutter & Agatisa, 2015; Farrell et al.,
2016; Best Start, 2020). For the remainder of this thesis, the term “prenatal care
providers” will denote healthcare professionals who provide care to individuals during
their pregnancy but do not specialize in genetics.
Non-invasive prenatal testing (NIPT) is a relatively new form of testing representing a
significant evolution of prenatal screening technology. This method includes a single
blood draw from the pregnant person and is an alternative screening method for fetal
aneuploidy. NIPT can be performed at 9-10 weeks of pregnancy, up until the time of
birth (Lo et al., 1997; Wright et al., 2012; Wright & Burton, 2009), with results available
within 5-10 working days (Natera, 2021a; Dynacare, 2020a). Since its implementation,
there has been a considerable uptake of publicly funded NIPT in Ontario (Dougan et al.,
2021), with prenatal care providers becoming more involved in the pre-test counselling
process for this test (Larion et al., 2014; McLennan et al., 2016; Gregg et al., 2016). This
dissertation presents a constructivist grounded theory study exploring how prenatal care
providers experience NIPT pre-test counselling and how they have integrated this
technology into their prenatal practice. Insight into the opinions and experiences of
providers who do not specialize in genetics can proactively inform what interventions are
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required to help these professionals counsel for increasingly complex genetic testing in
the future.

1.1

Types of Prenatal Screening

Screening, in general, refers to the process of using specific markers and defined
screening cut-off levels to identify individuals in a population at a higher risk for a
particular disorder (McCormack et al., 2013). Various prenatal screening tests are
available in Ontario (Table 1). These tests screen for different fetal and maternal
conditions, depending on what fetal, placental or maternal factors are analyzed.
Depending on the test, prenatal screening can be performed during the first trimester,
second trimester, or both. Prenatal screening can identify pregnant individuals at risk for
having a fetus with three common aneuploidies: trisomy 21 (Down syndrome), trisomy
18 or trisomy 13 (Pandya et al., 2019; Rink & Norton, 2016). For this thesis, individuals
who have a “high-risk” screening result refer to those at an increased risk for trisomy 21,
18 or 13 based on certain screening criteria established by the Ministry of Health (MOH)
in Ontario (see Appendix A).
Although most of these aneuploid pregnancies are not viable, fetuses with trisomy 21, 18,
13 can survive to term with medical and developmental consequences. These trisomies
are associated with growth retardation, intellectual disability, and multiple congenital
anomalies (Nussbaum et al., 2007). Trisomy 21 is the most common trisomy and the
single most common genetic cause of moderate intellectual disability with an average life
expectancy of over 50 years. Approximately 1 in 850 children are born with trisomy 21
(Nussbaum et al., 2007). Table 2 summarizes the prevalence and common features of
these aneuploidies.

1.1.1

Multiple Marker Screening

Enhanced first-trimester screening ((e)FTS) and maternal serum screening are examples
of multiple marker screens. (E)FTS is performed between 11 weeks two days and 13
weeks three days gestation, while maternal serum screening is performed between 14 and
20 weeks six days of pregnancy (Audibert et al., 2017). These prenatal screens include
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the analysis of maternal, fetal, and placental analytes (hormones or proteins) in a
pregnant individual’s blood (Nussbaum et al., 2007). Concentrations of these analytes can
be correlated with an increased chance of having a fetus with trisomy 21 or trisomy 18.
(E)FTS also includes the analysis of nuchal translucency (NT) using prenatal ultrasound.
NT is a measurement of the fluid accumulation between the skin and soft tissue of the
fetal neck. An increased NT (above 3.5 mm) can also be correlated with an increased
chance of having a fetus with trisomy 21 or trisomy 18. Results of either the (e)FTS or
serum screen, in combination with the individual’s age, are used to determine the risk of
someone having a fetus with trisomy 21 and 18 (Audibert et al., 2017). Certain thresholds
determine if the final result is reported as a “screen positive” or “screen negative.” For
example, a “screen negative” result for multiple marker screening in Ontario means the
chance that a pregnancy is affected with trisomy 21 is less than 1 in 350 (PSO, 2019a).
Multiple marker screens can also give information that guides pregnancy management, as
abnormal screening results can also be a marker for fetal and obstetric complications
(Dugoff, 2010). For example, abnormal analyte readings alone can be associated with
fetal loss (Duric et al., 2003), fetal growth restriction, preeclampsia (increased blood
pressure during pregnancy), placental abruption, preterm delivery (Dugoff et al., 2005;
Dugoff et al., 2004; Chandra et al., 2003; Audibert et al., 2017; Katz et al., 1990). In
addition, increased nuchal translucency is associated with fetal cardiac defects (Hyett et
al., 1996). However, the performance metrics of abnormal analyte readings (such as
sensitivity and positive predictive value, discussed below) are not high enough for any
serum analyte to be recommended as a screening test for adverse pregnancy outcomes
(Dugoff, 2010; Heazell et al., 2015).
It is important to note that the analytes used in second trimester marker screening can
identify neural tube defects, whereas first trimester marker screening (e)FTS does not.
Neural tube defects are birth defects of the brain, spine, or spinal cord (Nussbaum et al.,
2007). These defects are a leading cause of stillbirth, death in early infancy and disability
in surviving children (Nussbaum et al., 2007). If abnormal markers do identify a risk for
fetal or obstetric complications, follow-up ultrasound examination for growth or further
monitoring of fetal heart rate may be considered (ACOG-SMFM, 2020).
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1.1.2
1.1.2.1

Prenatal Ultrasound
First Trimester Ultrasound

Ultrasound has a vital role in prenatal screening. Regardless of screening choice,
guidelines recommend offering all pregnant individuals a first-trimester ultrasound
(optimally between 11-14 weeks) in order to confirm details such as fetal viability,
gestational age and number of fetuses (Audibert et al., 2017; ACOG, 2016; Norton et al.,
2017). First-trimester ultrasound provides an early anatomic assessment and, therefore,
could detect major structural anomalies (Nussbaum et al., 2007). These fetal
abnormalities can be associated with the common aneuploidies or occur as isolated
findings in a chromosomally normal fetus (Nussbaum et al., 2007). First trimester
ultrasound can detect neural tube defects (Engels et al., 2016; Meller et al., 2017).
The first trimester ultrasound also includes an NT scan (PSO, 2018). In addition to
trisomy 21 and 18, an increased NT can also be associated with structural malformations
such as congenital heart defects, abdominal wall defects, and fetal akinesia (impaired
fetal movement) (Audibert et al., 2017). An increased NT can also be observed in fetuses
with Noonan syndrome, a condition characterized by heart defects, unusual facial
features, skeletal malformations and possible developmental delays (Suskin et al., 2016).
Many guidelines recognize the importance of measuring NT due to these clinically
adverse conditions (Lee et al., 2015; Audibert et al., 2017; ACOG-SMFM, 2020;
Salomon et al., 2017; Gregg et al., 2016). If a patient declines (e)FTS, they can still
choose to have an NT ultrasound performed, where available (PSO, 2018).

1.1.2.2

Second Trimester Ultrasound

A second trimester ultrasound between 18-22 weeks is a routine part of prenatal care in
Ontario. It provides an assessment of fetal organ systems, including the heart, kidneys,
bladder, stomach, brain, sex organs, the amniotic fluid levels, location of the placenta,
and fetal heart rate (Audibert et al., 2017; Rink & Norton, 2016). SOGC-CCMG
guidelines recognize the second trimester ultrasound as the primary screening test for
detecting fetal structural abnormalities (Audibert et al., 2017). Guidelines recommend
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that all pregnant individuals be offered a second trimester ultrasound to screen for fetal
structural defects regardless of first trimester prenatal screen results (Audibert et al.,
2017; Gregg et al., 2016; American College of Obstetricians and Gynaecologists, 2016).
Second trimester ultrasonography is the least effective primary screening test for trisomy
21, as it detects only 50-60% of affected fetuses. Therefore, ultrasonography alone should
not be used to screen for trisomy 21 (Audibert et al., 2017).
Importantly, this ultrasound also includes detailed fetal cranial and spinal imaging and
assessment to detect neural tube defects, such as spina bifida, which occurs when the
spine and/or spinal cord doesn’t close properly (Nussbaum et al., 2007). Spina bifida
includes gradual loss of nerve function, which can present as bladder, bowel and sexual
dysfunction and loss of motor function in the lower extremities (Gotha et al., 2020). This
condition is one of the most common congenital anomalies, with an incidence of 1 in
3,000 to 4,000 pregnancies (De Wals et al., 2008).

1.1.3

Cell-free DNA Screening

NIPT is a prenatal screening test that detects cell-free DNA (cfDNA) in the plasma of
pregnant individuals. As genomic DNA is released from dying cells into the bloodstream,
DNA fragments from placental cells are detectable in the plasma of pregnant individuals
during pregnancy. Cell-free fetal DNA (cff-DNA) is abundant, stable, and stays in
maternal circulation for a few days after each pregnancy (Sayres & Cho, 2011).
Therefore, maternal plasma contains the entire fetal genome (Kitzman et al., 2012),
originating from apoptotic trophoblasts (placenta cells undergoing programmed cell
death) from the embryo (Tjoa et al., 2006; Alberry et al., 2007). Circulating cfDNA of
fetal origin comprises approximately 13% of the total cfDNA found in plasma (Nygren et
al., 2010). Different companies offering NIPT will report aneuploidy risk in diverse
ways. For example, some report risks as “positive” or “negative” while others report
“>99%” as high-risk and “<1/10,000” as low-risk (Skrzypek & Hui, 2017).
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Table 1
Comparison of available prenatal screening tests in Ontario
NIPT
Multiple Marker Screening

(Provincially funded labs)

Screening test
(e)FTS

Gestational age at
time of screen

MSS

PanoramaTM

Harmony TM

by Natera

by Roche

11 weeks 2

14 weeks - 20

9 weeks to

10 weeks to

days

weeks 6 days

term

term

~5 business

~5 business

5-7 calendar

7-10 business

days

days

days

days

Maternal

Maternal

blood work

blood work

First-trimester

only

- 13 weeks 3
days

Time to result

Components of
screen

Maternal blood Maternal blood
work only

work only

Basic panel

Basic panel

U/S

Conditions screened

T21

T21

T21

T21

T18

T18

T18

T18

NT

NT

T13

T13

SCAs

SCAs

(no opt-out)

(opt-in)

Fetal sex

Fetal sex

(opt-in)

(opt-in)

ONTD

Triploidy
(no opt-out)
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Table 1 (continued)
Comparison of available prenatal screening tests in Ontario
NIPT
Multiple Marker Screening
Screening test

Conditions screened
(continued)

(Provincially funded labs)
PanoramaTM

Harmony TM

by Natera

by Roche

Additional

Additional

Options

Options

Fetal and obstetric

22q11.2

22q11.2

complications

deletion

deletion

syndrome

syndrome

(e)FTS

MSS

Microdeletion
extended
panel*

Overall sensitivity

T21: 86.3%

T21: 99.8%

T18: 76.8%

T18: 94.4%

Specific sensitivities

T21: 88.8%

T21: 80.6%

T21: >99%

T21: >99%

based on test

T18: 78.2%

T18: 60.0%

T18: 98.2%

T18: 97.4%

T13: >99%

T13: 93.8%

Monosomy X:

Monosomy X:

94.7%

94.3%

22q11.2

22q11.2

deletion

deletion

syndrome:

syndrome:

90%

None given

type/provincial lab

Microdeletion
extended
panel*: 93.8%
to >99%
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Table 1 (continued)
Comparison of available prenatal screening tests in Ontario
NIPT
Multiple Marker Screening

(Provincially funded labs)

Screening test
(e)FTS

MSS

PanoramaTM

Harmony TM

by Natera

by Roche

False-positive

T21: 5.1%

T21: 6.7%

T21: 0%

T21: <0.1%

rates**

T18: 0.5%

T18: 0.2%

T18: <0.1%

T18: <0.1%

T13: 0%

T13: <0.1%

Monosomy X:
<0.1%
Each

22q11.2

Microdeletion

deletion

syndrome:

syndrome:

<1%

None given

Note. The data for the gestational age at time of screen, time to result, components of
screen, conditions screened for, specific sensitivities and false-positive rates for multiple
marker screening tests (including MSS and (e)FTS) are from Ontario’s Birth Outcome
Registry Network (BORN) PSO, 2019 (https://www.bornontario.ca/en/pso/results-andnext-steps/multiple-marker-screening-mms-results.aspx). Data for the PanoramaTM NIPT
test are from Natera TM, 2021 (https://www.natera.com/womens-health/panorama-niptprenatal-screening/). Data for the HarmonyTM NIPT test are from Roche, 2021
(https://www.harmonytest.com/global/en/nipt-test-for-expecting-parents-cell-freedna.html). The overall sensitivity data is adapted from “Performance of a universal
prenatal screening program incorporating cell-free fetal DNA analysis in Ontario,
Canada, 2021” by S. D. Dougan, N. Okun, K. Bellai-Dussault, L. Meng, H. E. Howley,
T. Huang, J. Reszel, A. Lanes, M.C. Walker and C.M. Armour, 2021. Canadian Medical
Association Journal, 193(30), E1156–E1163. (https://doi.org/10.1503/cmaj.202456).

9

MSS= Maternal serum screen, T21=trisomy 21, T18= trisomy 18, T13= trisomy 13 NT=
Nuchal Translucency, ONTD= Open neural tube defects, U/S= Ultrasound, SCA =Sex
chromosome aneuploidy.
*Panorama extended panel includes 1p36 deletion, 15q11–q13 deletions (Angelman
syndrome and Prader-Willi syndrome) and 5p deletion.
** Systematic reviews suggest a higher false-positive rate than those reported by the
manufacturers (Badeau et al., 2017; Varela-Lema et al., 2018; Iwarsson et al., 2017;
Taylor-Phillips et al., 2016).
In addition to trisomy 18 and 21, NIPT can screen for trisomy 13 and sex chromosome
aneuploidies (SCAs) involving the X or Y chromosome. Trisomy 13 occurs in
approximately 1 out of 10,000 newborns (Driscoll & Gross, 2009), with a clinical
presentation (phenotype) that includes central nervous system malformations and
congenital heart defects. Survival beyond the first year is rare (Nussbaum et al., 2007;
Gregg et al., 2013).
Individuals with SCAs can have variable phenotypes, with some not even receiving a
diagnosis due to a lack of any overt clinical features or receiving a diagnosis (Skuse et al.,
2018; Luthardt & Keitges, 2001; Demaliaj et al., 2018). Examples of SCAs include
Turner syndrome (monosomy X) and Klinefelter syndrome (XXY). Turner syndrome
occurs in approximately 1 in 2500 to 4000 female births and may cause up to 10% of all
first trimester miscarriages (Morgan, 2007). This syndrome is associated with short
stature, a webbed neck, and an increased risk of cardiac abnormalities. Features can also
include gonadal dysgenesis, the complete or partial loss of gonadal development, delayed
maturation, impaired social adjustments, and infertility (Morgan, 2007; Demaliaj et al.,
2018). Klinefelter syndrome is the most commonly occurring SCA, with an incidence of
approximately 1 in 600 male births (Ross et al., 2012). Features of Klinefelter syndrome
can include tall stature, reduced verbal IQ, educational difficulties, infertility,
hypogonadism (a decreased function of the testes), and azoospermia (the absence of
sperm) (Ross et al., 2012; Demaliaj et al., 2018).
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NIPT can also determine fetal sex as early as seven weeks gestation (Devaney et al.,
2011; Finning & Chitty, 2008; Costa et al., 2002). NIPT for fetal sex determination has
been used to ascertain the risk of transmission of X-linked genetic disorders, such as
Duchenne muscular dystrophy (Parks et al., 2016) and hemophilia (Hudecova et al.,
2017; Tsui et al., 2015). NIPT's determination of fetal sex also has implications for
screening individuals at risk for sex-limited disorders and disorders of sex determination.
Sex-limited disorders are conditions where the sex of the individual influences the
clinical presentation; however, the changes (mutations) in genes responsible for these
conditions are not located on the sex chromosomes (Shawky, 2014). Disorders of sex
determination are congenital conditions associated with abnormal development of
internal and external genital structures (Nussbaum et al., 2007).
In addition to aneuploidy screening, some laboratories provide expanded NIPT options
for microdeletion syndromes. A microdeletion is the deletion of a small piece of a
chromosome. These deletions are 1-3 million base pairs, the chemical building blocks of
DNA, in size (Nussbaum et al., 2007). These deletions’ exact size and location can vary,
but a specific critical region involving a particular gene(s) is usually involved (Nussbaum
et al., 2007). The phenotype of these individuals is due to the absence of these critical
regions.
Microdeletion syndromes are inherited, occur randomly during gamete development, or
occur early in fetal development (Nussbaum et al., 2007). Microdeletion syndromes can
have severe clinical presentations, including developmental delay, intellectual disability,
seizures and congenital heart defects (Nussbaum et al., 2007). However, like SCAs,
microdeletion syndromes can result in phenotypic variability and uncertain clinical
significance (Wapner et al., 2012). Some conditions may be undetected until adulthood or
completely remain undetected (Gillentine et al., 2018). Clinically relevant microdeletions
and duplications overall occur in 1.7% of all structurally normal pregnancies (Wapner et
al., 2012).
Common microdeletion syndromes include 22q11.2 (DiGeorge syndrome), 1p36
deletion, 15q11–q13 deletions (Angelman syndrome and Prader-Willi syndrome), and 5p

11

deletion (Cri-du-chat syndrome) (Hall, 2015). These microdeletions are individually rare,
but the combined at-birth incidence of these five syndromes is approximately 1/1,000
(Buiting, 2010; Dagli et al., 1998; Driscoll et al., 2017; McDonald-McGinn et al., 2020,
2021). The potential to provide early interventions for individuals affected by these five
syndromes are the primary considerations for choosing them for expanded testing (Hu et
al., 2019; Benn, 2016). Table 2 summarizes the common features of the conditions that
NIPT can screen for.
Table 2
Frequency of chromosomal abnormalities included on commercial NIPT screening tests
Common features
Condition

Prevalence in newborns

(Present from birth)

Autosomal chromosome aneuploidies:
Trisomy 21

1 in 800

Intellectual and developmental

(Down syndrome)

Most common autosomal

disabilities, neurological features, heart

chromosome aneuploidy in

defects, gastrointestinal abnormalities,

live births

characteristic facial features

Frequency strongly
dependent on maternal age

Trisomy 18

1 in 5,000

Growth deficiency, characteristic

(Edwards

More common in fetuses

craniofacial features, distinctive hand

syndrome)

that do not survive to term

posture, short sternum, heart

Frequency increases with

malformations

maternal age
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Table 2 (continued)
Frequency of chromosomal abnormalities included on commercial NIPT screening tests
Common features
Condition

Prevalence in newborns

(Present from birth)

Autosomal chromosome aneuploidies
Trisomy 13

1 in 16,000

Cleft lip and/or cleft palate

(Patau syndrome)

Frequency increases with

(inappropriate formation of lip or roof

maternal age

of mouth), cerebral defects,
anophthalmia (missing one or both
eyes), polydactyly (extra fingers)

Monosomy X

1 in 2,000-2,500 (females)

Short stature, webbed neck, heart

(Turner syndrome)

More common in fetuses

defects, impaired social adjustments,

that do not survive to term

gonadal dysgenesis, delayed
maturation, infertility

XXY syndrome

1 in 500-1,000 (males)

Tall stature and reduced verbal IQ (low

(Klinefelter

Most common sex

to normal range), educational

syndrome)

chromosome aneuploidy

difficulties, infertility, hypogonadism,
azoospermia

Sex chromosome aneuploidies
XXX syndrome

1 in 1, 000 (females)

Earlier growth, auditory processing
disorders, disorders in language
development and problems in forming
stable interpersonal relationships
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Table 2 (continued)
Frequency of chromosomal abnormalities included on commercial NIPT screening tests
Common features
Condition

Prevalence in newborns

(Present from birth)

Sex chromosome aneuploidies
XYY syndrome

1 in 1,000 (males)

Tall stature, macrocephaly (large head),
macroorchidism (increase of testicular
volume), hypotonia (decreased muscle
tone) and tremor

Microdeletion syndromes
15q11-q13 deletion

1 in 10,000-30,000

Obesity, delayed motor and language

of genes in regions

development, cognitive impairment,

on chromosome 15

hypogonadism (incomplete pubertal

(Prader-Willi

development and infertility), short

syndrome)

stature, characteristic facial features

15q11-q13 deletion

1 in 12,000-20,000

Severe developmental delay,

of gene UBE3A on

intellectual disability, severe speech

chromosome 15

impairment, gait ataxia (uncoordinated

(Angelman

walking), unique behaviour of frequent

syndrome)

laughing, microcephaly (small head),
seizures

22q11.2 deletion

1 in 4,000

Congenital heart disease, immune

syndrome

deficiency, characteristic facial

(DiGeorge)

features, learning difficulties, hearing
loss
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Table 2 (continued)
Frequency of chromosomal abnormalities included on commercial NIPT screening tests
Condition

Prevalence in newborns Common features
(Present from birth)

Microdeletion syndromes
5p deletion

1 in 20,000-50,000

High-pitched cry, microcephaly, broad

syndrome

nasal bridge, micrognathia (lower jaw

(Cri-du-chat)

is smaller than normal) and severe
psychomotor, mental retardation

1p36 deletion
syndrome

1 in 5,000-10,000

Developmental delay, intellectual
disability, seizures, vision problems,
hearing loss, short stature, distinctive
facial features, brain anomalies, cleft
lip and/or cleft palate, heart defects,
renal anomalies

Note. Adapted from “Genetics home reference”, by the U.S. National Library of
Medicine, 2021 (https://medlineplus.gov/genetics/).
The landscape of NIPT is rapidly evolving. Commercial laboratories already provide
expanded testing beyond the microdeletion syndromes mentioned above, including
testing larger deletions and trisomies 16 and 22 (Dynacare, 2020b). These conditions can
lead to complex, severe fetal anomalies (Bianchi & Chiu, 2019). NIPT has also been used
to detect genetic abnormalities such as achondroplasia, the most common nonlethal
skeletal dysplasia (prevalence of 1/26,000- 1/28,000 births) (Waller et al., 2018). This
testing has also been used to screen for single-gene conditions such as sickle-cell anemia
(Barrett et al., 2012; Tsui et al., 2015), β-thalassemia (Lam et al., 2012) and cystic
fibrosis (Bustamante-Aragones et al., 2008). NIPT is not currently clinically offered for
these conditions; however, its use will likely expand to include additional chromosomal
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abnormalities as future studies support the clinical validity of this application (Devers et
al., 2013; Ngan, 2018).
Sequencing of the fetal genome indicates that NIPT could detect a more comprehensive
range of genetic disorders, including the detection of milder conditions and traits (Fan et
al., 2012; Blumenthal-Barby et al., 2015; Hui & Bianchi, 2013; Benn & Chapman, 2016;
Lo et al., 2010). Private testing is also becoming more affordable. For example, InvitaeTM
offers NIPT for approximately $125 (CA) (Invitae, 2021) and companies such as
SneakPeak® offers NIPT for fetal sex screening for $80 (US) (SneakPeak, 2021).

1.2

Benefits and Limitations of Prenatal Screening

When evaluating whether a prenatal screening test is appropriate, stakeholders, including
clinicians, healthcare policymakers and patients, must balance the benefits and harms of
prenatal screening (Dondorp et al., 2015). These aspects are directly affected by the
performance measures of the test itself (clinical validity) and whether the test is reliable
and useful to patients (clinical utility) (Gregg et al., 2016; Burke, 2014).
Clinical validity of the screening test is the extent to which a test measures what it is
supposed to measure; essentially, it is the accuracy with which a laboratory test identifies
individuals with a clinical condition (Holtzman & Watson, 1999). Clinical validity is
defined by sensitivity and specificity and is independent of the prevalence of the
condition being screened (Gregg et al., 2016). Sensitivity and specificity are helpful when
determining which test to implement and for ensuring a quality screening system with
high performance (Dougan et al., 2021). For example, sensitivity, or detection rate, is the
proportion of affected individuals (or pregnancies) with a positive test result; this is
considered a “true positive” (Burke, 2014). Specificity is the percentage of unaffected
individuals who have a negative result, or “true negative.” (Burke, 2014). The falsepositive rate (FPR) is the proportion of unaffected individuals with a positive result. The
false-negative rate (FNR) is the proportion of affected individuals with a negative result
(Nussbaum et al., 2007). A highly sensitive test will identify a high percentage of
affected individuals and not generate many false-negative results. For example, a test
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with 90% sensitivity will correctly return a positive result for 90% of affected individuals
and return a false-negative result for 10% of affected individuals (Parikh et al., 2008).
In the decision-making process towards NIPT, patients and providers bestow great
importance on the accuracy of testing (Beulen et al., 2015; Carroll et al., 2013; Chen et
al., 2017; Chen et al., 2018; Farrell, Agatisa & Nutter, 2014; Lewis et al., 2014; Lewis et
al., 2016a; Lund et al., 2018; Seror et al., 2019; Skutilova, 2015; van Schendel et al.,
2016; Lewis et al., 2012a; Lewis et al., 2013; van Schendel et al., 2014; Kibel &
Vanstone, 2017; Lau et al., 2016; Farrell, Agatisa, Mercer, et al., 2015; Vanstone,
Yacoub, Giacomini, et al., 2015). NIPT has a high detection rate for trisomy 21 compared
to other forms of prenatal screening. For example, the overall sensitivity of multiple
marker screening for trisomy 21 is approximately 86.3% (Dougan et al., 2021).
Conversely, the sensitivity for detecting trisomy 21 for NIPT is greater than 99%
(Dougan et al., 2021). It is important to note that different sensitivity rates exist
depending on the condition screened. For example, the overall sensitivity for trisomy 18
is 77% for maternal serum screen, and 94% for NIPT (Dougan et al., 2021). The FPR of
(e)FTS for trisomy 21 is approximately 5.1% (PSO, 2019b) and the FPR for trisomy 21 is
lower for NIPT than other prenatal screening tests at <0.1% (Roche, 2021). The
sensitivities of the various microdeletion extended panels varies from 94% to greater than
99% (Lifelabs, 2019). Table 1 lists additional performance measures for these tests.
There is a chance that the results of an NIPT screen would not solely represent the
genetic makeup of the fetus, which may lead to false-positive results (Amant et al., 2015;
Pandya et al., 2019). As the fetal DNA tested originates mainly from the placenta, there
could be a discrepancy between the DNA of the cells in the placenta and the fetus's cells,
an anomaly known as confined placental mosaicism (CPM) (Nussbaum et al., 2007). The
presence of a chromosome abnormality in the placenta with normal fetal DNA occurs in
approximately 1-2% of NIPT cases (Audibert et al., 2017).
Studies have shown a 0.9- 5.6% chance that the initial NIPT test performed reports a “no
result,” which means the test has failed and requires a repeat blood draw (Bianchi et al.,
2014; Langlois et al., 2017; Nicolaides et al., 2013; Norton et al., 2015; Palomaki et al.,

17

2017; Quezada et al., 2015; Song et al., 2013). A repeat screen has shown to be
successful in 45% to 77% of these cases (Langlois et al., 2017; Palomaki et al., 2017;
Quezada et al., 2015). A no result outcome is unique to NIPT, as traditional prenatal
screening tests rarely report out a failed result (Benn et al., 2013). An NIPT test may fail
for several reasons, such as insufficient cff-DNA in the maternal sample, often referred to
as a low “fetal fraction.” A low fetal fraction is one of the most common reasons for
failure (Health Quality Ontario, 2019a). NIPT test failure may occur due to maternal
obesity or if the test is performed too early in pregnancy (Lyons et al., 1988; Health
Quality Ontario, 2019a). Fetal aneuploidy is also associated with low fetal fraction and
failed NIPT results (Pergament et al., 2014). Therefore, patients with failed NIPT screens
are at an increased risk (approximately 5%) for fetal aneuploidy (Norton et al., 2012;
Pergament et al., 2014; Norton et al., 2015).
Clinical utility includes considering the test metrics positive predictive values, negative
predictive values, cost, and a patient’s value system towards testing (Gregg et al., 2016).
Positive predictive values (PPV) and negative predictive values (NPV) of a test are
important measures of clinical utility. These measures are helpful when determining how
reliably a test can confirm or refute a suspected diagnosis and the chances of returning a
correct result (Audibert et al., 2017; Burke, 2014). PPV is the proportion of individuals
with a positive test result who are true positives. Conversely, NPV is the proportion of
individuals with a negative test result who are true negatives (Burke, 2014). Importantly,
the disease prevalence in the population tested strongly influences the predictive values.
Therefore, a test with high sensitivity could still have low positive predictive values and
yield a greater number of false-positive results when screening individuals with a low
likelihood of disease (Burke, 2014; Audibert et al., 2017). As the prevalence of trisomy
21, 18 and 13 varies in a high-risk population, the PPV will be variable for each
condition. For example, the chance that a positive screening test result is true positive for
NIPT screening in trisomy 21 has been reported to be 93% compared to 64% for trisomy
18 and 44% for trisomy 13 in a high-risk population (Wang et al., 2015).
The positive predictive value is especially relevant when considering the benefits and
limitations of prenatal screening in a population at low risk for aneuploidy. The lower
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prevalence of the aneuploidy leads to a lower PPV in the general population. Thus, fewer
individuals with a positive result in the general population will have an affected fetus,
and there will be a greater number of false-positive results (Audibert et al., 2017). For
instance, a 40-year-old individual has a 1/100 chance of having a live-born child with
trisomy 21. Assuming the sensitivity and specificity of NIPT are over 99%, the PPV, in
this case, is 93%, with a 7% chance that the test is a false-positive. In comparison, for a
20-year-old individual whose chance of a live-born child with trisomy 21 is lower at
1/1400, the PPV is 48%. Therefore, if a 20-year-old has an NIPT test result “positive” for
trisomy 21, there is a 52% chance that the fetus is not affected (Gabriel & Diskin, 2018).
Therefore, PPV can be significantly different for a “high-risk” pregnancy versus a “lowrisk” pregnancy. Conversely, for individuals who receive a negative result, the negative
predictive value will also depend on many factors but is overall very high (>99%) (Sachs
et al., 2015). A high NPV means that a negative result for someone in this population is
very reliable and could offer them reassurance. However, there is limited follow-up
genetic testing to confirm outcomes and accurately assess test performance.
Although NIPT has substantially higher performance measures for identifying
aneuploidies than (e)FTS and maternal serum screen, it is still considered a screening
test. As such, a positive or high-risk result from NIPT, or any prenatal screening test,
requires confirmation by diagnostic testing before making any decision about the
pregnancy (Audibert et al., 2017; Gregg et al., 2016; Dondorp et al., 2015; Benn et al.,
2015; Salomon et al., 2017; Royal College of Obstetricians & Gynaecologists, 2014).
Some individuals consider the uncertainty of prenatal screening to be a disadvantage as
they cannot use the test to make confident decisions about their pregnancy (Crombag, van
Schendel, Schielen, et al., 2016; Seror et al., 2019; Floyd et al., 2016; Farrell, Agatisa,
Mercer, et al., 2015). For example, patients accessing testing later in pregnancy may
place more emphasis on test accuracy and may be more inclined to opt for invasive,
diagnostic testing (Lewis et al., 2016a).
Prenatal diagnostic testing includes invasive procedures like chorionic villus sampling
(CVS) or amniocentesis. CVS is performed between 11 and 14 weeks of pregnancy and
involves obtaining a small piece of placental tissue. Amniocentesis can be offered
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starting at 15 weeks gestation and consists of a needle removing a small amount of
amniotic fluid (Audibert et al., 2017; Nussbaum et al., 2007). Both procedures provide
fetal cells for diagnostic testing, such as karyotyping, which produces an image of the
fetal chromosome (Nussbaum et al., 2007). Both CVS and amniocentesis are invasive
tests with about 1% or less (Akolekar et al., 2015). A benefit of receiving screening
results earlier in pregnancy is patients have a longer time to make decisions regarding
diagnostic testing (Gregg et al., 2016).
For many pregnant individuals, the most important benefit of NIPT was that it poses no
physical risk to the fetus (Farrell, Agatisa & Nutter, 2014; Floyd et al., 2016; Haidar et
al., 2018; Lewis et al., 2016a; Lewis et al., 2016b; Reese et al., 2018; Kibel & Vanstone,
2017; Lau et al., 2016; Farrell, Agatisa, Mercer, et al., 2015; Vanstone, Yacoub,
Giacomini, et al., 2015; Chen et al., 2017; van Bruggen et al., 2018). Despite the
understanding that an invasive diagnostic test is required to confirm results of NIPT,
some individuals identify the non-invasive nature of testing to be their main decisionmaking factor between tests (Floyd et al., 2016; Haidar et al., 2018; Lewis et al., 2012a;
Farrell, Agatisa, Mercer, et al., 2015; Vanstone, Yacoub, Giacomini, et al., 2015). For
some, especially individuals who do not intend to terminate their pregnancy, the risk-free
aspect of NIPT is vital, as they considered test results accurate enough to decline
confirmation through diagnostic testing (Haidar et al., 2018; Lewis et al., 2016a; Farrell,
Agatisa, Mercer, et al., 2015; Mozersky, 2015).
Another benefit to NIPT screening, compared to multiple marker screening, is the early
timing of testing. Obtaining screening results early in pregnancy provides individuals
with more time to make decisions about pregnancy management, giving them greater
control and satisfaction with their decisions (Farrell, Agatisa & Nutter, 2014; Lewis et al.,
2012a; Lewis et al., 2012b; How et al., 2019; Yi et al., 2013). Early access to information
for those individuals considering termination made the process much easier physically
and emotionally. For those who are not considering termination, obtaining information
earlier enables them and their partners to consider pregnancy management and prepare
emotionally, physically and financially for raising their child (Yi et al., 2013; Farrell,
Mercer, Agatisa, et al., 2014; Floyd et al., 2016; Haidar et al., 2018; Crombag, Boeije,
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Iedema-Kuiper, et al., 2016; Chen et al., 2017; Reese et al., 2018; Kibel & Vanstone,
2017; van Schendel, Kater-Kuipers, van Vliet-Lachotzki, et al., 2017; How et al., 2019;
Agatisa, Mercer, Mitchum, et al., 2018).
It is important to emphasize to patients that no prenatal screening test will pick up all
chromosome abnormalities (Audibert et al., 2017), and the conditions identified by these
tests are highly dependent on the screening markers used. Although NIPT is highly
efficient, its role and performance must be considered alongside and combined with other
screening modalities (Salomon et al., 2017). For example, unlike NIPT, multiple marker
screening can give information about fetal and obstetric complications (Dugoff, 2010). In
addition, prenatal screening such as NIPT does not replace routine fetal anatomic
screening (Gregg et al., 2016). Therefore, a second trimester ultrasound at 18-20 weeks
gestation is still recommended for all pregnancies, regardless of initial screening results
(Audibert et al., 2017; Gregg et al., 2016). Comprehensive diagnostic testing should be
offered to patients when a second trimester ultrasound identifies a fetal malformation
(Audibert et al., 2017; Gregg et al., 2016; Bianchi & Chiu, 2019).
As NIPT targets a mixture of DNA fragments of maternal and fetoplacental origin (total
circulating cfDNA), it can also disclose unexpected maternal, fetal, or placental results
known as incidental findings (Orta, 2016). For example, NIPT results could detect
residual cff-DNA from an unrecognized twin spontaneously lost during pregnancy
(vanishing twin) (Curnow et al., 2015; Grömminger et al., 2014). Also, chromosomal
mosaicism of maternal, fetal or placental origin can be identified (Lau et al., 2013; Hall et
al., 2013; Pan et al., 2014; Mao et al., 2014; Zhang et al., 2015; Choi et al., 2013; Pan et
al., 2013). Chromosomal mosaicism is when an individual has two or more populations
of cells consisting of different genetic makeup (Nussbaum et al., 2007).
NIPT can also reveal incidental maternal findings such as aneuploidy, microdeletions or
cancer (Amant et al., 2015). For example, NIPT has identified maternal chromosome
abnormalities (Lau et al., 2013; Wang et al., 2014; Flowers et al., 2015; Snyder,
Simmons, Kitzman, et al., 2016), including maternal SCAs such as Turner syndrome
(Wang et al., 2014; Bianchi et al., 2015; Mcnamara et al., 2015). Snyder, Curnow, Bhatt,
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et al. (2016) reviewed 79 cases where NIPT results included monosomy, trisomy, SCAs,
or multiple aneuploidies. Of these cases, seven (9%) were of maternal origin; one
attributed to maternal mosaicism, and six to maternal cancer. Lastly, 42 (53%) of these
cases were discordant with fetal results and remained unexplained; however, the authors
suggested these results may be due to placental mosaicism, vanishing twin, or a maternal
chromosome abnormality in cases where maternal results were not available (Snyder,
Curnow, Bhatt, et al., 2016). As DNA from an individual’s cancer cells sheds into the
bloodstream, NIPT could also reveal maternal cancer (Bianchi et al., 2015; Osborne et
al., 2013). Maternal cancers identified through NIPT includes maternal non-Hodgkin
lymphoma, acute T-cell lymphoblastic leukemia, anal cancer, and colorectal cancer
(Bianchi et al., 2015). Grace et al. (2017) used data from previous studies to suggest a 2040% risk of maternal cancer when multiple aneuploidies are detected using NIPT
screening.
The clinical utility determines the usefulness of the test to the patient, including the
affordability of testing, what a patient will do with the test results, and how this
information may shape their prenatal care (Gregg et al., 2016). These decisions are all
framed by the patient’s unique value system and can be complicated and emotionally
distressing (Lobel et al., 2005). A negative prenatal screen may ease a patient’s anxiety.
However, a positive test may cause increased anxiety and create difficult decisions about
diagnostic testing and subsequent questions surrounding the continuation of pregnancy.
For example, using NIPT early in pregnancy allows earlier diagnosis of a fetus affected
by a condition than what is possible with traditional prenatal screening methods. Earlier
diagnosis is beneficial as it can give individuals more time to decide on termination or
plan the clinical management of pregnancy and birth of a disabled child. Those wishing
to terminate can do so earlier, in a time that may be less physically and psychologically
traumatic in pregnancy (Hall et al., 2009). The benefits and limitations of prenatal
screening are essential for health providers to be aware of and discuss with their patients
during pre-test counselling to help them make informed decisions about screening
(Dondorp et al., 2015; Audibert et al., 2017; ACOG-SMFM, 2020).
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1.3
1.3.1

Prenatal Screening in Ontario
Evolution of NIPT

NIPT became clinically available in Ontario in 2011 (Vanstone, Yacoub, Giacomini, et
al., 2015), and private diagnostic laboratories began marketing this as a self-funded test
across Canada by 2012 (Dougan et al., 2021). Ontario operates a publicly funded singlepayer health care system: Ontario’s publicly funded Health Insurance Plan (OHIP). In
2014, OHIP began financing this test in high-risk pregnant individuals on a case-by-case
basis (Gamma Dynacare, 2014; Huang et al., 2018). Initially, there was no written or
publicized announcement regarding the policy to fund NIPT on an individual basis
(Gamma Dynacare, 2014) and OHIP circulated referral forms detailing the risk criteria
required for reimbursement to specialist genetics and obstetrics clinics and to prenatal
care providers (Vanstone, Yacoub, Giacomini, et al., 2015). By 2018, funding criteria
were codified and case-by-case approvals by the MOH were no longer required (MOH,
2018; Burgess et al., 2020).
Since 2016, Ontario began contributing NIPT data to the Better Outcomes Registry and
Network (BORN). BORN is a registry that collects health data about every pregnancy,
birth and newborn in Ontario (BORN, 2022). Therefore, NIPT screening results can now
be linked to other pregnancy and birth encounters within this archive. In 2017, prenatal
screening Ontario (PSO) was created, a prenatal screening oversight organization within
BORN Ontario. Funded by the MOH, its purpose is to enhance access to prenatal
screening, provide education, undertake ongoing quality assurance, and facilitate the
integration of technologies or screening options (PSO, 2020). The MOH eventually
codified funding for NIPT in 2018 (MOH, 2018; Burgess et al., 2020).

1.3.2
1.3.2.1

NIPT in Ontario from 2016 to Present
The Integrated Prenatal Screen

As interviews for this dissertation were conducted in 2016, it is essential to situate the
research within the context of prenatal screening practice in Ontario at this time. For
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example, in 2016, patients had the option of choosing between three multiple marker
screening tests. These tests include the (enhanced) First Trimester Screen” (e)FTS and
the “Maternal Serum Screen”, which are still offered presently. The “integrated prenatal
screen” (IPS) was still available in 2016 and combines measurements from the first and
second trimester screening tests (Wald et al., 1999). At the time, individuals could choose
IPS, which was more effective than first trimester screening at detecting trisomy 21 and
18 (Rink & Norton, 2016). Blood was drawn between 11-14 weeks in the first trimester
and 15-20 weeks. However, IPS results were not released until the second trimester blood
draw had been analyzed at 16 -21 weeks (Mt. Sinai Hospital, 2007). Consequently,
waiting until the second trimester for results meant patients could not consider earlier
follow-up diagnostic testing if the first-trimester screening results indicated a high-risk of
fetal aneuploidy. Some authors suggest that withholding first trimester results were
unethical as patients have the right to know this information (Copel & Bahado-Singh,
1999; Spencer & Aitken, 2004). In addition, individuals who did not follow up in the
second trimester or chose not to continue to the second step of IPS have no risk
assessment available (Rink & Norton, 2016).
In 2018, (e)FTS replaced IPS in Ontario, giving patients two options for multiple marker
screening tests: (e)FTS, and maternal serum screen. (e)FTS performs just as well as IPS
with earlier results (PSO, 2018, 2019b). The patient's gestational age, the number of
fetuses, and the availability of screening tests in their geographical area will determine
which of these two tests is possible for that individual. (e)FTS is considered the optimal
multiple marker screen for singleton pregnancies (PSO, 2019b). Maternal serum
screening is only offered to individuals with singleton pregnancies if the patient presents
after 14 weeks or an NT ultrasound is unavailable. In addition, the SOGC has stated that
the primary use of maternal serum screen for neural tube defects should be discontinued,
and the primary screening test for the detection of neural tube defects and other structural
abnormalities should be second trimester anatomical ultrasound with detailed fetal
imaging and assessment (Wilson et al., 2014). In December 2021, (e)FTS was
discontinued for twin pregnancies in Ontario. NIPT is now covered by OHIP for patients
pregnant with twins regardless of gestational age, maternal age, or other factors. A nuchal
translucency ultrasound is still recommended for twins where available (PSO, 2021b).
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Figure 1 outlines a current comprehensive prenatal screening process map of Ontario. All
prenatal screening and diagnostic tests are optional, and a patient may decline testing at
any point in this process. If a patient declines (e)FTS, they can still have an NT
ultrasound performed.

1.3.2.2

Increase in NIPT uptake

There has been an increase in uptake of NIPT in the low-risk population since 2016. The
clinical diagnostic laboratory, which offers HarmonyTM, reported a significant uptake of
NIPT use in the low-risk population between the years of 2014 (47.3%) and 2017
(60.3%) (n=903,789) (Chen et al., 2019). An increased uptake in NIPT has also been
observed in Ontario. A retrospective, population-based, descriptive cohort study reviewed
BORN data for all pregnant individuals in Ontario who received NIPT from January
2016 to December 2017. In addition to reporting uptake of NIPT in the high-risk
population, this review also noted a statistically significant increase in NIPT for the lowrisk populations over this study period (Bellai-Dussault et al., 2020). An increase in lowrisk pregnant individuals undergoing NIPT has been described as a “trend that is gaining
momentum” (Agatisa, Mercer, Coleridge, et al., 2018, p.1375).
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Figure 1
Prenatal screening process map of Ontario in 2022

Note. Prenatal screening options available in Ontario (PSO, 2019b). NT=nuchal
translucency, MSS=maternal serum screening, (e)FTS=enhanced first trimester
screening, NIPT=non-invasive prenatal testing, EDD=estimated due date. 1st tier: NIPT
performed instead of traditional prenatal screening.
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*If 1st Tier NIPT: Recommended that NT ultrasound still be performed
**Genetics or Maternal-Fetal Medicine (MFM) specialists are the only providers allowed
to submit for NIPT funding for category two.
An uptake in NIPT could be due to increasing health care provider and public awareness
of this testing over time, especially as commercial laboratories are undertaking pervasive
marketing to increase awareness and uptake of this testing (Farrell, Agatisa, Mercer &
Coleridge, 2015; Bellai-Dussault et al., 2020). After these interviews were conducted in
2016, updated clinical guidelines were released that recommend discussing NIPT with all
pregnant individuals, regardless of risk status (Audibert et al., 2017; Gregg et al., 2016;
ACOG-SMFM, 2020). Additionally, as of December 2021, any physician or nurse
practitioner can now order OHIP-funded NIPT for patients pregnant with twins as (e)FTS
was discontinued for twin pregnancies in Ontario (PSO, 2021b). Therefore, since 2016,
awareness of NIPT has become more widespread in Ontario and an increasing variety of
prenatal care providers are using this technology, including more community-based
clinicians (Dragojlovic et al., 2021; Burgess et al., 2020).
Importantly, many experts in prenatal care speculate that prenatal care providers will
increasingly become involved in genetic testing (Carroll, Grad, Allanson, et al., 2016;
Harding et al., 2019; Filoche et al., 2017). This may be primarily due to a limited number
of genetic counsellors or trainees available to meet the demand of all patients considering
undergoing genetic testing (Devers et al., 2013; Sachs et al., 2015; Alexander et al., 2015;
Tamminga et al., 2015; Suskin et al., 2016; Agatisa, Mercer, Coleridge, et al., 2018). In
2018, for example, there was an estimated one genetic healthcare professional per
100,000 people in Canada, with only 109 medical geneticists and 293 genetic counsellors
(Berberich et al., 2018). Specifically, as NIPT demand increases, more prenatal care
providers are counselling and providing NIPT to an expanding patient population (Larion
et al., 2014; McLennan et al., 2016; Gregg et al., 2016). Indeed, many genetic clinics no
longer accommodated low-risk NIPT patients who could be managed in primary care in
Ontario by 2016 (Burgess et al., 2020).
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It has been noted that most individuals prefer NIPT counselling to come from the first
care provider they saw during pregnancy, which in many cases was their primary care
provider (Lewis et al., 2014). In semi-structured telephone interviews by Bensend et al.
(2014), genetic counsellors discussed the benefits to individuals receiving genetic
services from these providers, such as improved access to services, convenience, and
local availability. Even if prenatal care providers referred their patients to genetics,
participants in the Bensend et al. (2014) study mentioned the referring doctor's influence
in creating expectations regarding testing before a patient’s appointment to genetics. In
addition, prenatal care providers have a trusting relationship with their patients, including
their knowledge of patients' medical and personal histories. This background knowledge
is something that patients value during the decision-making process (Carroll, Makuwaza,
Manca, et al., 2016; Bensend et al., 2014).
As prenatal care providers become further entrenched in genetic testing, they must
perform adequate pre-test counselling as their role changes to accommodate increased
prenatal screening demands. However, pregnant individuals have expressed a critical
concern about the lack of valuable informed-choice conversations with their prenatal care
providers (Health Quality Ontario, 2019b). Cernat et al. (2019) performed a systematic
review of individuals’ experiences and preferences for informed decision-making around
NIPT. They noted that most pregnant individuals had been disappointed by the
counselling they have received from non-genetic professionals, including family
physicians, general practitioners, and obstetricians (Cernat et al., 2019). Individuals have
expressed that the quality and type of information about NIPT needs to be improved and
expanded to better facilitate informed decision-making (Cernat et al., 2019). They desired
more information about the benefits and limitations of screening (Agatisa et al., 2015;
Floyd et al., 2016; Daley et al., 2017) and the potential next steps in the care pathway
following NIPT results (Farrell, Mercer, Agatisa, et al., 2014; Floyd et al., 2016).

1.3.2.3

Conditions Screened

Since 2016, the MOH has had an agreement with two companies to provide provincially
funded NIPT screening in Ontario: HarmonyTM by Roche (Harmony, 2021) and
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PanoramaTM by Natera (Natera, 2021a). Panorama is available as early as nine weeks
gestation, with results available within seven days (Lifelabs, 2019). HarmonyTM is
available at ten weeks gestation, and results are available within ten days (Harmony,
2021). Both HarmonyTM and PanoramaTM have basic prenatal panels that OHIP covers.
The basic prenatal panel offered by HarmonyTM includes screening for common trisomies
(13, 18, and 21), sex chromosome aneuploidies, and fetal sex. Screening for fetal sex and
sex chromosome aneuploidies are opt-in options and only covered by OHIP for
individuals who meet criteria in category two (Dynacare, 2020c). Alternatively,
PanoramaTM offers a basic prenatal panel that includes screening for the common
trisomies, sex chromosome aneuploidies, and triploidy (three copies of every
chromosome). An individual will only qualify for screening for sex chromosome
aneuploidies and triploidy if they meet criteria in category two. For those who qualify for
category two for this basic prenatal panel, there is no opt-out option for reporting sex
chromosome abnormalities and triploidy; fetal sex is an opt-in option (Natera, 2021a).
These are considered baseline testing options and were available to individuals in 2016
when these interviews were conducted.
Since 2015, PanoramaTM provides expanded testing in Ontario for five microdeletion
syndromes: 22q11.2, 1p36 deletion, 15q11–q13 deletions (Angelman syndrome and
Prader-Willi syndrome), and 5p deletion (Cri-du-chat syndrome) (Hall, 2015). The
performance data for microdeletion screening using NIPT is still limited (Vora &
OʼBrien, 2014; Health Quality Ontario, 2019a; Wapner et al., 2015; Allyse et al., 2015).
In addition, these conditions have variable expression and penetrance. Based on these
concerns of clinical utility and validity, clinical guidelines still do not recommend using
NIPT to screen for microdeletions in the low-risk population (Audibert et al., 2017;
Dondorp et al., 2015; Gregg et al., 2016; ACOG-SMFM, 2020). Despite this, many
people have ordered this testing, with NateraTM reportedly performing over 400,000 NIPT
screening tests for the 22q11.2 microdeletion in 2020 (Natera, 2021b). MOH in Ontario
does not fund these expanded tests, and an “expanded prenatal” panel option is available
for $185-245$ more (Panorama, 2020; Dynacare, 2020d).
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1.3.2.4

Funding for NIPT

Apart from twin pregnancies, Ontario has maintained the same funding model for NIPT
since 2014. Clinicians are reimbursed for counselling about NIPT at the same rate as
counselling for other prenatal screening options (MOH, 2021). NIPT is publicly funded
in Ontario as a first-tier screen test (performed instead of traditional prenatal screening)
for all patients with twin pregnancies and singleton pregnancies at high-risk for fetal
aneuploidy and SCAs (PSO, 2021a). According to the MOH, a pregnancy is considered
“high-risk” if it meets any criteria in two specific categories. Individuals with singleton
pregnancies qualifies for the first category (“Category I”) if they meet any of the
following criteria: are of advanced maternal age (greater than or equal to 40 years of age
at expected time of delivery), have a positive multiple marker screen test for aneuploidy,
have had a fetal NT measurement greater than or equal to 3.5 mm and/or had a previous
pregnancy or child with trisomy 13,18 or 21. Pregnant individuals with a screen positive
prenatal screening result qualify for publicly funded NIPT for the investigation of trisomy
21, 18 or 13 only (Dynacare, 2020c). Any physician or nurse practitioner can order NIPT
for individuals who qualify for Category I testing or for individuals who will pay for
screening themselves. Midwives in Ontario are independent prenatal clinicians who
provide care to low-risk individuals. They have never been able to order NIPT in Ontario
and must refer their patients to a physician for counselling and follow-up (PSO, 2021a).
An individual qualifies for Category II testing if they have congenital fetal anomalies
identified on ultrasound that are associated with an increased risk of trisomy 13, 18, or
21. Other criteria in this category soft markers, ultrasound markers that are not congenital
anomalies per se, that indicate a risk of trisomy 13, 18 or 21. Lastly, individuals are
eligible for this category if they request NIPT for sex chromosome determination based
on a previously identified risk of a sex-limited disorder or ultrasound findings are
suggestive of a sex chromosome aneuploidy or disorder of sex determination (Dynacare,
2020c). Genetics or maternal-fetal medicine (MFM) specialists are the only providers
allowed to submit for NIPT funding for Category II. See Appendix A for the Ministry of
Health guidelines for funding of NIPT. The Prenatal Screening Ontario Advisory
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Committee (PSO, 2019b) recommends this criterion to optimize performance and costs
(Okun et al., 2014; Bellai-Dussault et al., 2020).
In 2019, Health Quality Ontario published a holistic assessment of NIPT’s use in the
average population. This review included evaluating clinical benefits and harms, costeffectiveness, and patient preferences related to NIPT screening for trisomies 21, 18, 13,
SCAs and microdeletions. Compared with NIPT, offered as a second-tier test, contingent
to a high-risk status or increased risk (e)FTS, IPS or maternal serum screen result, NIPT
offered as a first-tier screening test detected more chromosomal anomalies but resulted in
a considerable increase in the total budget. As an increased uptake of NIPT is not
necessarily associated with a decrease in cost associated with the care for a pregnancy,
child or adult with aneuploidy, first-tier NIPT has not been deemed cost-effective for the
average-risk population in most provinces (Audibert et al., 2017; Health Quality Ontario,
2019a), including Ontario (Okun et al., 2014; Dougan et al., 2021). In addition, this
assessment found that patients who underwent NIPT discussed the need for improved
pre-and post-test counselling for NIPT and were concerned about the quality of
information they received from their clinicians about the conditions NIPT can screen for
(Health Quality Ontario, 2019b). Therefore, Health Quality Ontario concluded that NIPT
should remain a publicly funded screening test only for high-risk pregnancies. However,
unlike other prenatal screening and diagnostic testing, individuals who do not qualify for
public funding or would like to screen for additional conditions can purchase NIPT as a
first-tier test through private pay (PSO, 2021a). Testing begins at $495-$550 (CA) for the
baseline panels (Panorama, 2020; Dynacare, 2020d).

1.4 Pre-test Counselling for NIPT
Professional societies and expert groups recommend pre-test genetic counselling to
ensure individuals make well-informed decisions about pursuing NIPT (Audibert et al.,
2017; Gregg et al., 2016; ACOG-SMFM, 2020; Salomon et al., 2017; Devers et al.,
2013). Informed decision-making refers to the decision-making process, and informed
choice refers to the actual decision made (Hall et al., 2009). Informed consent is the legal
agreement by the patient under the conditions that they made a voluntary decision, were
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appropriately informed and could make said decision (Deans & Newson, 2011). In
Canada, informed choice is a key principle of prenatal screening (Audibert et al., 2017;
Chitayat et al., 2017; Summers, 1994). An informed choice in the context of prenatal
screening is made when an individual is effectively and sufficiently informed about their
screening options. This choice includes considering how their pre-existing values and
beliefs influence their decisions about managing their pregnancy (Marteau, 2009; KaterKuipers, de Beaufort, Galjaard, et al., 2018; Deans & Newson, 2011). An informed
decision allows a person to act autonomously, which is a core principle for prenatal
testing (Lewis et al., 2017).
The specific features of NIPT technology raise ethical concerns, such as the erosion of
informed choice. For example, due to the simplicity of this procedure, there is a risk that
pregnant individuals will view NIPT as just “another blood test” and choose testing
without fully understanding its importance or implications (Cernat et al., 2019). Many
researchers also fear that NIPT may be routinized, as this simple blood test could become
a standardized part of the prenatal care pathway (Lewis et al., 2016a; Lewis et al., 2013;
van Schendel et al., 2014; Yi et al., 2013; Mozersky, 2015). Correspondingly, an
individual’s acceptance of the test is highly correlated to institutional and provider
support, rather than the individual making autonomous decisions about testing (Press &
Browner, 1997). In addition, this “easy and risk-free” (Farrell, Mercer, Agatisa, et al.,
2014; van Schendel et al., 2014; van Schendel, Kater-Kuipers, van Vliet-Lachotzki, et al.,
2017), early and highly accurate test may mean pregnant individuals feel external
pressures to undergo prenatal screening, as it is perceived as a responsibility of doing the
right thing (Farrell, Agatisa & Nutter, 2014; Ngan et al., 2020; Salema et al., 2019). From
a different perspective, selective abortion of affected fetuses expresses negative or
discriminatory attitudes towards the disability and those who carry it (Parens & Asch,
1999). Society may become less supportive of affected children based on the “easy” and
accurate NIPT test, giving people an option to avoid the birth of a child with a particular
condition, which leads to increased discrimination and stigmatization of these individuals
in society (Parens & Asch, 1999; Kater-Kuipers, de Beaufort, Galjaard, et al., 2018;
Health Quality Ontario, 2019a; van Schendel, Van El, Pajkrt et al., 2017; van Bruggen et
al., 2018).
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1.5 Significance of Study
Despite their increasing importance and role in discussing NIPT with pregnant
individuals, more studies are required to explore how prenatal care providers experience
being at the forefront of this counselling. The premise of this study centers around the
novel features of this technology, such as its unprecedented commercial development
(Chitty & Kroese, 2015) and early timing in pregnancy. Understanding how prenatal care
providers navigate the complexities and nuances of counselling for NIPT within their
practice could identify specific barriers in this process and subsequently inform what
further support is required so these clinicians can provide the highest quality of care.
Support could include improvements to best practice guidelines to specifically support
prenatal care providers’ needs. In addition, results from this study could inform policies
that further clarify how NIPT is used in practice (Khoury et al., 2007; Lobb & Colditz,
2013).
This research explores Ontario prenatal care providers’ experiences and perceptions of
using NIPT to screen for expanded conditions. In addition, a broad range of common and
rare diseases with known and uncertain clinical significance could be prenatally screened
for soon, due to the technological advancements of this methodology. Understanding
prenatal care providers' opinions on the development of increasingly complex genetic
screening can proactively inform what interventions are required to help prenatal care
providers navigate prenatal testing in the future. More broadly, findings can inform the
creation of supportive environments for patients being offered genetic tests by prenatal
care providers in an era where genomics is being used more commonly in healthcare.

1.6 Purpose
This constructivist grounded theory study aims to generate a substantive theory to explain
the processes involved with prenatal care providers' pre-test counselling of pregnant
individuals. Specifically, it explores how these professionals have integrated NIPT in
their clinical practice in Ontario, identifies potential counselling barriers, and explores
their experiences with expanded prenatal screening options.
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1.7 Research Questions
The research question that guided this constructivist grounded theory study was: From
the perspective of prenatal care providers delivering care to pregnant individuals in 2016,
what has been their experience with pre-test counselling for NIPT in Ontario?
Sub-questions include:
1)

What challenges and barriers have prenatal care providers experienced when pretest counselling people about NIPT?

2)

What support is available to improve pre-test counselling of NIPT by prenatal
care providers?

3)

What are prenatal care providers perspectives on using NIPT to offer and counsel
for additional indications such as fetal sex, expanded testing (for trisomy 16 and
22, and microdeletion/microduplication syndromes) or potential monogenic
disorders? Furthermore, what are their perceptions about incidental findings and
NIPT?

1.8 Declaration of Self
The methodology used in this study was constructivist grounded theory as formulated by
Kathy Charmaz (Charmaz, 2000, 2007, 2014). Constructivist grounded theory purports
that researchers hold prior ideas and skills that play a role in the co-construction of
theory. Charmaz (2014) suggests that researchers examine how their personal and
professional experiences can influence how they see the world and data and give
researchers starting points for initiating the research and analysis of the data. To declare
the self, I will state my past experiences that influence the depth of my exploration.
I completed my Master’s degree in Genetic Counselling in 2011. My research skills have
been developed by studying as a doctoral candidate at Western University, London,
Ontario and working as a research coordinator, research assistant, and research genetic
counsellor. Currently, I work as a laboratory genetic counsellor at CHEO Hospital,
Ottawa, Ontario.
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This research was motivated and influenced by my experience and training as a genetic
counsellor; this included my involvement as a genetic counselling student in a prenatal
clinic where I counselled patients about their various prenatal testing options. I
experienced an emotional counselling session that affirmed the importance of preprenatal counselling during my training. I provided post-test counselling for a couple
whose physician ordered multiple marker screening. They were given a “high-risk” result
for having a child with Down syndrome. They were upset, claiming to have known
nothing about the full consequences of the screening test. They saw the test as routine
blood work during one of their clinical visits. This information led them down a new
decision-making pathway and changed their pregnancy experience. The emotional effects
of their inadequate pre-test counselling resonated with me as a student genetic counsellor.
As such, my research interests focus on how prenatal counselling issues may become
more pronounced with NIPT, which can screen for a greater variety of genetic conditions
than traditional prenatal screening.
Genetic counsellors receive training in counselling individuals about the medical,
psychological, and familial implications of genetic diseases (Resta et al., 2006). My
genetic counselling education has provided foundational knowledge surrounding ethical
principles and considerations occurring in clinical practice. As a counsellor, I see myself
as a bridge between two very different worlds, moving back and forth between the very
objective world of genetics research and the complex and highly emotional social world
of the families affected by this science.
In addition, my current work as a laboratory genetic counsellor has influenced the
analysis of this research. Part of my job includes responding to inquiries and providing
information and support to healthcare providers who do not specialize in genetics and
advising them regarding the appropriate use of genetic tests, limitations/accuracy of tests,
possible testing outcomes, sample requirements, interpretation of results, and general
genetics-related questions. I liaise between clinical professionals and genetic laboratories
to ensure continuity of care through counselling, testing, and follow-up. As genetic
professionals, I believe it is crucial to educate prenatal care providers who may be
struggling with the counselling for genetic tests. Providing such support allows genetic
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counsellors to ensure that patients receive the best possible care. These guiding interests,
experiences, and disciplinary perspectives have helped form the research questions of this
study and guide the research process itself (Charmaz, 2006).

1.9 Organization of the Dissertation
This dissertation is in a monograph format and contains six chapters, including the first
chapter, which provides the introduction, background information, significance, purpose
and research questions for this research study. Chapter two presents a review of the
current literature on healthcare providers' views and experiences with counselling patients
for NIPT. Chapter three presents the methodology, constructivist grounded theory, used
in this study. Chapter four presents the data findings. Chapter five presents a discussion
of the findings, followed by Chapter six, which summarizes the study's strengths
limitations, and presents implications and directions for future research.
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Chapter 2

2

Literature Review

The following chapter reviews the literature on healthcare providers' views and
experiences on NIPT pre-test counselling and their thoughts regarding future testing.
Several studies explore pregnant individuals’ and their family’s views and experiences
surrounding NIPT (Agatisa et al., 2015; Farrell, Agatisa, Mercer, et al., 2015; Floyd et
al., 2016; Haidar et al., 2018; Lewis et al., 2012a; Lewis et al., 2012b; Lewis et al., 2014;
Lewis et al., 2016a; Lewis et al., 2016b; Reese et al., 2018; van Schendel et al., 2014).
However, fewer studies exist which examine healthcare professionals' experiences with
pre-test counselling for NIPT, including prenatal care providers who are at the forefront
of offering this test (McLennan et al., 2016). As per Charmaz's (2006) recommendations,
a preliminary literature review should identify and discuss the most significant findings in
the area to inform study design without forcing data into preconceived categories.
Therefore, a narrative review was conducted to identify and summarize what has been
previously published in this specific area to avoid duplication, determine what areas of
study need strengthening and, importantly, highlight gaps in the literature (Derish &
Annesley, 2011; Pautasso, 2013; Grant & Booth, 2009).

2.1

Search Strategy

For this review, a search was conducted using Scopus, PubMed, Google Scholar,
CINAHL and Western Libraries databases for genetic counselling, genetics and medical
literature conducted between 2014 and 2021. This timeframe was chosen because NIPT
became publicly funded for those at high-risk for fetal aneuploidy in Ontario in early
2014 (Vanstone, Yacoub, Giacomini, et al., 2015). The key search terms, which were first
searched on their own, include: cell-free DNA, cfDNA, non-invasive prenatal testing,
non-invasive prenatal screening and clinicians, providers, professionals, and genetic
counsellors. These two results were combined with the terms: thoughts, perspectives,
beliefs, attitudes, behaviours, expectations, or experiences. The references for all
included articles were searched to include papers not found through the initial searches.
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I reviewed the articles and identified the following thematic areas: ‘advantages and
limitations of testing,’ ‘scope of testing,’ ‘pre-test counselling considerations,’ and
‘support required.’ Prenatal care providers discuss various ethical considerations for
using NIPT in their clinical practice throughout these themes.

2.1.1
2.1.1.1

Advantages and Limitations of Testing
Advantages

It is well established that providers believe the accuracy of NIPT is a major advantage
over other screening methods (Gammon et al., 2016; Horsting et al., 2014; Brewer et al.,
2017; Alexander et al., 2015; Beulen et al., 2015; Hill et al., 2012; Yotsumoto et al.,
2012). Providers have discussed how higher levels of accuracy are reassuring for both
themselves and their patients, noting this advantage as a key driver for their patients
choosing NIPT for aneuploidy (Agatisa, Mercer, Coleridge, et al., 2018; Yi et al., 2013;
Lewis et al., 2014; Brewer et al., 2017). These studies involved healthcare professionals
commenting on the accuracy of NIPT overall when compared to conventional screening
methods. However, other performance measures, such as positive predictive value (PPV)
and false-positive rates affect patient and provider’s perspectives about NIPT testing have
been less investigated. For example, measures such as the PPV for common aneuploidies
in low-risk individuals are lower than PPVs reported in high-risk individuals.
Consequently, fewer individuals with a positive result in the general population will have
an affected fetus, leading to higher false-positive results (Audibert et al., 2017). Although
these performance measures have been an essential part of prenatal screening for
decades, they are important to NIPT screening as it is increasingly being used among the
low-risk obstetric population (Suskin et al., 2016; Palomaki et al., 2017).
The fact that NIPT can be offered at an earlier stage in pregnancy compared to other
prenatal screening options has been mentioned as a major advantage by several
healthcare professionals (Bennett et al., 2016; Brewer et al., 2017; Ngan et al., 2017;
Yotsumoto et al., 2012; Ahmed et al., 2017; Barrett et al., 2017; Kim et al., 2018; Hill et
al., 2013). Earlier testing is seen as an advantage because it could enable more time for
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decision-making regarding pregnancy management, including more time to prepare for
raising a child with a disability or earlier termination, which could be both physically and
psychologically easier to undergo (Gammon et al., 2016; Hill et al., 2013, Ngan et al.,
2017). During interviews conducted by Hill et al. (2013) regarding NIPT for single-gene
disorders, various healthcare professionals state that the earlier results of NIPT meant
pregnancy termination could occur earlier and could be performed by vacuum aspiration.
This method is safer for surgical abortion and can be completed in a primary care office,
abortion clinic, or hospital (World Health Organization, 2012). Providers in the Hill et al.
(2013) study also indicated that earlier testing was beneficial for couples considering a
termination of pregnancy as the pregnancy was not physically obvious and recognizable
features of the fetus were not visible on ultrasound (Hill et al., 2013). However, what has
not been explored is how providers incorporate pre-test counselling for NIPT into an
early pregnancy visit. Insight into this process may illuminate specific challenges and
barriers they may face during this busy time. Most importantly, this knowledge could
inform what additional guidance and support is required for prenatal care providers
juggling multiple topics early in pregnancy.
Although NIPT is not diagnostic, many genetic counsellors and other prenatal care
providers have indicated that the non-invasive nature of this screening test is its major
advantage over invasive diagnostic tests such as amniocentesis and CVS (Sayres et al.,
2011; Kim et al., 2018; Ahmed et al., 2017; Hill et al., 2013). Providers view NIPT as an
emotionally easier test that can reduce anxiety and stress for patients compared to
diagnostic options. They believe that patients can focus on whether the information
gained from this blood test would be valuable to them without the need to weigh the risk
of miscarriage into the decision (Hill et al., 2011; Hill et al., 2013; Agatisa, Mercer,
Coleridge, et al., 2018; Yotsumoto et al., 2012; Ngan et al., 2017; Ngan, 2018; Bennett et
al., 2016). Clinicians noted that the simplicity of NIPT made it easier to explain to
patients (van Schendel, Van El, Pajkrt et al., 2017; van den Heuvel et al., 2010).
However, providers are also concerned that the ease of testing may lead to NIPT
becoming a routine part of prenatal care and accepted by pregnant individuals without
proper consideration (van den Heuvel et al., 2010; Hill et al., 2011; Hill et al., 2013;
Skirton & Patch, 2013; Alexander et al., 2015; Tamminga et al., 2015; Bennett et al.,
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2016; Ahmed et al., 2017; Haidar et al., 2018). For example, in interviews with U.K.
genetic counsellors, respondents felt that diagnostic testing involves a more complex and
riskier procedure; the risks involved act as a “safeguard” in prenatal testing, making both
patients and professionals consider the implications of the test compared to a blood draw
(Alexander et al., 2015). Therefore, the low-risk nature of this test has been explored as a
possible risk to a patient’s informed decision-making. However, further investigation is
required into how the simplicity of testing has impacted prenatal providers’ pre-test
counselling. This inquiry includes whether clinicians believe patients are being
counselled adequately by other prenatal care providers in the community. Investigating
this aspect of counselling can provide further insight into how this process can be
improved to enhance the decision-making of patients who may not consider the full
implications of NIPT results.

2.1.1.2

Limitations

A limitation of NIPT includes the additional conditions that it cannot screen for, such as
conditions identified by other prenatal screening methods, including ultrasound (Kim et
al., 2018; Hill et al., 2013; Suskin et al., 2016). To compensate for these shortcomings,
providers commented on the value of information taken from other screening tests
(Horsting et al., 2014) and reported using NIPT in conjunction with another form of
traditional screening in the first trimester (Suskin et al., 2016; Martin et al., 2018; Kim et
al., 2018; Brewer et al., 2017; Tamminga et al., 2015; Suskin et al., 2016; Filoche et al.,
2017). For example, to investigate the clinical implementation of NIPT by members of
the Australian Association of Obstetrical and Gynaecological Ultrasonologists, Hui et al.
(2015) conducted an anonymous online survey with its members (n=54). The main
reasons for performing traditional first-trimester screening alongside NIPT were to detect
structural anomalies (100%), to predict adverse obstetric outcomes such as preeclampsia
(45%) as well as to reassure patients (24%) (Hui et al., 2015). It is important to
investigate if prenatal care providers experience difficulties conveying the confines of
what NIPT can test for and why these obstacles may exist. If providers face difficulties
conveying these limits, it can set unrealistic expectations for testing and ultimately
prevent patients from making an informed choice.
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There is a consensus from providers that it is imperative to inform patients that follow-up
diagnostic testing is recommended for a positive NIPT result (Ramdaney et al., 2018;
Weingarten, 2016; Ngan, 2018; Geeter, 2015; Tamminga et al., 2015; Hill et al., 2013;
Kim et al., 2018; Chan et al., 2018; Brewer et al., 2017; Haidar et al., 2020). However,
some prenatal care providers worry that this message is lost, and some patients and
providers misperceive NIPT as a diagnostic test (Hui et al., 2015; Haymon et al., 2014;
Chan et al., 2018; Brewer et al., 2017; Haidar et al., 2020). Consequently, providers are
worried that patients are making pregnancy decisions, such as termination, without
performing follow-up diagnostic testing after a positive NIPT result (Begleiter & Finley,
2014; Mennuti et al., 2013; Hui et al., 2015). This major limitation should not be missed
in the pre-test counselling process (ACOG-SMFM, 2020; Audibert et al., 2017; Gregg et
al., 2016). A more in-depth exploration of what factors perpetuate this misconception in
providers and patients is required, including providers’ perspectives. Further
investigation of these perspectives may identify barriers and challenges that could inform
additional education and support required to provide adequate pre-test counselling that
addresses this misperception.

2.1.2

Scope of Testing

Many providers believe NIPT should be offered to low-risk individuals as a first-tier test
(Horsting et al., 2014; Musci et al., 2013; Hui et al., 2015; Benn et al., 2014; Silcock et
al., 2015; Tamminga et al., 2015; Weingarten, 2016; Ahmed et al., 2017; Martin et al.,
2018; Kim et al., 2018; Ngan, 2018; Di Gioacchino et al., 2019; Suskin et al., 2016; Ngan
et al., 2017; Haymon et al., 2014). A small portion of these clinicians, through interviews,
discussed why they were willing to offer NIPT to all individuals, regardless of risk status.
Some believed it was important to provide access to a superior screening test (Suskin et
al., 2016; Ngan et al., 2017). Others felt that it was important to consider patient
preference (Haymon et al., 2014) and allow patients to make their own decision towards
testing (Di Gioacchino et al., 2019). In practice, providers who both do and do not
specialize in genetics are offering NIPT screening to individuals in the general population
as a first-tier test (Horsting et al., 2014; Musci et al., 2013; Haymon et al., 2014;
Buchanan et al., 2014; Weingarten, 2016; Hui et al., 2015; Brewer et al.,2017; Suskin et
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al., 2016). As those individuals who are not eligible for any universal or subsidized
government funding must pay out of pocket for NIPT, clinicians raised concerns about
equity issues involved in providing a superior technology to only those who can afford it
(Sayers et al., 2012; Horsting et al., 2014; Suskin et al., 2016; Haidar et al., 2020). Some
prenatal care providers have noted that a patient’s ability to pay for testing influenced
their decision to offer NIPT to that individual (Birko et al., 2019; Burgess et al., 2020;
Filoche et al., 2017). A more in-depth analysis is required to investigate Ontario prenatal
care providers’ perceptions of offering NIPT for aneuploidy testing and expanded
conditions through private pay. This information is especially relevant as NIPT screening
options expand. Understanding these views and concerns may help with future
regulations and directives between private and public testing and address disparities in
access. This knowledge can also inform future guidance and support for prenatal care
providers offering this counselling.
It has been well documented that healthcare professionals are concerned that NIPT is
being used for non-medical sex identification or sex selection, which many feel is an
improper use of this technology (Hill et al., 2013; Allyse et al., 2015; Swaney et al.,
2016; Alexander et al., 2015; Ahmed et al., 2017; Agatisa, Mercer, Coleridge, et al.,
2018; Flynn, 2018; Gammon et al., 2016; Geeter, 2015). Providers noted that a patient’s
interest in learning fetal sex is an important motivation to undergo NIPT, especially for
individuals at low fetal risk for common aneuploidies (Agatisa, Mercer, Coleridge, et al.,
2018; Flynn, 2018). General obstetricians, MFM specialists, specialists in reproductive
endocrinology and infertility, and genetic counsellors in a U.S. study reported that an
advantage to NIPT is obtaining results early in the pregnancy, as patients often wanted to
know the sex of the baby as early as possible (Gammon et al., 2016). As more individuals
use NIPT, it is also predicted that the number of patients who intend to use NIPT for nonmedical sex selection will also increase (Orr-Ferdinand, 2021).
Although patients use NIPT for non-medical sex determination and selection, there is a
significant gap in the literature on prenatal care providers’ in-depth thoughts and
experiences with counselling patients who intend to use NIPT for this purpose. Some
genetic counsellors in the U.S. have noted that screening for fetal sex has caused
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difficulty in pre-test counselling as some individuals prioritize using NIPT for this
purpose (Agatisa, Mercer, Coleridge, et al., 2018; Geeter, 2015). Counsellors described
experiences where patients only wanted to know the fetal sex and declined to view fetal
aneuploidy results (Agatisa, Mercer, Coleridge, et al., 2018) or didn’t understand the
possibility that an SCA could also be identified (Geeter, 2015). Orr-Ferdinand (2021)
conducted an anonymous online survey of open-ended questions to learn about U.S.
genetic counsellors’ experience counselling patients who intended to use NIPT towards
non-medical sex selection. Counsellors reported ethical dilemmas, emotional distress, and
cognitive dissonance from encountering patients using prenatal tests for fetal sex
identification and non-medical sex selection (Orr-Ferdinand, 2021). Exploring prenatal
care providers’ perspectives on this topic is also important as a major part of their patient
population could include low-risk individuals interested in using NIPT for this indication.
Examining this process could reveal prenatal care providers’ comfort with encountering
these cases and their potential ethical concerns. As prenatal care providers face situations
in the future where patients request NIPT for non-medical fetal sexing, this information
could serve as practical guidance for what additional support is necessary to help prenatal
care providers navigate this ethically charged topic.
Some providers have expressed positive attitudes toward broadening prenatal screening
results to gain more information about the fetus (Kim et al., 2018; Gammon et al., 2016).
However, genetic counsellors and other prenatal care providers have voiced concerns
about using NIPT for conditions such as SCAs based on the uncertainty of their clinical
significance, especially in the context of prenatal testing, where not all clinical data is
available (Agatisa, Mercer, Coleridge, et al., 2018; Geeter, 2015; Flynn, 2018; Gammon
et al., 2016). A survey by Geeter (2015) given to prenatal genetic counsellors (n=163)
from the National Society of Genetic Counsellors’ (NSGC) listserv included closed and
open-ended questions regarding their views on using NIPT to screen for SCAs. Some
counsellors thought NIPT was only clinically useful in detecting Turner syndrome but not
for other SCAs, which they felt had little clinical significance. Many providers believe
that NIPT should only be used for severe early-onset disorders (Benn et al., 2014;
Yotsumoto et al., 2012; Tamminga et al., 2015) and for disorders characterized by
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neonatal death or death within the first year of life (Tamminga et al., 2015; Filoche et al.,
2017).
Genetic counsellors and prenatal care providers have expressed concern that NIPT will
expand to screening for adult-onset conditions or non-medically relevant traits that are
not currently tested for invasively (Haidar et al., 2020; Bennett et al., 2016). The potential
for expansion of scope could promote the use of NIPT to screen for the “perfect” child
(Haidar et al., 2020; Alexander et al., 2015). As NIPT expands its testing options, it is
essential to explore what prenatal care providers believe are appropriate boundaries for
this testing and why. These values are essential to review as these healthcare
professionals may have to provide counselling on conditions available to screen for but
go beyond their comfort level professionally and ethically. This input is essential in
developing guidance for counselling patients for current expanded options and creating
future policies and guidelines.
Providers have agreed that the decision to offer NIPT for other disorders in the future
should be based on factors such as clinical utility and clinical validity (Sayres et al.,
2011; Hill et al., 2013; Skirton & Patch, 2013; Yotsumoto et al., 2012). However, some
genetic counsellors have shown concern for the lack of validation data currently available
for microdeletion syndromes, given the rarity of these conditions (Flynn, 2018). For
example, Agatisa, Mercer, Coleridge, et al. (2018) conducted interviews in 2016 with 25
prenatal genetic counsellors in the U.S. to understand their experience with the continued
expansion of NIPT screening. These counsellors felt that more validation studies are
required, with improved positive predictive values and detection rates, before offering
NIPT for microdeletions (Agatisa, Mercer, Coleridge, et al., 2018). More investigation is
needed regarding how the accuracy, false positive rate, and PPV affect providers' and
patients’ views towards microdeletion syndrome screening using NIPT. This area may
not be explored due to a lack of knowledge and awareness of this testing availability.
With the growing number of low-risk individuals interested in NIPT and manufacturers
including more rare disorders on their test menus, it is imperative to explore the prenatal
care providers’ understanding of this validation data. How these measures are understood
and applied can influence people’s confidence and decision-making (Health Quality
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Ontario, 2019b). Therefore, an exploration into the impact of this information could
influence a provider’s pre-test counselling session.

2.1.3

Pre-test Counselling Considerations

Many clinicians recognize the importance of pre-test counselling in general, and many
emphasize how the process should provide patients with accurate and comprehensive
information about NIPT (Benachi et al., 2019; Filoche et al., 2017; Alexander et al.,
2015; Hill et al., 2011; Suskin et al., 2016). Many clinicians emphasized various topics to
cover during the pre-test counselling session to aid decision-making. These topics include
the range of conditions screened for, the performance of testing (including test accuracy,
the possibility of false-negative and false-positive results), the need for a diagnostic test
in the event of a high-risk screen, cost and waiting time for results (Buchanan et al.,
2014; Weingarten, 2016; Ngan, 2018; Geeter, 2015; Tamminga et al., 2015; Hill et al.,
2013; Kim et al., 2018; Filoche et al., 2017).
Providers have expressed concerns regarding patients' lack of understanding of NIPT and
their subsequent ability to make informed choices towards screening (Alexander et al.,
2015; Yotsumoto et al., 2012; Ngan et al., 2017; Agatisa, Mercer, Coleridge, et al., 2018;
Yi et al., 2015; Ngan, 2018). Some genetic and non-genetic professionals from Canada
and other countries are concerned that other prenatal care providers are not delivering
adequate pre-test counselling (Horsting et al., 2014; Alexander et al., 2015; Agatisa,
Mercer, Coleridge, et al., 2018; Ngan, 2018). It is essential to explore prenatal care
providers’ perspectives on NIPT's pre-test counselling practices in Ontario. These
viewpoints could identify barriers they may encounter in the decision-making process.
This perspective could proactively identify potential challenges in pre-test counselling for
expanding NIPT testing in the future.
Prenatal care providers have reported that time constraints of a clinical encounter as a
major barrier in providing informed consent for NIPT and other prenatal testing options
(Farrell et al., 2016; Kim et al. 2018; Gammon et al., 2016; Ngan, 2018. Burgess et al.,
2020; Filoche et al., 2017; Farrell et al., 2016; Benachi et al., 2019). In interviews
conducted with genetic counsellors in the U.K., respondents expressed concerns about
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other prenatal care providers’ abilities to provide adequate counselling within the context
of an already overstretched service (Alexander et al., 2015). Some providers have
reported using pre-prepared notes or brochures about prenatal testing or NIPT (Kim et al.,
2018) or propose using educational videos (Gammon et al., 2016) to overcome these time
restrictions. More investigation is required on how prenatal care providers in Ontario
maneuver counselling for NIPT within busy, time-pressured prenatal visits. Such analysis
could provide more information about the potential barriers these non-genetic specialists
face when undergoing pre-test counselling in a routine prenatal visit. In addition, these
perspectives can inform what additional support is needed for clinicians who may be
struggling to provide adequate pre-test counselling in their practice.
Genetic counsellors and prenatal care providers from the U.S. have discussed how
screening for expanded conditions introduces pre-test counselling challenges. Due to the
variety of different genetic conditions and phenotypes associated with each microdeletion
available, providers were apprehensive about the uncertainty, volume, and complexity of
information they may have to discuss during the counselling process (Gammon et al.,
2016; Agatisa, Mercer, Coleridge, et al., 2018). Of the 111 genetic counsellors from the
U.K. surveyed by Alexander et al. (2015), almost half (46%) purported that if NIPTbased screening is introduced for a broader range of disorders, it should be made
available as a fixed list rather than having individuals choose from a catalogue of
disorders. Tamminga et al. (2015) agree that health professionals may raise objections to
allowing patients to choose from a list of disorders, as counselling would become a
complicated and time-consuming task. With the current list of expanded conditions
offered with NIPT, and the potential to expand to more tests, it is important to investigate
how providers integrate these options into pre-test counselling. However, very little
research has explored prenatal care providers’ perceptions on delivering pre-test
counselling for these expanded conditions, despite these options being available to
pregnant individuals for private pay in Ontario. An investigation into what barriers these
professionals may face in offering this testing could reveal where possible support is
required to help prenatal care providers deliver better pre-test counselling for these
expanded options.
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2.1.4

Support Required

Prenatal care providers have consistently reported about their inability to provide
adequate pre-test counselling for NIPT based on their lack of knowledge and confidence
in the test (Hill et al., 2011; Horsting et al., 2014; Alexander et al., 2015; Gammon et al.,
2016; Suskin et al., 2016; Filoche et al., 2017; Weingarten, 2016; Yi et al., 2015; Ngan,
2018). For example, a survey was distributed online through SOGC in 2016 to assess
obstetrical provider knowledge and attitude toward this testing. Providers, including
obstetricians, MFM specialists, general practitioners, and midwives (n=207) were unsure
of NIPT details, such as the capabilities of what NIPT can test for and when the earliest
gestation age at which this screening can be offered (Chan et al., 2018). Healthcare
professionals have reported a need for more updated education and training about NIPT
(Weingarten, 2016; Gammon et al., 2016; Suskin et al., 2016; Alexander et al., 2015;
Horsting et al., 2014; Weingarten, 2016; Gammon et al., 2016; Agatisa, Mercer,
Coleridge, et al., 2018). Importantly, more recent studies report that clinicians, including
genetic counsellors, are requesting more education and training for NIPT screening for
conditions beyond aneuploidy, such as sex chromosome abnormalities (Fleddermann et
al., 2019; Benachi et al., 2019). As recent as 2018, prenatal care providers in Canada
have expressed a need for education about NIPT and they have shown a lack of
awareness of testing (Burgess et al., 2020; Haidar et al., 2020). As NIPT migrates from
specialized healthcare providers to primary care prenatal practice, these providers must
receive additional education. Importantly, ongoing education is crucial as the knowledge
gap will widen as NIPT’s test menu expands. Therefore, an in-depth exploration into
what may be causing educational challenges for prenatal care providers is required. This
investigation can inform strategies for filling this current knowledge gap and can help
ensure these providers are kept up-to-date on the continual expansion of NIPT.
Providers have stated the methods they use to learn about NIPT, including formal
education activities such as presentations, workshops, or seminars. Others have said they
learn through a review of the literature, society’s recommendations or guidelines, word of
mouth and discussion with peers or genetic counsellors as educational resources (Yi et
al., 2015; Swaney et al., 2016; Weingarten, 2016; Kim et al., 2018; Ngan, 2018). More
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explicitly, clinicians have expressed the desire for this information to come from
definitive, trustworthy and unbiased sources (Horsting et al., 2014; Gammon et al., 2016;
Filoche et al., 2017; Alexander et al., 2015; Suskin et al., 2016). Genetic counsellors have
suggested spending time creating educational resources for prenatal care providers
(Suskin et al., 2016; Agatisa, Mercer, Coleridge, et al., 2018). In addition, genetic
counsellors in the Agatisa, Mercer, Coleridge, et al. (2018) study emphasized a greater
need to collaborate with obstetricians to optimize the counselling and decision-making
process during a pre-test counselling session. However, these educational efforts will all
take significant time and resources (Gammon et al., 2016); therefore, it is essential to
understand what targeted education prenatal care providers need in order to provide this
support as sufficiently as possible.

2.2 Conclusion
The literature reveals that clinicians recognize the importance of pre-test counselling in
general and emphasize that patients receive accurate and comprehensive education
surrounding NIPT during this process. Providers identified challenges and barriers such
as the time-pressured counselling, complex discussions, and concerns regarding current
and future expanded test options. However, a more in-depth examination of how prenatal
care providers in Ontario provide pre-test counselling for NIPT is required. Exploring
this process from the perspectives and experiences of these clinicians can bridge the gap
between practice and research and identify any challenges and barriers this particular
group may experience when providing pre-test counselling for NIPT.
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Chapter 3

3

Methodology and Methods

This chapter presents the methodology and methods used to investigate prenatal care
providers’ experience of offering NIPT during pre-test counselling. I begin the chapter
with a brief overview of the methodology used to guide this study, constructivist
grounded theory by Charmaz, and the philosophical perspectives that influenced this
choice. I also describe the research sample, setting, recruitment strategies, data collection
and management, data analysis strategies and ethical considerations. Lastly, a discussion
regarding rigour is presented. The study’s purpose supported using a qualitative
approach, as these methods are useful when focusing on the subjective human
experience, capturing a phenomenon from an individual’s perspective. In this case, the
qualitative approach was used to develop a framework that describes providers’
experience of counselling for NIPT in their practice (Polit & Hungler, 1993).

3.1

Grounded Theory Methodology and Philosophical
Underpinnings

Methodology is the process or strategy behind the methods chosen to obtain the desired
outcomes (Crotty, 1998). The methodology used in this study was constructivist
grounded theory as formulated by Kathy Charmaz (Charmaz, 2000, 2003, 2006, 2014).
Grounded theory was developed in 1967 by two sociologists, Glaser and Strauss. They
proposed that theory can be generated from data (Charmaz, 2000) rather than comparing
data to preconceived logically deduced hypotheses (Glaser & Strauss, 1967). Grounded
theory involves conducting inquiry through a systematic, inductive, and comparative
approach to bridge the gap between research and theory (Glaser & Strauss, 1967; Bryant
& Charmaz, 2007). The final theory arises from real-life observations and enables the
researcher to be guided directly by the actual research process and data.
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Grounded theory, as defined by Glaser and Strauss, Strauss and Corbin, and finally
Charmaz, will be discussed. Grounded theory has several distinct methodologies, each
with some variations in their philosophical underpinnings. Although Glaser and Strauss
never distinctly defined their philosophical paradigm, classical grounded theory is
considered to be rooted in the positivist paradigm (Kenny & Fourie, 2015). Paradigms are
“a basic set of beliefs that guide action” (Guba, 1990, p. 17). Positivism assumes that
reality is objective and described by measurable properties, independent of the researcher
or instruments (Myers, 1997). Correspondingly, Glaser has said that the theory generated
by classic grounded theory should be as “objective as humanly possible” (Glaser, 2002,
p.5), providing a formal theoretical explanation of fundamental social processes.
Verification of this theory occurs after quantitative analysis (Glaser & Strauss, 1967).
According to Glaser & Strauss (1967), the role of the researcher should be a distant and
detached observer to minimize bias. The literature review should be delayed until after
data analysis to prevent the researcher from developing preconceived ideas (Glaser &
Strauss, 1967). Previous literature should only be used to “challenge emergent theory and
locate the emergent theory within the current body of knowledge” (Heath, 2006, p. 527).
Classical grounded theory aims to arrive at a core category that denotes a central
phenomenon that connects all other categories. Once a core category is discovered, the
researcher hypothesizes its relationship with the remaining categories (Glaser & Strauss,
1967).
Some of the methods utilized by classical grounded theory are central to all versions of
this methodology. For example, data collection, analysis, and theory construction occur
iteratively. In addition, data analysis for all grounded theory approaches first involves
breaking data into smaller segments (word-by-word or line-by-line) and labelling it based
on their characteristics or properties. The “constant comparative method” is also a core
concept of all grounded theory studies, which involves finding patterns within data by
comparing data against one another (Glaser & Strauss, 1967; Corbin & Strauss, 2008;
Charmaz, 2014). All forms of grounded theory utilize theoretical sampling. This method
involves taking theoretical ideas previously developed from early analysis and using
these concepts to guide additional data collection. This data could include new
participants, new questions in subsequent interviews, and/or seek out recent literature to
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elaborate the developing theoretical categories and address conceptual gaps (Glaser &
Strauss, 1967; Corbin & Strauss, 2008; Charmaz, 2014). All grounded theory also
involves the researcher engaging in memo writing, preliminary analytic notes about their
thoughts regarding the data, and data analysis process to develop theoretical ideas and
direct theoretical sampling (Glaser & Strauss, 1967; Corbin & Strauss, 2008; Charmaz,
2014). Lastly, a core concept of all grounded theory is to remain theoretically sensitive,
which involves balancing an open mind with the ability to identify what is theoretically
significant during data collection and analysis (Birks & Mills, 2015).
Strauss worked with Corbin in the 1990s to develop an interpretivist grounded theory
methodology. This version rejects positivist thinking and is grounded in the subjectivist
paradigm, which assumes that reality is dependent on how people perceive and
understand it (Strauss & Corbin, 1990; Strauss & Corbin, 1994). This second genre is
founded on symbolic interactionism, a sociological perspective that assumes people think
about their actions rather than respond mechanically to stimuli (Park & Burgess, 1921).
Furthermore, symbolic interactionism is focused on the subjective meaning people place
on objects, behaviours, or events based on what they believe is true. Corbin states:
“meaning does not come out of an interplay between subject and object but is imposed on
the object by the subject” (Corbin & Strauss, 2008, p.9). The researcher’s role in this
version of grounded theory is acknowledged as a subjective interpreter of data. Corbin
states that it is not possible to “separate who I am as a person from the research and
analysis that I do” (Corbin & Strauss, 2014, p. 11). In contrast to classical grounded
theory, a review of the literature is encouraged before data collection and during this
process in order to inform research questions; increase theoretical sensitivity; stimulate
reflections, data comparisons and observations; and confirm or explain results (Corbin &
Strauss, 2014). Therefore, Strauss & Corbin's (1998) version also incorporates deduction
in the analysis process, which involves testing abstract ideas against emerging data
(Singh & Estefan, 2018).
Interpretivist grounded theory emphasizes a very structured approach to coding and
analysis, and the researcher intervenes intensively using analytical tools and questions
(Strauss & Corbin, 1998; Walker & Myrick, 2006). Coding also involves breaking down
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and rebuilding codes to create more significant and descriptive categories, leading to a
formal theoretical explanation. Like classic grounded theory, the aim is to arrive at a core
category that connects all other categories. Verification occurs when multiple
perspectives confirm the same data (Strauss & Corbin, 1994).

3.1.1

Constructivist grounded theory

A student of Glaser and Strauss, Kathy Charmaz’s constructivist grounded theory also
centers around a subjectivist paradigm. Charmaz ’s methodology embraces symbolic
interactionism and has roots in constructivism (Birks & Mills, 2015; Charmaz, 2006).
Constructivism focuses on how and why individuals construct meanings, actions, and
processes when in specific situations (Charmaz, 2003, 2006, 2014). Charmaz maintains
that the iterative data collection and analysis processes, alongside the intimate connection
researchers and participants have with the data and the emerging theory, make grounded
theory development a co-constructed endeavour (Charmaz, 2014). This version assumes
that the researcher’s values, priorities, positions, and actions impact views and
interpretations. Charmaz states: “we [as researchers] are part of the world we study and
the data we collect. We construct our grounded theories through our past and present
involvements and interactions with people, perspectives, and research practices”
(Charmaz, 2006, p.10). Constructivist grounded theory promotes researchers to be
reflexive about these influences and how they may affect their interpretations of the data
and emerging theory development (Charmaz, 2006).
Before data analysis, a preliminary literature review is performed to examine and
understand how previous research and theories influence their research (Charmaz, 2014).
Charmaz advocates for using the current literature to inform all phases of the project
(Charmaz, 2014; Kenny & Fourie, 2015); this includes a comprehensive literature review
to inform the discussion of the findings/theory and place the study within the current
research context of the phenomenon studied (Charmaz, 2014). Both induction and
deduction are used when and where needed to make sense of the grounded data.
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3.2

Rationale for the Constructivist Grounded Theory
Approach

Research methodology and methods must suit the research question (Beeson, 1997). This
study aimed to describe prenatal care providers’ perspectives and clinical experiences
with prenatal counselling since the introduction of NIPT in Ontario. Qualitative inquiry
was chosen as a method to describe, discover, and document aspects of a process that
cannot necessarily be anticipated (Beeson, 1997). This technology's implementation in
clinical settings have unexpected consequences on clinicians’ practices, including the
pre-test counselling process (Vanstone, Yacoub, Giacomini, et al., 2015; Burgess et al.,
2020). Grounded theory is a qualitative research design to which an explanation (theory)
of a process is generated from participants who have experienced the process. This
methodology is useful in studying a process “…where there are major gaps in our
understanding, and where a new perspective might be beneficial” (Schreiber, 2001, p.
57). Although prenatal care providers are increasingly becoming involved in genetic
counselling for NIPT, little is known about the process they experience when counselling.
Therefore, constructing a theory “grounded” in data will provide new knowledge about
what experiences and psychosocial processes occur in practice (Grubs & Piantanida,
2010) and will inform what future research is needed.
In addition, “to ensure a strong research design, researchers must choose a paradigm that
is congruent with their beliefs about the nature of reality” (Mills et al., 2017, p.26).
Before starting this study, I was deeply embedded in this field of research as a genetic
counsellor with prior experience in health professional education and prenatal
counselling. Therefore, the emphasis on distance from a phenomenon in classic grounded
theory and Strauss & Corbin’s approach did not seem achievable. I chose constructivist
grounded theory as its methods emphasized the importance of being reflexive of my own
experiences in order to remain open to the data and enhance theoretical sensitivity
(Charmaz, 2006).
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3.3

Sampling

A purposeful sampling strategy involves identifying and selecting information-rich cases
(Patton, 2002) by identifying and recruiting individuals who are knowledgeable about
and experienced with the phenomenon of interest (Cresswell & Clark, 2011). Initially,
purposive sampling was conducted in this study to recruit professionals who do not
specialize in genetics (prenatal care providers) who have experience with counselling
patients about NIPT in a clinical setting. To be eligible for the study, participants met the
following criteria: prenatal care providers who have experience with counselling clients
about NIPT in a clinical setting, are currently licensed and practicing in Ontario, are at
least 18 years of age, and can communicate in English. These individuals worked in
various settings, from community-based practices to academic hospitals and specialty
clinics, providing services to individuals experiencing low-risk or high-risk pregnancies.
High-risk pregnancies involved pregnant individuals with a higher-than-average chance
of developing complications. These complications include existing health conditions,
obesity, multiple births, and young or old maternal age (UCSF, 2019). Obstetrician
gynecologists (OB/GYNs) provide prenatal care for low and medium-risk patients at an
office or hospital (Best Start, 2020). Maternal-Fetal-Medicine (MFM) specialist are
obstetrician-gynecologists who have received additional education, practical experience,
and certification in the management of high-risk pregnancies, and work in hospitals or
specialty clinics (uOttawa, 2022). Residents are physicians who have completed their
Doctor of Medicine program and are undergoing further training under the direct or
indirect supervision of clinicians in different specialties of care. These providers are often
involved in a patient’s first medical contact in teaching hospitals and clinics (PARA,
2022). These healthcare professionals were purposefully sampled as they counsel patients
for NIPT in both high- and low-risk settings They have a range of length of time in
practice and have received different training dependent on their place in practice at the
time of implementation of NIPT, which is essential to collect a range of experiences and
perspectives from providers who have been counselling in a prenatal setting. Therefore,
an emphasis was placed on identifying a variety of healthcare professions to understand
how these different groups experienced NIPT in their own practices. Clinicians or health
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professionals were excluded if they did not encounter NIPT professionally. Participants
were limited to those who gave informed consent to have their interview audio recorded.
Dr. Barbra de Vrijer and Dr. Meredith Vanstone initially identified eligible participants
based on their knowledge of prenatal care providers in the community.
Theoretical sampling, which involves simultaneous data collection and analysis, was also
utilized in this current study to ensure the final developed theory is grounded in the data
(Grubs & Piantanida, 2010; Mills et al., 2014). This technique consists of the researcher
following leads in the data to sample new participants, asking new questions in
subsequent interviews, and/or seeking out recent literature to understand further what is
being shared or interpreted throughout the research process (Charmaz, 2014). Initially,
prenatal care providers recruited for this study included residents, obstetriciangynaecologists, and MFM specialists. These professionals expressed concern that family
physicians may have additional barriers that prevent them from providing adequate pretest counselling for NIPT. Primary care providers, including a nurse practitioner,
midwives, and several family physicians, were recruited to investigate these barriers
further. The primary care providers who were subsequently interviewed were able to
finalize a significant theme from this study, which was the need for more support for
family physicians, including better pre-test counselling strategies and dissemination of
updates and guidelines for NIPT.
This ongoing, non-random sampling technique is meant to obtain a representation of the
variants of contexts, events, and situations rather than obtain a statistical representation of
a group (Glaser et al., 1968; Strauss & Corbin, 1990; Corbin & Strauss, 2008). I engaged
in theoretical sampling until theoretical saturation was reached. Theoretical saturation
refers to the point in data collection when no new theoretical understandings emerge from
the data and when all relevant theoretical concepts have been identified, explored, and
exhausted (Charmaz, 2006). Therefore, the quality of the data in theoretical saturation is
more important than the frequency with which it recurs (McCann & Clark, 2003). The
data was verging on theoretical saturation after collecting and analyzing 15 participant
interviews. However, primary care providers, including midwives, family physicians and
one nurse practitioner, were sought to investigate what support they may require in
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delivering adequate pre-test counselling for NIPT. This additional recruitment was based
on earlier data suggesting primary care providers may face additional counselling
barriers. A final sample size of 19 participants was reached for this study when
theoretical saturation was determined.

3.4

Recruitment

Dr. Barbra de Vrijer and Dr. Meredith Vanstone initially identified potential participants
and reached out to them by email. If interested, these clinicians provided their emails to
our research team. A standard email script outlining the study (see Appendix B) was
emailed to interested contacts. The email gave a brief overview of the study, including an
official letter of information and consent form (see Appendix C). Interested clinicians
responded directly to me by email. I subsequently emailed back, answered any questions,
and, for those who met eligibility criteria, set up an interview time and location based on
their availability. Snowball sampling was used as the recruitment method for this study,
which involved initial participants referring our research team to other colleagues who
have relevant but different experiences with NIPT. These participants then referred us to
other eligible colleagues, which continued until theoretical saturation occurred.
Participants were from London, Hamilton, Toronto, and Kingston. At the beginning of all
interviews, I answered questions and obtained informed consent from all participants.

3.5

Data Collection

This study used semi-structured one-to-one interviews; the most common form of data
collection used in grounded theory studies. These types of interviews allow the researcher
to guide the interview in a general direction while being flexible enough to generate and
explore new insights about the topic that may not have been previously predicted (Willig,
2008). Data was collected from March 20 to July 15, 2016. Each participant was
interviewed once. Interviews were scheduled at a time and place agreed on by the
participants and took place in an available private room in their hospital, private office, or
over the telephone. Participants had a choice as to whether they would like to be
interviewed in person or over the phone. A total of 10 participants decided to be
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interviewed by phone. The interviews lasted approximately 30-60 minutes and ended
when the participant felt they had nothing more to add. CMBusiness and Transcription
Services performed the verbatim transcription of each interview. After receiving
completed transcripts from the transcriber, I read each one while listening to the audio
interview to ensure accuracy and completeness.
At the beginning of each interview, demographic data were collected from each provider,
including years of professional practice and what type of patients they see (individuals
experiencing high or low-risk pregnancy), which could affect a participant’s feelings or
attitudes about NIPT. The interviews were conducted using an interview guide (see
Appendix D). The questions were open-ended to facilitate discussion and elicit valuable
data (Charmaz, 2014). An example of an open-ended question was: “How do you
typically encounter NIPT in clinical practice?” Prompts were used to facilitate the
conversation and elicit more in-depth descriptions from participants. For example, when
discussing pre-test counselling to patients, one provider noted that they “…think that
people understand” prenatal screening, but wondered “…if they really get the whole
thing…”. I probed further and asked, “What gives you those indications that [patients]
might not understand?”
Field notes were taken throughout the data collection process. Field notes are written
records of observational data that provide contextual information, including descriptions
of the sights and sounds of the physical environment and any non-verbal reactions of the
participants during interviews (Hammersley & Atkinson, 2002; Jackson, 1990). These
notes supplement language-focused data to provide essential context to inform data
analysis (Montgomery & Bailey, 2007). An example of a field note I wrote involved how
the participant spoke; it was labelled “What they aren’t saying” and included the
comment “The last interview (OB/GYN-010) had a lot of pauses and seems like she was
filtering what she was saying” (Field note, April 11, 2016).
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3.6

Data analysis

Coding is the backbone of the analysis process in grounded theory (Charmaz, 2000) and
includes defining what the data is about and seeking conceptual abstraction of the data
(Bryant & Charmaz, 2007; Charmaz, 2000). Utilizing QUIRKOS™ qualitative analysis
software to help manage the analysis, as per Charmaz (2000), I engaged in three types of
coding: initial, focused, and theoretical.
Before any coding occurred, I read the transcript in its entirety to get a sense of what was
shared and reviewed the field notes to remind me about the interview. I then conducted
initial line-by-line coding by fracturing data into small blocks of text to remain close to
the data. At this stage, all codes created were expressed as gerunds, which identify
actions and processes within the data, such as ‘relying on genetic professionals’ or
‘facing difficulties with educating patients.’ Initial coding generated as many ideas as
possible from the early data and allowed me to look at processes without imposing
preconceptions and gain insights about what kinds of data to collect next (Charmaz,
2014).
Next, focused coding was used to condense and sharpen the splintered data to highlight
significant or frequent codes. Focused coding allowed me to synthesize and explain
larger segments of data. I decided on what initial codes were most prevalent or important
and contributed the most to the analysis. Throughout this process, the constant
comparative method was used to compare codes and processes within each informant's
data and across informants to form categories and subcategories. It was an emergent,
iterative process of comparing new codes or concepts to existing ones to look for
similarities, differences, patterns, relationships, refinements, and dimensions. This
comparative analysis provided a way to see which codes were related conceptually
(Charmaz, 2006). Coding during this phase was more selective and directed towards
developing a theory, and therefore I identified codes that were more analytical than others
to categorize the data (Charmaz, 2004, 2014). Through this comparison of codes,
categories and subcategories were eventually developed. The terms “categories” (themes)
and “subcategories” (subthemes) were adopted from Charmaz and used to describe the
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model that was developed from the data analysis (Charmaz, 2014). For example, I related
the codes ‘facing difficulties with educating patients,’ ‘struggling with managing
expectations,’ and ‘difficulty with prioritization of information,’ to create the
subcategory: ‘difficulties experienced with counselling.’ Charmaz (2006) notes that the
literature can illuminate theoretical categories and expand on ideas in the field. In
previous studies, a lack of time was identified as a barrier to counselling patients about
NIPT (Gammon et al., 2016; Farrell et al., 2016). In my interpretation, I related this data
with ‘difficulty with prioritization of information’ and eventually ‘difficulties
experienced with counselling.’
I then engaged in theoretical coding, which is the process of refining the final categories
of a developing theory and relating them to one another (Charmaz, 2006). This process,
for example, allowed me to see how the subcategory ‘engaging patients in decisionmaking’ is affected by ‘difficulties experienced with counselling,’ which is also linked to
the ‘ethical considerations’ subcategory. These subcategories all relate to ‘pre-test
counselling considerations,’ which became a major category in this model. Meetings with
my advisory committee were held intermittently throughout the research process to
discuss the emerging theory and inform the prospective analysis. Eventually, two major
categories were derived, which explored how the process of prenatal screening has been
enacted since the introduction of NIPT.

3.7

Reflexivity

Reflexivity plays an important role in qualitative research (Finlay & Gough, 2003).
Although a diversity of definitions and theoretical positions on reflexivity exist, many
transpire beyond the breadth of this study. I used the following definition of reflexivity as
proposed by Charmaz (2014, p.344):
[reflexivity is] ...the researcher's scrutiny of the research experience, decisions,
and interpretations in ways that bring him or her into the process and allow the
reader to assess how and to what extent the researcher’s interests, positions, and
assumptions influenced inquiry. A reflexive stance informs how the researcher
conducts his or her research, relates to the research participants, and represents
them in written reports.
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Although constructivist grounded theory recognizes the researcher as a co-constructor of
data and theory, Charmaz warns against forcing data into preconceived codes, categories,
and/or theories (Charmaz, 2014). To prevent this from happening, she suggests constantly
engaging in the reflexive process throughout all phases of research (Charmaz, 2014).
Reflexivity in this sense allows the researcher to scrutinize their decisions and understand
how these affect the research process and, ultimately, their findings (Burr, 1999;
Charmaz, 2014; Finlay & Gough, 2003). In doing so, reflexivity can also improve rigour
in grounded theory methodology (Finlay & Gough, 2003, p.28). A researcher's
willingness to identify these factors is essential (Charmaz, 2014). As such, I continually
reflected, examined, and explored my relationship with the data through this research
process to develop self-awareness of these subjective factors (Denzin & Lincoln, 2005).
Reflexivity was essential in this study to examine various aspects of conducting research,
including my preconceptions about the topic, my experiences during interviews, and the
analysis process. These factors influenced how I planned the study, conducted the
interviews, analyzed data, and wrote throughout this process. I wrote reflective notes
after interviews and analysis to examine my feelings towards each participant’s
comments and their ideas towards NIPT in a prenatal setting in order to uncover my
values and assumptions.
After each interview, I wrote a reflexive note which assessed my performance as both an
interviewer and participant and assessed any biases or feelings I may have had
throughout (Mauthner & Doucet, 2003). An example of a reflexive note I wrote was
regarding how I revealed my profession as a genetic counsellor (GC) after an interview:
“… [when I] mention that I'm a GC- that surprises them, and then they seem immediately
conscious about whether or not they spoke well of our profession” (reflexive note, March
31, 2016). In this note, I was reflecting on my co-construction of reality with this
participant and how, as described by Charmaz, “…research participants…pursue
purposes that influence their respective views and actions in the presence of [the
researcher]” (Charmaz, 2006, p.15). I was concerned about “social desirability bias,”
where respondents in qualitative research respond in a way that they perceive to be
acceptable but not entirely reflective of their reality (Bergen & Labonté, 2020). In this
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case, I was worried that prenatal care providers would not respond truthfully about their
relationship with genetic counsellors and interactions with genetics if they were aware of
my professional background. Based on this reflection, I did not reveal that I was a genetic
counsellor until the end of the interviews.
I also wrote reflexive notes throughout the research process. For example, I wrote a
reflexive note involving my background as an educator: “In analyzing this paper - I
realize as an educator at heart - I am looking for the misconceptions of providers- and
trying to find a critical view of what needs to be corrected from a provider's perspective
as well as a patient's perspective, which is tough because this is not always what's
happening here...” (Reflexive note, April 19, 2018). In this case, being reflexive about the
nature of the analysis prevented me from forcing superficial categories from my data.
Although I coded openly, I acknowledged that my background in education and genetic
counselling might make me sensitized towards specific factors in the area of prenatal
screening and decision-making that have been previously developed.
I constructed memos throughout the analysis process to bring the data to a conceptual
level, develop the characteristics or properties of the categories, and fine-tune my
subsequent data-gathering. Memos were written using Microsoft OneNote™ software.
Early memos were more tentative and less theoretically developed to uncover processes
in the data. An example of an early memo that I wrote was labelled “timing” and was
very short. After my 9th interview, I had noted that an MFM specialist discussed how
“time-consuming” pre-test counselling was for NIPT. As a genetic counsellor whose
entire visit can involve pre-test counselling only, this was something I had not thought
about prenatal counselling from the perspective of a prenatal care provider, who saw this
counselling as a competing priority in a larger prenatal session. Afterwards, I wrote a
memo: “Ask about expanded testing opportunities- ask how this will change timing: will
this influence the way [providers] pre-test counsel?” (Memo, April 8, 2016). Later
memos written further into analysis had more conceptual ideas to identify incomplete
categories and gaps in data analysis (Charmaz, 2014). I noted the concept of timing
showing up in various areas in my analysis: “timing is really important: time to think
about testing time to make an informed decision, time to create this concept of “baby” in
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[a patient’s] head: this experience can be transformative: the experience of testing, and
changing [their] thoughts of pregnancy: what does that do to [their] concept of “baby”
what changes for these women?” (Memo, November 22, 2017). Gradually, memos
shifted to categorizing the data and became more analytical. These advanced memos
framed the idea of prioritizing information shared during a counselling session, and
eventually, this idea fits into the subcategory of ‘difficulties experienced with
counselling.’ See Appendix E for an example of how this category was generated from
the data.

3.8

Quality Criteria of Constructivist Grounded Theory

Scholars have no consensus about standards and guidelines for conducting and evaluating
qualitative work (Ravenek & Rudman, 2013; Caelli et al., 2017). However, I believe that
quality criteria should be congruent with the research's underlying paradigm(s), aims, and
goals. As such, I used specific quality criteria related to constructivist grounded theory.
Charmaz provides guidelines for grounded theory studies centred around credibility,
originality, resonance, and usefulness (Charmaz, 2014).
Credibility is ensured by providing enough evidence for your claims to allow your reader
to assess whether the data supports the findings (Charmaz, 2014). One way this was
achieved was by involving my supervisors in discussing developing categories. I also
completed memos and field notes throughout the data collection and analysis process;
these were written after conducting and coding each interview and during each round of
coding. This reflexivity enhances credibility by allowing the reader to evaluate how my
experience, decisions, and interpretations influenced inquiry. Furthermore, credibility is
achieved if the researcher is intimately familiar with the topic (Charmaz, 2014). This
closeness is accomplished by conducting all data collection by myself. In addition, I
engaged in a constant comparative analysis which kept my analysis close to the gathered
data. Member checking is when researchers seek participant feedback on previous data,
analyses, interpretations, and conclusions regarding the accuracy and credibility of the
account (Creswell & Poth, 2018). I engaged in member checking by asking participants
about developing categories based on preliminary analysis. For example, I asked a
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provider whether they discuss expanded testing options with their patients: “… what
we’re hearing so far is it’s not really discussed. What are your thoughts about offering
NIPT screening…for [the expanded panel]?”
In addition, a thorough literature review strengthens the credibility of a constructivist
grounded theory study (Charmaz, 2006). An initial scan of the literature was conducted at
the onset of the study to inform the study design and identify sensitizing concepts (see
Chapter 1). A formal literature review was also conducted (see Chapter 2), which focused
on providers’ perspectives on NIPT after completing the data collection and analysis to
avoid stifling the creative process during data analysis, as per Charmaz's
recommendations (Charmaz, 2014). The literature is subsequently used to inform the
discussion of the newly formed theory (Kenny & Fourie, 2015).
Concerning originality, Charmaz emphasizes the need for one’s research to have social
and theoretical significance and provide fresh insights and a new conceptual rendering of
the data (Charmaz, 2014). As such, study questions arise from providers’ perspectives
and are developed around pre-test counselling for NIPT, a new and rapidly expanding
prenatal test. The findings are described in relation to the practical and applicable aspects
of the medical literature, such as the bioethical literature and psychosocial process
models discussed in genetic counselling and prenatal literature. Few studies exist which
examine providers’ experiences with incorporating NIPT in their practice.
According to Charmaz (2006, 2014), a study achieves resonance by having categories
that portray the studied experience's fullness, drawing links between larger groups,
institutions, and individual lives to offer deeper insights about a population's lives. My
study addresses these links by drawing connections between the various healthcare
workers who can be involved with prenatal care and how offering NIPT impacts the
process of prenatal screening, including counselling, in practice settings. Resonance is
also achieved, according to Charmaz, by focusing on the statements, intentions,
interpretations, and words taken for granted to ensure that each category suitably explains
the participants’ experiences. Thus, the developed theory appears relevant from the
participant’s viewpoint (Charmaz, 2014). I tried to summarize the participants’ overall
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statements to understand what they wanted to describe their experience during the
interviews. I provided in-depth descriptions and used direct quotes to illustrate the themes
that describe the providers’ experience. I also asked participants to clarify particular
descriptions during the interview whenever I felt opaqueness or wanted them to describe
a topic further. For example, to understand providers’ beliefs regarding who should be
involved in the future directions of NIPT, I asked, “who should decide?” or “who do you
think should be choosing these limitations [to testing]?” For some of the issues where I
noticed a lack of clarity after the interview was completed, I tried to provoke a response
from subsequent participants by adjusting the interview guide and using prompts.
Usefulness is achieved when the analysis offers interpretations that people can use in
everyday life and sparks further research in other substantive areas (Charmaz, 2014).
Despite their increasing importance and role in offering NIPT to pregnant individuals,
few studies have explored how prenatal care providers experience being at the forefront
of this counselling practice. Therefore, this overall research contributes to our
understanding of how Ontario prenatal care providers are experiencing pre-test
counselling for NIPT and its expanding test options. These findings have implications for
future research in prenatal screening and NIPT. More broadly, practical links can be
made between this research and prenatal care providers who are becoming more involved
in providing genetic testing in their practice.

3.9

Ethical Considerations

Ethics approval was obtained from the Health Sciences Research Ethics Board (HSREB)
of Western University (Original McMaster University REB #14-056, reciprocal Western
University REB#106393) to conduct this study. The approval demonstrates that ethical
requirements stipulated in the Tri-Council Policy Statement of Canada (2nd edition) were
satisfied (Government of Canada, 2014). The key ethical considerations of this study will
be addressed in this section: informed/process consent, protection from harm, privacy,
confidentiality, and anonymity. Informed consent was obtained from all participants prior
to the interview. Written consent was obtained from the interviewed participants face-toface, and oral consent was obtained and documented for the interviewed participants over
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the telephone. The letter of information included details such as the purpose of the
research, what is expected of the research informant, anticipated risks and benefits, and
how confidentiality and privacy will be protected (see Appendix C). A master list of
participants was created to link names with an identifier code if participants wanted to
withdraw all or part of the data after the interview. Participants were given a physical
copy of the consent document or emailed an electronic version to refer to at any time.
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Chapter 4

4

Results

The following chapter describes the findings of the constructivist grounded theory study,
which explored prenatal care providers' experiences of offering NIPT. The theoretical
model was generated from the empirical data of semi-structured interviews with 19
clinicians. Providers described their thoughts and experiences on pre-test counselling for
traditional aneuploidies, fetal sex, SCAs, microdeletion syndromes and incidental
findings. The model explains how prenatal care providers enact pre-test counselling for
NIPT, including challenges faced and support required when offering NIPT to patients.
Through iterative data collection and analysis, I constantly compared codes, memos and
field notes with each other and emerging categories to the point of theoretical saturation
which was when no new themes emerged. After 15 participants were sampled, I
approached additional primary care providers to confirm the counselling barriers
identified by this group. A final sample size of 19 participants was reached for this study
when theoretical saturation was determined.

4.1

Participants

A total of 19 prenatal care providers who encounter NIPT professionally in their clinical
settings in London, Hamilton, Toronto, or Kingston participated in this study (Table 3).
The final sample included family physicians (FP), maternal-fetal-medicine specialists
(MFMs), two senior residents in obstetrics and gynaecology, obstetrician-gynaecologists
(OB/GYN), midwives and one registered nurse. These individuals worked in various
settings, including community-based practices, academic hospitals, and specialty clinics,
and provided services to individuals at low- or high-risk for maternal or fetal
complications in pregnancy. The number of years of independent practice for these
physicians varied from less than one year to 39 years, with a median of eight years.
Additional participant demographics such as age and gender were not included as it was
not relevant to the purpose of the current study.
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Table 3
Characteristics of participating healthcare professionals
Number of individuals

Average number of years

interviewed

Study group

in independent practice

7

FP

13

4

MFM

18

3

OB/GYN

19

2

R

<1*

2

MW

6

1

RN**

10

FP= Family physician, MFM= Maternal-fetal medicine specialist, OB/GYN=
Obstetrician-gynaecologist, R=OBGYN Resident, MW=Midwife, RN =Registered nurse
* Participants in their 4th and 5th year of their OBGYN residency
**Registered nurse working with individuals with maternal or fetal complications in
pregnancy

4.2

The Model: Prenatal Care Providers’ Involvement
with Pre-test Counselling for NIPT in Ontario

The theoretical model, ‘prenatal care providers’ involvement with pre-test counselling for
NIPT in Ontario’, explains how prenatal care providers navigate the process of prenatal
pre-test counselling since the introduction of NIPT in Ontario. The model shown in
Figure 2 consists of two main categories, ‘pre-test counselling considerations’ and
‘support required,’ and six interconnected subcategories. The category ‘pre-test
counselling considerations’ illustrates the difficulties faced by prenatal care providers
when counselling patients for NIPT. This category also demonstrates how their ethical
concerns about testing impact their ability to engage patients in decision-making about
this test. Prenatal care providers also described the ongoing education, professional
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support, and regulations necessary to successfully undergo pre-test counselling for NIPT,
as reflected in the second category, ‘support required.’ For example, providers discussed
how ethical concerns regarding pre-test counselling for NIPT must be addressed through
regulations and directives. They emphasized the importance of disseminating these
guidelines to prenatal care providers. In addition, some of the difficulties experienced
with counselling for NIPT are a product of deficits in prenatal care provider education,
and genetics professionals were mentioned as an important link in providing this
education. Lastly, the large arrow in the model shows how the two main categories relate
to each other: the support required by prenatal care providers influences all aspects of
pre-test counselling considerations. Supporting evidence for the main categories and
subcategories are presented in detail below.
Figure 2
Prenatal care providers’ involvement with pre-test counselling for NIPT in Ontario
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4.2.1

Category #1: Pre-test Counselling Considerations

4.2.1.1

Ethical Considerations

The subcategory ‘ethical considerations’ encompasses the ethical aspects of pre-test
counselling for NIPT that providers have identified. Some of these ethical concerns made
pre-test counselling difficult for prenatal care clinicians to provide and have influenced
additional regulations and directives they believe are needed to support this process. For
example, many providers expressed concern that individuals are not making fully
informed decisions when considering NIPT. Some participants attributed this ethical
concern to patients not receiving sufficient information about NIPT during pre-test
counselling. As individuals are not “…fully counselled…[they] don’t always understand
what they’re getting into” [OB/GYN-04]. Some providers discussed their own
experiences with patients who have been negatively affected by inadequate counselling
from other prenatal care providers:
I find in practice the most frustrated women that I see…are usually the ones that
have sort of been guided down one path, such as genetic testing, and then being
sort of blind-sided by a result, and then kind of wishing they had never gone down
that road in the first place because it was just not what they expected. [MW-015]
Other providers said their patients had misconceptions about prenatal screening, such as
the difference between a screening and diagnostic test: “…we get a lot of our referrals
from the community, so sometimes their referring doctor has already planted it in their
head... I’d probably say the most common misconception is that it is a diagnostic test”
[RN-013]. Specifically, a few providers were worried that a family physician’s pre-test
counselling “gets rushed” [MW-015] based on the limited time they have with their
patients to provide this service:
…again, again, again, we have to explain the difference between a screening and
a diagnostic test. I had one patient that came back really, really, really upset for
counselling … it was a false-negative. Nobody had time to explain…[NIPT] is a
screening [test]… [MFM-009]
Prenatal care providers also discussed the importance of equal access to NIPT as an
effective first-trimester screening test. Some providers stated accessibility to testing is a

69

social responsibility, their professional duty was to stay current with the technology, and
their professional obligation was to offer the test. Some also mentioned that offering
NIPT as a private-pay (self-paid) option was a viable way for individuals to have access
to screening even if they may not qualify for public funding. One provider commented on
patients’ rights: “as a consumer able to buy a product commercially, it’s their right to
purchase [NIPT]” [MFM-003]. Similarly, one provider believed that patients had the
right to pay for NIPT for the indication of sex selection even “if the public system feels
that it’s inappropriate to cover it… [but]...they want to pay out of pocket, I’m fine with
that” [OB/GYN-002]. Others discussed the ability to pay for expanded screening as “…a
great resource for [patients] to have” [RN-013] for those individuals who would like to
pay for “reassurance” [FP-011] but do not qualify for public funding.
Conversely, many providers raised concerns regarding equal access to NIPT, including
the discrepancy between testing services across provinces and the affordability of the test
for individuals who do not qualify for public funding in Ontario. One provider noted that
at the time of interviewing, NIPT was “…a rich person’s test” [FP-008]. Another
mentioned the moral conflict they had with individuals having access to expanded
disorders through private pay with something that would otherwise not be funded through
public testing: “It doesn’t seem right that someone with money can get more information,
for me…I don’t know what the right answer is, but that’s a quagmire as well…” [FP-16].
Providers discussed the ethical challenges that can be associated with offering NIPT for
conditions beyond the traditional aneuploidies of trisomies 21, 18 and 13. For example,
many participants were conflicted with offering screening for conditions with variable
clinical presentations, such as Turners or Klinefelter syndrome. This concern was
amplified when discussing the expanded use of NIPT to screen for microdeletion
syndromes, such as 22q11, cri-du-chat, Prader Willi/Angelman syndrome and 1p36
deletion syndrome. These syndromes can: “have a much more variable appearance, much
more variable effect on what’s going on with the fetus…” [MFM-006]. One clinician has
not offered expanded testing for microdeletions because “the only thing that comes with
bringing that up is more questions” [OB/GYN-004]. One provider compared these
uncertain phenotypes to something such as: “...a major structural anomaly, there could be
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some fairly significant physical restrictions, health issues that go forward with that. The
microdeletions, I think, are even worse in terms of that broadness” [MFM-006].
Ultimately, providers were concerned that NIPT would be used for screening for
conditions in which the clinical severity was uncertain. However, some participants
thought it was appropriate to use NIPT to screen conditions beyond the traditional
aneuploidies in order to gain more information about the fetus. They emphasized the
importance of properly educating patients before deciding to go forward with testing and
ensuring “transparency” [MW-015] regarding the potential range in phenotypes that
could occur for some conditions. One OB/GYN discussed the nuances involved in pretest counselling for sex aneuploidies:
To do that kind of counselling properly takes a lot of time and a clear
understanding of the ethical issues that arise when you counsel for something that
is non-lethal, variable expression, that’s a lot of stuff to bring forward…
[OB/GYN-004]
Many participants raised ethical concerns regarding the “slippery slope” [FP-014; FP018; MW-019] that could result from offering NIPT for disorders beyond common
aneuploidies. Providers used phrases like “opening the floodgates” [R-001] and opening
up “a can of worms” [OB/GYN- 004; MFM-003; MFM-006] to describe the issues they
faced about expanding testing. Some providers were enthusiastic about the prospect of
accessing information they had never seen before. In contrast, others were concerned
about the implication of not necessarily knowing how to interpret that information: “…
it’s one of those things that, the horse might be able to get out of the barn and then you
actually lose the ability for it to be done well” [OB/GYN-004].
Participants also expressed concerns about using NIPT to screen for indications that they
considered to be inappropriate. There was a concern that NIPT could go into “scary
territory” [MW-015], and providers wondered what the limits to testing should be. They
mentioned that it was a matter of ethical debate of whether this test is going to “be used
or abused” [OB/GYN-002], with the extreme end leading to patients undergoing genetic
selection for the “perfect baby” [OB/GYN-002], “designer babies” [MFM-005] or to
“grow [the] perfect race” [OB/GYN-010]. One provider noted: “maybe someday we will
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be selecting our baby’s hair colour and eye colour and gender… it’s kind of a fear…in
terms of the risks and benefits of more knowledge and more information” [FP-011].
Participants were very concerned about the use of NIPT for sex selection, as many
considered this an inappropriate indication for screening: “…you don’t want to do this
[NIPT] willy-nilly. Hopefully, we’re not doing it just for gender” [OB/GYN-002].
Another participant was unsure how to respond if the request for NIPT for sex selection
alone surfaced: “… that’s one of my big worries…I don’t even know how you would
approach that or try to prevent that from happening…” [FP-014]. Another physician
discussed how they felt “lucky” to practice in a city where this does not take place but
noted that it could occur: “in a different city [in Canada] where there might be different
cultural norms…” [FP-012]. In practice, some providers discussed counselling their
patients on how NIPT reveals fetal sex in conjunction with other results of this screen.
However, one provider explicitly withholds this information from patients based on their
fear of sex selection: “… I don’t tell [my patients] about the gender selection, so I’m
already sort of withholding some information as far as in their decision to make the test
right, to do the test because I’m worried about gender selection…” [FP-016].
Feelings about offering NIPT for conditions beyond traditional aneuploidies were
obfuscated with the importance of a patient’s right to know available information. In
terms of sex selection, one provider stated that “…this is something for ethical debates in
terms of all or nothing… I believe that we have to tell them, and I agree it’s indefensible
not to” [R-007]. In terms of offering NIPT for microdeletions, providers stated that they
would struggle with providing patients with this information and controlling what testing
should be offered: “I don’t think that it’s my job to say which things should and shouldn’t
be offered because it’s health information that truly is the patient’s. It’s not our
information, so I don’t know” [MFM-003]. Many providers stated it was also important
to disclose any incidental findings, and it was unethical to withhold this information.
However, one provider expressed the dilemma of a patient possibly having this incidental
information on their permanent medical records and the potential insurance implications
in the future [RN-013].
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4.2.1.2

Difficulties Experienced with Pre-test Counselling

The subcategory ‘difficulties experienced with pre-test counselling’ describes the
challenges providers face while counselling patients about NIPT. Some of these
difficulties contribute to the ethical concerns of testing. In addition, these difficulties
ultimately affect how prenatal care providers engage patients in decision-making about
this test. For example, many providers mentioned the time constraints, including pre-test
counselling for NIPT and prenatal testing in an already busy session. One family
physician described pre-test counselling for prenatal screening to be “more challenging
than any other counselling” they do in their office, as “…there is so much to tell
somebody who knows so little in such a short amount of time” [FP-017]. Counselling
about NIPT itself was described as a “time-consuming” [MFM-009] process by one
provider. This struggle was emphasized by family physicians who grappled with the
competing priorities of other topics to discuss during a patient’s prenatal session,
especially if it was the first visit:
I’m talking about…their nausea, and how they’re coping with their
fatigue…about their regular blood test, and how they have to come back for a
physical and all that stuff. So it’s a lot to talk about. Talking about the minutia of
what a particular test might find…is probably not going to happen realistically.
Unless I’m there for two hours, which I don’t have time for… [FP-012]
In contrast, one midwife discussed how they had more time to provide pre-test
counselling compared to family physicians:
I think that [pre-test counselling for NIPT] gets rushed, because in the physicians’
world they have a lot more clients and patients than I do, so I understand that their
time is limited and they don’t have as much of it. [MW-015]
Providers were balancing this conversation while still acknowledging the importance of
early prenatal screening with NIPT: “it is a long visit in addition to all the stuff, are you
eating well, are you happy you’re pregnant…And you really have to do it early because
the screening time is so early. So it’s difficult” [FP-106]. One family physician noted that
they bring patients back for a separate visit for prenatal counselling, as their appointments
are usually only 15 minutes and there is a lot of information to cover: “…when the
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patient comes in initially telling me they’re pregnant… there’s too much in that visit to
go through their whole medical history, coordinate their obstetrical care and provide pretest counselling” [FP-017].
Family physicians see patients the first prenatal visit when patients have “a lot to think
about” [FP-011]. Consequently, physicians noted that individuals might not be receptive
to discussing prenatal testing early in pregnancy due to competing priorities. “[My
patients] are probably more interested in hearing ‘who is going to deliver my baby’ and
‘which hospital is it at’ and ‘do I need to take my vitamins’ ” [FP-016]. Family
physicians described the tonal shift that occurs once NIPT is brought up in the session:
“[The patient is] more worried about losing the baby than something being wrong with
the baby, and then it shifts, okay now is everything okay with the baby” [FP-011].
Another provider was not sure whether discussing NIPT was a welcomed conversation at
the initial prenatal visit: “I [say to them] ‘I know you’re pregnant, and it’s happy news,
but we also have to discuss this…in a timely fashion’… it’s sort of like a very serious
conversation that they have to…bend their mind around” [FP-016]. Providers also
explained having difficulties with balancing how much information they should give to
patients regarding the potential for NIPT test to reveal incidental findings:
I don’t want to tell [my patients] too much information right off the bat because
most people come back with a normal result, but I also have to leave them
prepared that there could be unexpected things that will be picked up. [MFM-003]
Participants discussed how they struggled to manage patient expectations surrounding
prenatal screening in general, and how this can prevent patients from making fully
informed decisions. As one provider noted, “[When it] comes to any screening test, it’s
often challenging to find a way to describe to patients what the test can and cannot do for
them” [R-001] including the expectation that a negative screening test means the fetus is
“healthy” [OB/GYN-004; OB/GYN-010; FP-011]. Screening tests were described as
“confusing” [R-001, FP-018] in nature, as the average individual’s concepts such as
false-positives and false-negatives are unfamiliar and hard to understand. According to
some providers, NIPT is often viewed as a diagnostic procedure by patients, and a
positive result did not need any additional follow-up testing. As discussed previously, this
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misconception can be particularly problematic if the patient does not receive appropriate
pre-test counselling.
Providers mentioned how pre-test counselling for conditions such as Turner syndrome
and Klinefelter syndrome could be challenging based on the range in phenotypic
variation, making it difficult to counsel patients based on the uncertainty of outcomes in
pregnancy. In addition, difficulties experienced with pre-test counselling for NIPT are
“multiplied exponentially” [R-001] if NIPT is used to screen for rare microdeletion
syndromes. Providers felt that the phenotypic variability of these disorders was not as
well defined as the aneuploidies that NIPT currently tests for and may therefore make
informed decision-making more difficult. One provider thought that screening should be
kept “specific” in order to reduce the risk of “…counselling difficulties that are going to
be less than if we start expanding…” [MFM-005]
Some providers compared the difficulty of informed decision-making to the same
phenomenon that already occurs with microarray testing: “… there are all kinds of
differences in microarray … that have no clinical significance. But you still have to
counsel the couple on ‘well, your baby has this difference…but we don’t know what it
means’ ” [MFM-003]. Although these are difficult concepts to understand and counsel
patients about, providers suggested that the lessons learned with pre-test counselling for
microarray testing could serve as a guide for expanded testing in NIPT:
Hopefully, genetics will learn how we’re managing, how we’re dealing… We’ll
have an opportunity to kind of have some counselling about more surreal and
more kind of esoteric concepts, potentially, and that may help guide how we
would talk about that in an NIPT setting with some of those more expanded
testing options. [MFM-006]
Individual expectations of expanded testing were mentioned as especially problematic
when patients pay for the tests themselves. One family physician discussed
misconceptions that their patients who pay out of pocket have had: “... I think that they
felt that they were getting more than what they got. I think that they thought the
microdeletions were included in it …” [FP-008]. Another provider noted the complexities
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that would arise from different needs for pre-test counselling: “The private sector would
say, if I can pay for it, I want to pay for anything possible. But if you have two different
tiers, you have two different needs for counselling.” [OB/GYN-004]

4.2.1.3

Engaging Patients in Decision-Making

Participants discussed how they engaged their patients in decision-making during pre-test
counselling for NIPT. This activity was affected by the challenges they faced while
counselling. First and foremost, participants described the importance of allowing
patients to explore whether prenatal screening, including NIPT, is appropriate for them
based on their attitudes, values, expectations, and perceptions:
[This conversation] …can be very illuminating. It can…shed a lot of light on how
that client is as a person…what their values are, what their biggest concerns are,
as well as what their baseline level knowledge is around their pregnancy. [MW015]
Providers stated how highly anxious patients might want to undergo prenatal screening,
such as NIPT, based on the information it can provide. One OB/GYN, who provides care
for both low-risk and high-risk patients, noted how prenatal screening might not be an
appropriate choice for individuals who are highly anxious about fetal health and
wellbeing, and need reassurance: “They have anxieties, but their anxieties are more
about, is the baby put together normally, not around the genetics so much” [OB/GYN010]. Providers mentioned that their patients’ current perceptions, goals and expectations
might be influenced by their previous pregnancy experiences, such as facing challenges
with becoming pregnant or having experienced a perinatal loss. They stated that these
individuals might not want additional risks associated with some prenatal screening tests,
such as amniocentesis. In addition, providers mentioned that genetic testing results would
not alter pregnancy management for some people, and therefore genetic testing may not
be appropriate for them.
Participants also described what information they share with patients about NIPT to
enhance informed decision-making. They review the benefits and limitations of NIPT
with patients, often in the context of other prenatal tests. Specifically, many providers
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explain that NIPT is not a diagnostic test, and confirmatory diagnostic testing is required
after positive results. Some also emphasize that NIPT cannot replace all prenatal
screening, as the test does not screen for placental insufficiency, intrauterine growth
restriction, or congenital anomalies, such as spina bifida. Of note, very few report
discussing with their patients that there is a possibility of placental mosaicism [FP-014;
MFM-005; MFM-009, R-001], inconclusive results [RN-013], or false-positive results
[MFM-003; FP-011].
Participants discussed how pre-test counselling involves reviewing several benefits of
NIPT with patients, including that NIPT has higher accuracy than the conventional
prenatal screening test offered at the time of this study. Although most providers did not
mention that this technology is not as accurate for aneuploidies beyond trisomy 21, many
tell patients that NIPT is non-invasive. The non-invasive nature of NIPT was considered
a benefit compared to an invasive procedure like an amniocentesis: “NIPT definitely can
save some of those women the risk of exposure to an invasive procedure like an
amniocentesis and give us a little bit more of that yes or no answer” [MFM-006].
Some providers also tell their patients that NIPT is an earlier screening test than IPS, and
they noted that early results provide patients more time to make decisions regarding
follow-up testing if desired. One provider thought that the decision to terminate a
pregnancy if an anomaly was detected: “…would be much more difficult after you’ve
seen a couple of ultrasounds [at 21 weeks] than…to terminate a pregnancy at 12 weeks”
[FP-011]. When these interviews were conducted in 2016, (e)FTS was not yet available.
Instead, IPS was offered as the most superior prenatal screen (Rink & Norton, 2016);
however, results were not available until second trimester at 16-21 weeks (Mt. Sinai
Hospital, 2007). During this time, a patient may have undergone a detailed anatomical
second trimester ultrasound offered in the second trimester between 18-22 weeks (PSO,
2019b).
In contrast, (e)FTS is now offered instead of IPS and performed during the first trimester
between 11-13 weeks (PSO, 2018, 2019b). This earlier screening option makes
termination possible before the second trimester detailed ultrasound. Despite this, NIPT
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can be performed starting at 9 weeks, which is earlier than (e)FTS and IPS. Participants
felt this early screening may improve decision-making not only from the perspective of a
patient, but also as a decision that they can make about the pregnancy “before the world
knows about [it]” [FP-008].
Participants also discussed with their patients how NIPT involves the analysis of fetal
DNA for specific chromosome aneuploidies. Some providers mentioned informing
patients that NIPT could reveal fetal sex, but very few reveal that NIPT could screen for
specific SCAs. Most said they do not discuss expanded testing options with their patients,
and none address the potential for incidental findings. The decision to not discuss these
additional results with patients was by choice or by being unaware these results were
possible or available.

4.2.2

Category #2: Support Required

4.2.2.1

Need for Regulations and Directives

Participants expressed the need for regulations and guidelines regarding prenatal genetic
counselling and specified what that would mean for expanding NIPT. Many of the ethical
concerns described above by providers inform the type of regulations and directives they
believe are necessary to develop. Some providers mentioned that the pressure from
industry had initiated the rapid development and implementation of NIPT, and that this
specific test had been adopted quickly in practice settings as a result. With this pressure, a
few providers were concerned that other prenatal care providers were ordering NIPT in a
way that was not cost-effective nor morally appropriate. One provider explained their
personal experience during a conference where other providers were discussing ordering
NIPT for patients:
I heard people in the room say, ‘yeah, but if you only have this, you get it
covered’… it’s almost like people are looking for those little signs to just get it
covered. And I don’t think that it’s completely fair for some people to say, ‘oh
we’re going to stretch’…so [the patient’s age] is greater than 40, it can be
covered…[some providers]…just order it…[and]…say there is a soft sign and it’s
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covered…And that’s what … the companies who are doing the test, are telling
you because it’s their marketing to get more testing…I tend to be thinking about
economics as well and that bothers me a lot. [FP-008]
There was also a fear that NIPT would be misused for expanded testing unless stricter
regulations were implemented.
With the technological advances of screening, many questioned the limit to NIPT.
Current policies and guidelines about expanded testing were considered “patchy” [R-001]
and needed to be updated to mirror current options. One provider noted, “technology
might be moving faster than policy” [R-001]. Prenatal care providers noted that it was
essential to develop additional regulations and directives as the conditions offered by
NIPT continued to expand and become more clinically and ethically complex. This need
was felt by providers who struggled with ethical questions of offering NIPT for sex
selection and expanded disorders with variable phenotypes. These additional regulations
were fundamental to address increasing industry pressure to offer expanded testing. Some
also discussed the importance of distinguishing what conditions should be publicly
provided for NIPT versus the privately available screening. One clinician also mentioned
the importance of regulating how pre-test counselling occurs for both public and private
screening: “…if it’s not streamlined in the way it’s rolled out and how the counselling is
provided, then I think that becomes very messy” [OB/GYN-004].
When discussing what conditions are appropriate to offer NIPT for, a few providers did
not know or have an opinion on what should be included. Many providers mentioned that
a disorder might be appropriate to screen for if it is clinically significant, especially when
considering the general population: “I think there’s going to need to be a lot more
discussion, a lot more upper-level genetics…what is the utility of screening for this in the
general population” [MFM-006]. In addition to clinical utility, many would approve of
screening for a disorder if screening would yield high rates of performance measures
such as accuracy, specificity, false-negative and/or false-positive rates. Genetic
counsellors, geneticists, MFMs, midwives, nurse practitioners, family physicians,
OB/GYNs, pediatricians and researchers were identified as essential stakeholders in
creating policies and guidelines on expanded testing.
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In 2016, many prenatal care providers were still becoming familiar with NIPT. Many
providers in this study were unaware that NIPT could yield unexpected fetal or maternal
findings. Some also mentioned the importance of providing more standardized
information about NIPT and additional guidelines on counselling patients for any
condition other than the commonly known chromosome abnormalities. One provider
described feeling uncomfortable offering pre-test counselling or ordering expanded NIPT
testing for a patient:
… if anybody asks me about ordering the 22q deletion or the microdeletions… I
wouldn’t feel comfortable counselling somebody on that and ordering the
microdeletion panel, because that’s definitely out of my scope of practice…as a
family physician to be educating our patients on things that are so, so specific.
[FP-017]
Providers also described their discomfort between the available conditions offered with
private-pay NIPT, compared to what they feel comfortable counselling: “…people can
pay for whatever they want, but …I only feel comfortable ordering a test if I feel
comfortable and capable of interpreting the results and discussing those results with the
patient” [FP-017].

4.2.2.2

Education and Dissemination of Information

Providers mentioned that they learned about NIPT through various methods, including
conferences, meetings, information through their genetics department, continuing
medical education, the Ministry of Health, companies offering the test, specialty
organizations such as the SOGC and word of mouth from other professionals. However,
some of the difficulties prenatal care providers were experiencing with counselling can be
attributed to a lack of dissemination of information. In 2014, OHIP did not publicly
announce its policy to fund NIPT for high-risk women in Ontario. Instead, referral forms
detailing the risk criteria necessary for reimbursement were circulated to specialist
genetics and obstetrics clinics and providers in obstetrical care. This initial dissemination
of information was considered suboptimal by some participants. They described this
dissemination process as “haphazard” [MFM-005]:
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… It’s only by emails… not very widely, through genetics that we were able to
figure out initially that they were covering it for certain indications. Now it’s
fairly clear, but when we were first starting it wasn’t clear what they were
covering and what they weren’t covering… [MFM-005]
Participants discussed experiencing information delays about how new technology is
implemented into practice:
…I always think that it’s sort of something that happens a lot where sometimes
we don’t catch wind of a new change that’s happening. And we don’t adopt it
until a year or two later it seems, for various things, depending on who you work
with, what their interests are, how up-to-date they are. [FP-012]
By 2016, the funding process was more publicized and streamlined in Ontario as MOH
no longer required preapproval for every patient. All participants reflected on how
important it was to have specific information about NIPT readily available in order to
successfully integrate this technology into clinical practice. This information included
NIPT in general, information about expanded testing, and any newly generated
regulations and directives.
Many providers expressed concern that family physicians are not well-versed in NIPT,
and the need for better dissemination of information was emphasized for this group.
Better dissemination strategies were deemed especially important to develop as there is a
“…push to have more family doctors understanding it and offering it…” [R-007]. Indeed,
some participants, including family physicians, discussed how they had expanded their
role in offering NIPT based on the limited resources currently available in genetics. One
family physician described a change in practice in response to this increased demand:
… I think a lot of family docs are just referring. But that’s what I was doing at the
beginning when NIPT was first available, I was referring all my patients. But then
I realized, okay, the genetics clinic cannot accommodate every single person
that’s interested in NIPT because there’s just too many of them, and then that’s
when a lot of the OBs just started ordering it themselves. So, then I realized, okay,
this is something I have to become comfortable with myself as well. [FP: 017]
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Since 2016, many more prenatal care providers are offering pre-test counselling for NIPT
as specialist clinicians are rejecting referrals from cases managed in primary care.
Another obstetrician discussed the importance of family physicians in the initial pre-test
counselling phase: “I don’t do the initial screening, where the family doctor does all the
groundwork… they’re going to be doing the bulk of the counselling, the IPS testing,
etcetera…” [OB/GYN-002]. If any expanded testing was requested from patients, one
family physician noted that he would refer that patient to a genetics professional: “That’s
something that, again, my information, what I need to know is to refer to somebody who
knows more about it and appropriate testing” [FP-011]. Even after the initial conversation
with their patients about NIPT, some family physicians emphasized the importance of
knowing when to make the correct referral.
There was an expressed need for current regulations and directives to be made more
transparent and easily accessible to providers. Providers also emphasized a need for more
transparency with the development of policies and guidelines surrounding NIPT:
To some extent, it seems like a big black box to those of us who aren’t privy to
how it all comes out. And it just seems weird. You’re like, I know why I’m not
involved … this is actually a conversation family doctors, in particular, are having
every day. I think it just seems a little bit more cloaked than it needs to be. Just a
bit more transparency, I guess, is what I’m saying. [OB/GYN-004]
Providers noted how difficult it was to remain updated about ongoing NIPT policies and
guidelines changes. One provider noted that clinical guidelines for NIPT have: “…no
clear indication of where to go for newer information or the best place for new
information…,” which was important, “especially with something so rapidly changing
like this” [Resident-007]. This provider recommended that a “fantastic addition” to the
SOGC website would be the indication of where to go for NIPT's newest, most up-to-date
information. Another provider used Cancer Care Ontario as an example of an
organization that effectively disseminated information. New screening guidelines were
distributed via a pamphlet in paper-based and electronic formats [FP-017].
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Ongoing education was an essential piece that providers relied on to counsel their
patients about NIPT and its ever-changing landscape. Some participants described their
knowledge surrounding NIPT as being at a “surface-level” [MW- 015] and admitted
having limited knowledge about specific information on this technology, such as the
testing’s limitations and how well NIPT performs in comparison to other prenatal tests.
I think I have enough of a knowledge base that I’d be able to say something
coherent to a patient in a way that they would leave feeling a little bit understood.
But in terms of the sensitivities and expressivity of those tests and what that
means, I was very honest with the patient yesterday, and I said, ‘I don’t know
much about that,’ but she still wanted to go ahead and order the test. [FP-17]
This inadequate knowledge is especially relevant as participants expressed concern that
family physicians were not well-versed in NIPT and that better dissemination of
information to this particular group could enhance the inadequate counselling observed.
Providers revealed a preference for in-person educational methods and electronic formats
to receive up-to-date information about NIPT. Those who could attend conferences and
other educational opportunities within their professional organizations appreciated these
forms of ongoing education. Others suggested creating outreach programs for primary
healthcare providers or using pre-existing ones (annual clinical days or pharmaceutical
days) to inform a larger portion of providers about NIPT in the community: “…So then
you can reach a lot of people, and even if you don’t reach everybody, well, you’re
reaching a colleague of those other people who will then talk about it” [FP-012]. Other
providers wanted more electronic forms of communication, especially for those
colleagues who are unwilling or unable to attend educational sessions in person.

4.2.2.3

Importance of Genetic Professionals

Some participants described how genetic professionals were integral in educating and
disseminating information about NIPT and emphasized how ongoing support is required
as testing options continue to expand. Some participants would refer their patients to a
genetic professional, such as a genetic counsellor, for further information on NIPT. The
time of referral to a genetics professional differed between providers. Some participants
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would automatically refer any patients interested in NIPT (it is important to note that this
represents practice at the time of these interviews, in 2016. Genetic clinics in Ontario no
longer accept referrals for cases that meet criteria for NIPT set by the MOH (Category
I)). Other providers would only refer if a patient had a positive screening result and/or
adverse findings on ultrasound. Others said they would only refer to genetics if the result
revealed something beyond common aneuploidies or outside their scope of practice. For
example, when discussing pre-test counselling for fetal SCAs, one obstetrician stated the
importance of specialized counselling for this indication:
I think it speaks to why it thus far has been in the hands of a very sub-group... I
think it becomes very challenging for parents to understand that information,
certainly in a small amount of time, and make educated decisions. It would be
very dependent on the practitioner sharing the information with them. [OB/GYN004]
Another provider discussed the logistical reasons as to why genetic professionals should
be involved with these kinds of cases: “…I think for something like Klinefelters, for
instance, that would be something more that genetics should follow up with because there
may be additional testing for the child as they get older that needs to be done through
paediatrics” [MFM-003].
Many providers discussed that in addition to taking referrals, genetic professionals play
an important role in providing education about NIPT to providers in other medical
disciplines. Some of them discussed personal experiences in which they received
information about NIPT rollout from the genetics department. Many providers who
worked in locations in close proximity to a genetics department appreciated having the
support:
I don’t think I would change the way we’re educated on it because we’re very
lucky that we have that good … that they’re right down the hallway, and we can
talk to them about it, and stuff like that. Because they know what’s going on, on a
daily basis, in terms of changes… [RN-013]
Some participants felt that genetic professionals play an important role in the ongoing
education of NIPT for many prenatal care providers and could offer guidance on NIPT
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regulations. Another provider noted that “…hallway consults…[were] very helpful”
[OB/GYN-010] to be kept informed. The next chapter will discuss the results, followed
by implications for practice and future research.
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Chapter 5

5

Discussion

The model “prenatal care providers’ involvement with pre-test counselling for NIPT in
Ontario” describes the unique pre-test counselling process experienced by Ontario
prenatal care providers and the ongoing support required to fulfill their expanding role in
prenatal genetics. Providers discussed how they engage patients in decision-making about
NIPT and the ethical and practical challenges that created barriers to counselling on
NIPT. In turn, these barriers inform regulations, guidelines, education and support
required to improve this counselling process. This chapter describes how the study
contributes to the existing body of knowledge on prenatal care providers’ experience with
NIPT in clinical practice and details implications for clinical practice and future research.

5.1

Pre-test Counselling for NIPT Considerations

Prenatal care providers discussed navigating pre-test counselling as a frontline healthcare
professional in a landscape where NIPT is rapidly evolving. In this study, prenatal care
providers discuss ethical conflicts and difficulties with providing counselling in an
already busy prenatal session while struggling to remain educated and informed of
ongoing updates. This study also provides an in-depth analysis of prenatal care providers’
experience with pre-test counselling for NIPT for conditions beyond traditional
aneuploidies, a process traditionally outside their scope of prenatal counselling. Although
there has been an increase in the number of prenatal care providers who offer NIPT since
these interviews were conducted in 2016 (Dragojlovic et al., 2021; Burgess et al., 2020;
Bellai-Dussault et al., 2020), many of these ethical considerations remain.

5.1.1

Ethical Considerations

A significant finding of this study is the tension prenatal care providers feel towards
offering NIPT for screening beyond traditional aneuploidies, such as non-medical sex
determination, sex selection, SCAs and microdeletion syndromes. Providers feel unease
about using NIPT for these additional purposes due to conflicting personal and
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professional values and ethical principles. For example, many participants were worried
that NIPT would be used for sex identification or sex selection, which they considered
inappropriate use of this technology. Other providers and medical ethicists have
expressed concerns that NIPT is being used for these purposes as well (Alexander et al.,
2015; Mozersky et al., 2017; Toews & Caulfield, 2014; Chapman & Benn, 2013;
Nuffield Council on Bioethics, 2017; Allyse et al., 2015; Benn, 2014; Bowman-Smart et
al., 2020; Chapman & Benn, 2013; Bennett & Whiting, 2018; Agatisa, Mercer,
Coleridge, et al., 2018; Orr-Ferdinand, 2021).
The use of NIPT to determine fetal sex may be in focus for some of these participants as
they could encounter low-risk patients motivated to use NIPT for this reason alone. NIPT
for sex determination is attractive to low-risk patients as fetal sex can be reported earlier
than ultrasound and it is safer than invasive techniques such as CVS (Colmant et al.,
2013; Agatisa, Mercer, Coleridge, et al., 2018; Flynn, 2018). This strong desire to know
the sex of the fetus among patients may be due to bonding and planning purposes, as
previous studies have shown that knowing the fetal sex helps strengthen the parental
bond with the fetus early in pregnancy (Shipp et al., 2004; Burke, 1992). As an example
of people’s interest, NIPT’s use for sex determination is a featured frequently asked
question on the Lifelabs website for PanoramaTM (LifeLabs, 2021). Indeed, companies
like SneakPeak® have capitalized on this interest and offer NIPT screening for fetal sex
early in pregnancy and marketed towards low-risk individuals (SneakPeak, 2021).
Canada specifically does not have any law prohibiting abortion, including abortions for
sex selection (Law Library of Congress, 2020). Two providers in this study noted that
individuals in Canada might have cultural beliefs favouring sex selection. A strong
preference for a male child could be due to religious reasons in some cultures (Borooah
& Iyer, 2004; Arnold & Zhaoxiang, 1986), a belief that there is better treatment available
for the mother and son, or a son would have higher status within the family (Rogers et al.,
2007). Patients report that they would choose, and have utilized, NIPT solely for nonmedical sex determination and sex selection (Farrell, Agatisa & Nutter, 2014; Sahlin et
al., 2016; Crabbe et al., 2019; Bennett & Whiting, 2018; Bowman-Smart et al., 2020). In
addition, there is evidence that abortions have occurred for sex selection in specific

87

communities in Canada (Solomon, 2007; Urquia et al., 2016; Yasseen & LacazeMasmonteil, 2016).
Reproductive autonomy is a crucial aspect of prenatal screening in Canada and refers to
the right of an individual to decide and control their own reproductive decisions (Haidar
et al., 2018). Some providers in this study struggled with withholding information about
fetal sex based on this reproductive right. Orr-Ferdinand (2021) conducted an anonymous
online survey in 2020 consisting of open-ended questions to learn about U.S. genetic
counsellors’ experiences of counselling patients who intended to use NIPT towards nonmedical sex selection. These counsellors also emphasized the importance of patient
autonomy when considering NIPT for this purpose (Orr-Ferdinand, 2021). Proponents of
procreative liberty also argue that sex selection is a practice of reproductive autonomy as
an individual has the right to choose the sex of the fetus to fulfill an individual’s social
and familial needs (Puri & Nachtigall, 2010; Robertson, 2003; Seavilleklein & Sherwin,
2007; Wertz & Fletcher, 1998).
Based on this tension, one participant stated they felt “lucky” that they do not practice in
a geographical area in Canada where they would have to face patients interested in sex
selection. Another participant reportedly deals with this discomfort by withholding
information during pre-test counselling that NIPT can detect fetal sex. Similarly, in a
survey of obstetric physicians from the United States, not all respondents discussed fetal
sex detection with their patients (19% never/rarely and 15% sometimes) (Farrell et al.,
2016). In contrast, none of the genetic counsellors from the Orr-Ferdinand (2021)
interview study denied patients access to fetal sex information. This difference could
represent a growing comfort in providers discussing NIPT for sex selection from 2016 to
2020. This distinction could also be due to variations in how healthcare professionals
handle these conversations. Genetic counsellors from the Orr-Ferdinand (2021) study
reportedly compartmentalize their conflicting personal values to prioritize a patient’s
reproductive autonomy. Strategies like these may be essential to discuss with prenatal
care providers to reduce stress and increase preparedness for discussing NIPT for nonmedical sex selection.
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Prenatal care providers’ discomfort with using NIPT for non-medical fetal sexing can
also create a divide in communication between these healthcare professionals and their
patients. Studies have shown that some patients using NIPT for non-medical sex
determination often do not share their intentions with medical professionals caring for
them (Bennett & Whiting, 2018; Bowman-Smart et al., 2020; Crabbe et al., 2019). As
many providers in the current study were concerned about using NIPT to screen for fetal
sex for non-medical reasons, pregnant individuals may withhold this motivation from
their clinician based on fear of being judged for their decision to use NIPT for this
purpose.
Some providers also felt uncomfortable with the idea of offering NIPT for screening for
SCAs and microdeletion syndromes. Three participants in this study described this
scenario as opening up a can of worms. This phrase emphasizes the ethical complexity
involved when considering these expanded indications for NIPT. For example,
beneficence is the ethical practice of using professional judgment and evidence to assess
the benefits of performing a genetic test against the potential harm it could cause their
patients (Beauchamp & Childress, 2001; Meulen, 2005). In line with this ethical
principle, participants considered the potential benefits and harms of implementing NIPT
for SCAs and microdeletions in current and future contexts.
Participants struggled with the prospect of offering NIPT to use for expanded conditions
based on the lack of perceived benefits to testing. The Society for Maternal-Fetal
Medicine (SMFM), the American College of Obstetricians and Gynaecologists (ACOG),
and the American College of Medical Genetics and Genomics (ACMG) organized a
workshop in 2017 for members from several professional organizations and commercial
laboratories to discuss the goals of prenatal genetic testing (Norton & Wapner, 2018).
From this discussion, participants expressed that genetic screening and testing should
improve perinatal outcomes for patients and their families (Dukhovny & Norton, 2018).
Participants of this current study may feel that there is not enough information about
conditions such as SCAs and microdeletions that would change the overall clinical
outcome for these patients. Guidelines reinforce the use of NIPT for clinically significant
conditions only. International Society of Prenatal Diagnosis states that: “…[NIPT]
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should be limited to clinically significant disorders with a well-defined severe
phenotype” (Benn et al., 2013, p.730). In addition, ACMG recommends informing all
pregnant individuals of the availability of the expanded use of NIPT to screen for
“clinically relevant” chromosome abnormalities (Gregg et al., 2016, p.6).
Providers questioned the clinical usefulness of screening for conditions with unclear
phenotypes. The concern for providers seemed to be that testing would bring up more
questions than answers perceived as pertinent to screening. Likewise, researchers have
raised caution that the drive for microdeletion screening is due to feasibility and genotype
rather than clinical need (Hashiloni-Dolev et al., 2019; Di Renzo et al., 2019).
In contrast, a few providers expressed optimism about using NIPT to gain more
information about the fetus in the future; this was also a goal shared by other prenatal
care providers when asked their opinions regarding the expansion of NIPT to include
microdeletions (Gammon et al., 2016; Kim et al., 2018). A more recent survey of
European prenatal care providers indicated that, although the current use of expanded
panels is relatively low, there is a strong interest in the future use of expanded panels for
select microdeletions (such as 22q11.2, Prader Willi-Angelman, Cri du Chat, WolfHirschhorn, and 1p36), followed by whole autosome aneuploidy and subchromosomal
copy number changes at the resolution of standard karyotyping (≥7 Mb) (Benachi et al.,
2019).
The perceived potential for expanding NIPT use could be due to a belief that the severity
of these syndromes justifies screening. For example, although microdeletion syndromes
can have variable phenotypes, they can also result in physical and intellectual
impairments that could be more severe than traditional aneuploidies (Wapner et al., 2015;
Chitty et al., 2018). Provider interest in obtaining additional information about the fetus
could result from the ever-evolving prenatal and postnatal interventions steering towards
NIPT being beneficial for these conditions (Dukhovny & Norton, 2018; National
Research Council, 2001; Di Renzo et al., 2019; Handleman & Harris, 2005). Therefore,
the prenatal screening and testing focus could change from screening for potentially
untreatable disorders for information purposes only or possible pregnancy termination to
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identifying conditions within fetuses that would benefit from an early diagnosis
(Dukhovny & Norton, 2018).
Some participants struggled with gatekeeping what other disorders should be screened for
beyond traditional aneuploidies, partly due to their belief in reproductive autonomy.
Disability activists argue against the assumption that the presence of a disability, in the
context of a chromosomal anomaly, is automatically considered severe harm a child or
potential child (Owen et al., 2020). From this ethical perspective, the concept of clinical
significance for patients can be broader and highly context-dependent compared to what
medical professionals may believe is clinically useful and actionable (Jamal et al., 2017).
Consequently, using NIPT to screen for expanded conditions is a legitimate exercise of
reproductive choice. Many individuals may also want to know as much as they can about
the fetus (Riedijk et al., 2014; van der Steen et al., 2015) regardless of their risk status
(Hochner et al., 2020). These desires could include the need to know about conditions
beyond common aneuploidies (van der Steen et al., 2018), such as fetal sex, conditions
with uncertain implications or late-onset conditions (Benn & Cuckle, 2014; Farrimond &
Kelly, 2013). There are concerns that the action of health services qualifying choice to
“serious disorders” does not adequately reflect the diverse reproductive choices that
individuals may wish to make if given the opportunity (Dondorp et al., 2015; de Jong &
de Wert, 2015; Stapleton, 2017; Munthe, 2015).
Clinical guidelines and expert groups also emphasize patient autonomy in decisionmaking. For example, ACMG states: “patient preferences for information should play a
pivotal role in guiding the use of [NIPT] in prenatal care” (Gregg et al., 2016, p.3).
Therefore, as this technology is available, and patients become aware of this as an option
in prenatal testing, denying individuals available testing is difficult to justify ethically
(Chitty et al., 2018; Geeter, 2015). Indeed, omitting information about SCAs and
microdeletions in a pre-test counselling session could be considered paternalistic and a
way to restrict patient autonomy (Mcgillivray et al., 2012). In line with this belief, other
healthcare professionals have reported offering NIPT for microdeletions and SCAs to
give patients autonomy of choice (Yang et al., 2020; Flynn, 2018).
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Notwithstanding, the concept of reproductive autonomy addresses only the individuals’
choice and disregards the social, economic, and organizational context in making
screening decisions. In analyzing the concept of reproductive autonomy for NIPT through
a social lens, participants may have also been cautious about using NIPT for expanded
reasons through the lens of a public screening program. Other experts have noted that a
publicly funded prenatal screening program promoting complete reproductive autonomy
is impractical due to resource constraints (Munthe, 2015; Donley et al., 2012; Schmitz et
al., 2009; Harper & Clarke, 1997; de Jong & de Wert, 2015; Wilkinson, 2015).
Providers were also worried about NIPT stumbling into “scary” territory and wondered
what the limits to this testing should be from a societal perspective. It is important to
consider the wider societal inequalities and injustices when developing guidelines,
policies, and regulations pertaining to NIPT (Shakespeare et al., 2017). For example,
experts are concerned that the potential for non-medical sex selection promotes gender
discrimination and gender essentialism (Browne, 2017; Chapman & Benn, 2013; King,
2012; Seavilleklein & Sherwin, 2007; World Health Organization, 2011). Disability
activists state that prenatal screening such as NIPT may imply a discriminatory message
to people living with specific diseases (Dondorp et al., 2015; Shuster, 2007; The German
Ethics Council, 2013; Wertz et al., 2003; International Bioethics Committee, 2015). They
caution how the expansion of NIPT can reinforce the medical model that disability itself,
not societal discrimination against people with disabilities, is the problem to be solved
(Owen et al., 2020).
Still viewing screening through a social lens, participants were concerned that NIPT
screening could lead down a “slippery slope” towards the quest for a “perfect child” with
society practicing eugenics and aiming for “designer” children (Newson, 2008; Chachkin,
2007; Ma et al., 2013). The powerful slippery slope metaphor conjures the visual of a
slow descent, and participants described the feelings of sliding downwards towards using
NIPT for additional conditions as a “complicated” and “loaded” process. The slippery
slope argument towards new technology plays an essential role in medical law and ethics
(de Jong et al., 2010). This argument presents the position that if all groups involved
allow one seemingly harmless act or process to occur, this creates an opportunity to slide
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down a dangerous path towards a disastrous outcome (Walton, 2015). As NIPT has the
potential to detect many different conditions, disability activists argue it has an acute
potential of being eugenic (Glover, 2008; Parens & Asch, 2000). Similarly, healthcare
professionals in Quebec, interviewed to explore their perceptions and views regarding
issues raised by NIPT, raised concerns that this technology could be used for eugenic
purposes (Haidar et al., 2020). Eugenics in this context refers to techniques and policies
that allow for the reduction of children born with “undesired” attributes while promoting
the reproduction of people with “desired” attributes (Thomas & Rothman, 2016).
Opponents of non-medical sex selection contend that sex selection is the start of this
slippery slope, which could open the door for NIPT being used for other non-medical
reasons (Chapman & Benn, 2013; Dondorp et al., 2013; Yu, 2015; Alexander et al.,
2015). As NIPT has the potential to detect many different conditions, disability activists
argue it has an acute potential of being eugenic (Glover, 2008; Parens & Asch, 2000).
Similar to the fear of discussing NIPT for sex selection, prenatal care providers in our and
previously published studies raised the concern of eugenic practices with NIPT
technology in particular (Bianchi et al., 2015; Bryant et al., 2006; Lewis et al., 2012a),
and are afraid of navigating an ever-expanding test menu of conditions. A discomfort
with the future of expanded screening options for NIPT highlights the need for additional
regulations and support for providers who continue to play a more prominent role in pretest counselling for these morally complex topics.
Prenatal care providers in our study also struggled with gatekeeping who should be
offered NIPT. Counsellors from Orr-Ferdinand’s (2021) study valued the ethical
principle of justice and did not want to act as a gatekeeper of NIPT and wanted to treat all
patients in the same way regardless of their motivations for testing (Orr-Ferdinand,
2021). The principle of justice in the context of prenatal screening relates to equal access
to prenatal screening for all pregnant individuals (Kater-Kuipers, de Beaufort, Galjaard,
et al., 2018). It is perhaps due to this belief that many participants in this study, along
with other providers, emphasize the importance of all individuals having access to NIPT
and are willing to offer this test to low-risk individuals (Horsting et al., 2014; Musci et
al., 2013; Hui et al., 2015; Benn et al., 2014; Silcock et al., 2015; Tamminga et al., 2015;
Weingarten, 2016; Ahmed et al., 2017; Martin et al., 2018; Kim et al., 2018; Ngan, 2018;
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Di Gioacchino et al., 2019; Suskin et al., 2016; Ngan et al., 2017; Haymon et al., 2014).
Participants in this study believed that private pay is a way to provide access while still
maintaining a practical public funding model. Likewise, many genetic counsellors (65%)
decided that discussing private pay options within a publicly funded healthcare system
was ethical, based on patient autonomy (Di Gioacchino et al., 2019).
Some prenatal care providers in this study discuss NIPT with all individuals, with the
caveat that some may not be eligible for public funding. This practice is contrary to many
guidelines relevant in 2016 which did not recommend NIPT as a first-tier test in averagerisk pregnancies due to the lack of performance data available for this population
(Langlois et al., 2013; Wilson et al., 2013; ACOG-SMFM, 2015). However, around the
time of these interviews, studies had emerged which reported high sensitivity and
specificity for NIPT in the general population (Song et al., 2013; Pergament et al., 2014;
Dan et al., 2012; Nicolaides et al., 2012; Bianchi et al., 2014; Norton et al., 2015; Bianchi
et al., 2012; Dar et al., 2014; Zhang et al., 2015). Unlike other professional statements,
the American College of Medical Geneticists and ISPD did not limit NIPTs use to
individuals at increased risk for aneuploidy (Gregg et al., 2013). ISPD’s position
statement released in 2015 stated that NIPT should be offered as a primary test to all
pregnant individuals. They noted that individuals “…perceive risk differently, [and] may
prefer particular approaches or may choose to finance their testing personally. Patient
requests for testing that falls outside recommendations should not be the sole basis for the
denial of testing” (Benn et al., 2015, p.732). Providers in this study may have been aware
of these studies, and felt comfortable discussing NIPT with all individuals based on the
individual’s own interest in testing.
Marketing materials at the time may have also influenced providers to offer NIPT to a
wider target population. Vanstone, Yacoub, Winsor, et al. (2015) used inductive
qualitative content analysis to examine how NIPT is constructed using informational
documents, including professional statements and manufacturer information for providers
and laypeople. A major finding from this study was that while many professional
statements at the time described NIPT for use in a high-risk population only,
manufacturer information described a much wider target population. This information
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included ambiguous or vague statements that allude to NIPT being used for any pregnant
or any pregnant individual who may be interested (Vanstone, Yacoub, Winsor, et al.,
2015). NIPT's potential worldwide net market worth has been measured in billions of
dollars (Marketers Media, 2022; Fortune Business Insights, 2021; Renub Research,
2022). This value creates a considerable incentive to frame the clinical use of this testing
as beneficial to the broadest cohort of users possible (Murdoch et al., 2017). As a result,
companies advertise NIPT as a first-tier screen for all pregnant women in order to
increase the market size (Heger, 2014).
Participants in this study may have offered NIPT to all individuals based on the growing
evidence that the testing can be applied to low-risk individuals and to uphold ethical
principles of reproductive autonomy and justice, despite policy recommendations at the
time. They may have also been influenced by manufacturer messaging, which promoted
the use of NIPT for a wider target population. This practice highlights the gap in practice
and policy that can occur due to a rapidly evolving technology and the importance of
remaining current with ongoing changes to NIPT. Eventually, other clinical guidelines
were updated after these interviews, which now recommend offering NIPT to all
pregnant individuals, regardless of risk status (Audibert et al., 2017; Gregg et al., 2016;
ACOG-SMFM, 2020). For example, SOGC-CCMG updated practice guidelines released
in 2017 recommend that pre-test counselling should include offering all individuals NIPT
where available, “with the understanding that it may not be provincially funded”
(Audibert et al., 2017, p.806).
A similar path seems to be occurring for offering expanded panels for NIPT. Although
guidelines currently do not recommend routine NIPT screening for fetal microdeletions
(Gregg et al., 2016; ACOG-SMFM, 2020; Audibert et al., 2017), some providers in this
study believe that patients should have access to these screening options based on its
availability. Clinically relevant microdeletions and duplications occur in greater than 1%
of all pregnancies regardless of a person’s aneuploidy risk (Nussbaum et al., 2007).
Therefore, some experts suggest that all individuals should be offered expanded testing
(Wapner et al., 2015; Wapner et al., 2012). Manufacturer information also promotes
using these expanded panels for a wider target population, based on the fact that
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“…microdeletions occur in pregnancies at the same rate for mothers of any age” (Natera,
2021a, p. 3). Although professional position statements currently do not recommend
routine NIPT screening for expanded panels, providers may feel the need to uphold
reproductive autonomy and justice principles and offer expanded screening to a wider
target population. Therefore, professional position statements should provide guidance on
how to counsel for expanded screening, given its current availability and use.
Unfortunately, not all individuals can pay for NIPT privately, and therefore equity of
access becomes a significant concern (Hui et al., 2015; Benn & Chapman, 2016; BellaiDussault et al., 2020; Rink & Kuller, 2018). Participants were troubled that not everyone
who wants testing has access to it due to costs. Equity of access has been a concern for
other providers in Quebec (Haidar et al., 2020), the United States (Allyse et al., 2015) and
other countries (Yi et al., 2015; Ngan et al., 2017; Kater-Kuipers, Bunnik, De Beaufort, et
al., 2018; Filoche et al., 2017). Patients from Ontario have suggested additional
government funding to alleviate these inequalities (Vanstone et al., 2018; Vanstone,
Yacoub, Giacomini, et al., 2015; Haidar et al., 2018). However, some patients
acknowledge that using additional public funds for NIPT could send a message that the
government encourages testing uptake. In turn, funding may hinder patient autonomy and
make individuals feel that participation is expected (Haidar et al., 2018; van Schendel et
al., 2017; Farrell, Mercer, Agatisa, et al., 2014). In addition, several scientific societies
and health technology assessments have also argued against NIPT as a first-tier test due
to a lack of unbiased and clear evidence that first-tier NIPT would be a good use of health
care funding (UK National Screening Committee, 2015; Canadian Agency for Drugs and
Technologies in Health, 2014). For example, Health Quality Ontario assessed the costeffectiveness of NIPT as a first-tier test in an average-risk population. The authors
concluded that NIPT was not yet financially viable as a publicly funded first-tier test for
the average-risk population, as it would lead to a substantial increase to the Ontario
Healthcare budget of $35 million per year in 2017 Canadian dollars (Health Quality
Ontario, 2019a). Lastly, public funding is not financially feasible to cover all expanded
options. One participant noted the moral conflict with some individuals having access to
expanded panels through private pay, while others cannot afford this option. This
dilemma may become more pronounced as options for NIPT expand, and providers will
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have to decide whether they are comfortable discussing private-pay options with all
patients.
Pregnant individuals largely prefer their information about NIPT comes from clinician
counselling (Agatisa et al., 2015; Farrell, Agatisa & Nutter, 2014; Lewis et al., 2013; Lau
et al., 2016; Agatisa, Mercer, Mitchum, et al., 2018; Farrell, Agatisa, Mercer, et al.,
2015). However, participants from this study were concerned that other prenatal care
providers are not spending enough time to appropriately counsel patients on NIPT,
resulting in patients making uninformed decisions about testing. Prenatal care providers
have expressed similar concerns in Hong Kong, Pakistan, and the Netherlands (Ngan et
al., 2017; Ahmed et al., 2017; Kater-Kuipers, Bunnik, De Beaufort, et al., 2018). For
example, 90% of Hong Kong obstetricians and midwives indicated that they were
“somewhat” or “extremely” concerned about the lack of pre-test counselling that occurs
for NIPT (Ngan, 2018). Assessment surveys and qualitative interviews with patients
confirm that the content of initial discussions about NIPT may not be sufficient to meet
their reported information and decision-making needs (Piechan et al., 2016; Constantine
et al., 2014; Lewis et al., 2016b; Farrell, Agatisa & Nutter, 2014; Lewis et al., 2013;
Agatisa et al., 2015; Farrell, Agatisa, Mercer, et al., 2015; Lau et al., 2016). There is a
reported lack of communication from providers to patients about the benefits, limitations,
and follow-up during the pre-test counselling process (Piechan et al., 2016; Spelten et al.,
2015; Samura, 2020; Martin et al., 2015).
After receiving referrals from the community, providers from this current study describe
encountering frustrated patients who were improperly counselled and, as a result,
erroneously believed that NIPT is a diagnostic test. These accounts correspond to other
reports regarding patients who have not been counselled adequately about NIPT by their
prenatal healthcare providers. For example, panelists from patient advocacy groups
reported that their organizations often receive panicked messages from patients with
NIPT screen positive results that they understood as definitive from their providers
(Meredith et al., 2016). Notably, our findings highlight providers’ concerns that family
physicians specifically do not spend enough time discussing NIPT with their patients.
This was even discussed by midwives and the nurse practitioner who were interviewed
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for this current study. Family physicians in this study confirmed the challenges of
prioritizing information in an otherwise busy prenatal visit. Patients have also reportedly
been disappointed by family physicians’ incomplete and inconsistent information
(Vanstone et al., 2018; Lewis et al., 2012a). This concern is increasingly relevant based
on the surge in family physicians in Ontario who have been offering NIPT to patients
since 2016 (Dragojlovic et al., 2021; Burgess et al., 2020).
A lack of adequate pre-test counselling for NIPT becomes a burgeoning concern with the
expansion and complexity of available screening options. For example, the PanoramaTM
baseline NIPT panel has no opt-out option for sex chromosome abnormalities and
triploidy (Natera, 2021a). Therefore, patients must receive the proper counselling to
understand the possibility of all results. Other test options include the baseline NIPT
panel and screening for 22q11.2 deletion syndrome or the entire microdeletion extended
panel. The first conversation with their prenatal care provider about prenatal testing may
involve navigating these options. Consequently, with the variety of testing now available,
it is crucial that appropriate pre-test counselling occurs to ensure patients are informed
about the benefits and limitations to each before deciding to undergo testing.

5.1.2

Difficulties Experienced with Pre-test Counselling

Participants emphasized how challenging it was to fit in pre-test counselling for NIPT
and prenatal testing in a busy prenatal session. Professional societies recommend
discussing aneuploidy screening and diagnostic testing with all pregnant individuals as
early as possible (ACOG-SMFM, 2020, Audibert et al., 2017; Benn et al., 2015; Chitayat
et al., 2017). In addition, prenatal genetic screening is often offered to all patients at the
first prenatal visit (Colicchia et al., 2016; Farrell et al., 2016). However, participants in
this current study consider these initial visits information heavy. Early pregnancy visits
usually include detailed physical assessments and in-depth discussions surrounding a
patient's medical history (Best Start, 2020; Heathy Families BC, 2012). Genetic
counsellors in the U.K. expressed concerns that other prenatal care providers cannot
provide adequate counselling within the context of this already overstretched service
(Alexander et al., 2015). Notably, primary care providers who engage in generalist
practice in this current study, found pre-test counselling for NIPT challenging based on
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the small part in their overall practice it played and the little time available to cover a
large amount of information. In a recent survey of primary care providers from the
United States, only 20% said they had sufficient time in their practices to counsel patients
about genetic risk for disease (McCauley et al., 2017). One midwife in this present study
noted that family physicians’ time might also be limited given the large volume of
patients they may see. Indeed, a recent survey reported that primary care physicians in
Canada saw a median of 100 patients per week in 2019 (Canadian Institute for Health
Information, 2020). Therefore, competing priorities in an otherwise busy prenatal session
can impede prenatal care providers’ ability to engage patients in decision-making about
NIPT.
Other providers have identified the time constraints of a clinical encounter as a barrier for
informed decision-making for NIPT and other prenatal testing options (Minkoff &
Berkowitz, 2014; Lewis et al., 2013; Gammon et al., 2018; Gammon et al., 2016; Ngan,
2018; Burgess et al., 2020; Filoche et al., 2017; Farrell et al., 2016; Benachi et al., 2019;
Alexander et al., 2015; Suskin et al., 2016). Pregnant individuals agree that the time
available for consultation is not sufficient for thorough counselling (Lewis et al., 2013),
and patients call for more information about NIPT from clinicians (Lewis et al., 2016b;
Farrell, Mercer, Agatisa, et al., 2014; Lewis et al., 2013; Agatisa et al., 2015; Farrell,
Agatisa, Mercer, et al., 2015; Lau et al., 2016). Individuals who had undertaken NIPT in
Hong Kong noted in interviews that they often had various questions and concerns that
went unaddressed due to the short appointment time with their provider (Lau et al.,
2016).
Professional societies state that pre-test counselling should be performed in a manner
“which allows patients sufficient time to understand information and make informed
decisions regarding testing…” (American College of Obstetricians and Gynecologists,
2017, p.1). Obstetricians and Gynaecologists from Australia and New Zealand have
indicated that 15 minutes is an appropriate length of time for pre-test counselling (Filoche
et al., 2017). In reality, the time spent on pre-test counselling is far less. In a survey of
South Korean obstetricians (n=203) regarding attitudes and practices of prenatal
screening and NIPT, two-thirds of respondents spent between 1 to 5 minutes on prenatal
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counselling for fetal aneuploidy (Kim et al., 2018). In addition, providers may not be
covering all recommended counselling points. A qualitative study by Colicchia et al.,
2016 analyzed transcripts and audio recordings of 210 obstetricians' first prenatal visits
and found that only 1.5% of these providers covered all ACOG-recommended points for
prenatal screening during the first prenatal visit (American College of Obstetricians and
Gynecologists, 2007) and these sessions lasted less than 2 minutes (Colicchia et al.,
2016). These results confirm prenatal care providers' challenges with prioritizing NIPT
counselling, among other topics, within the limited time allotted for an early prenatal
visit.
Despite the importance of this initial conversation, some prenatal care providers note how
it can be difficult to make patients receptive to having this discussion. This challenge
may be in part due to what Mishler (1984) describes as communication between two
distinct worlds, including the biomedical world of physicians and the “life-world” of
patients (Hunt et al., 2005, p.303). These differences in perspectives have been described
as a “different language” (p. 303) being spoken between clinicians and patients by Hunt
and colleagues (2005). As part of their everyday clinical work, prenatal care providers are
primarily concerned about identifying and preventing health issues (Kleinman, 1980;
Cohen et al., 1994). In contrast, patients exist in a world where health and illness are
highly context-specific and rooted within their personal life histories, as well as their
social and environmental situations (Hunt & Arar, 2001). Participants in this study, along
with bioethicists, note that prenatal screening is often introduced within the context of the
first prenatal visit while patients may still be adjusting to the news of a pregnancy (Allyse
et al., 2013). During this time, individuals and their partners may also be experiencing
feelings of joy, happiness, and pleasurable future expectations about their pregnancy and
anticipated child (Kleinveld, 2008; Lou et al., 2017). Primary care providers recognize
that a patient’s primary focus might be the overall protection and nurturance of their
pregnancy.
Based on these competing priorities, it is not surprising that participants struggle to
discuss prenatal screening during one of the first prenatal visits. Providers noted how
screening creates the possibility that something could be wrong with the fetus and,
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therefore, may be an unwelcome serious conversation during this time in pregnancy.
Similarly, when discussing screening, some women have noted that they declined
screening because they “did not think about it at all” (Bakkeren et al., 2020, p. 115) or
did not want to think about what to do with a possible abnormal test result (García et al.,
2008).
This study provides insight into the challenges prenatal care providers face with initiating
the prenatal screening conversation while juggling various tenets of prenatal care within
the same prenatal visit. Participants describe their initial discussion about a patient’s
pregnancy as a conversation that shifts into biomedical knowledge and evaluation, which
can devalue a woman’s “embodied knowledge” (Lou et al., 2017, p. 1321) and
experience of pregnancy (Remennick, 2006). A patient’s overall reception of NIPT and
how this technology has the potential to alter the broader patient experience of pregnancy
is an area of research that has not received a lot of attention (Alexander et al., 2015). The
need to discuss screening early in pregnancy with patients, especially NIPT, adds further
complexity to this initial prenatal visit. Currently, professional society documents focus
on NIPT counselling alone, giving very little guidance on approaching this conversation
in the broader context of a prenatal screening visit.
Based on the previously discussed time constraints and competing priorities, providers
were cautious about sharing too much information during pre-test counselling about the
incidental findings that can occur with NIPT. Although providers believed it was
unethical to withhold incidental findings from patients after testing, they did not discuss
the possibility of these results in their pre-test counselling. Providers may have felt that
this information fell beyond the scope of a routine prenatal session and could overwhelm
patients. Guidelines available at the time of these interviews were variable in how they
discussed incidental findings for NIPT. Some guidelines only mentioned that incidental
findings could occur with this testing (ACOG-SMFM, 2015; Gregg et al., 2013).
However, others directly stated that pre-test counselling for NIPT should include the
possibility of unexpected findings (Benn et al., 2015; Sachs et al., 2015). Since these
interviews, other guidelines have been updated to discuss the importance of pre-test
counselling for incidental findings (Audibert et al., 2017). For example, ACMG states:
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“Although it is not the purpose of [NIPT] to identify clinically relevant maternal genomic
information, patients and providers should be aware of the potential for inadvertent
discovery of such information…” (Gregg et al., 2016, p.7).
Information overload is an identified risk of pre-test counselling, where individuals can
become burdened by the amount of information and choices offered (Bunnik et al., 2013).
Indeed, when clinicians present too much information in too short of a time, patients can
feel overwhelmed (Farrell, Agatisa & Nutter, 2014; Lewis et al., 2014; Barr & Skirton,
2013; Piechan et al., 2016; Agatisa, Mercer, Mitchum, et al., 2018), which can confuse
and overload the patient and ultimately hinder the decision-making process (Chervenak
& McCullough, 2014; Dondorp et al., 2016; Stapleton, 2017; Farrell, Agatisa & Nutter,
2014). Orta (2016) specifically designed a survey for members of the NSGC to
investigate Genetic Counsellors' clinical practice surrounding incidental findings for
NIPT. Half of the counsellors (56%) indicated that they do not always include the
possibility for incidental findings in their pre-test counselling as this information further
complicated pre-test counselling (Orta, 2016). Information overload in patients is a
significant challenge to address in pre-test counselling, especially as NIPT screening
expands and exacerbates the risk of overwhelming patients with information (Bedei et al.,
2021).
Participants also experience difficulties managing patient expectations for prenatal
screening and struggle to find ways to have patients fully understand the scope and
limitations of screening tests in general. Patients may have unrealistically high
expectations about what a prenatal screening test can tell them based on the increasing
medicalization of pregnancy. The medicalization of pregnancy is the phenomenon of
ever-expanding medical management and surveillance, and how pregnant individuals
engage and depend on these medical technologies to manage their pregnancy (Inhorn,
2007; Lupton, 1999; Davis-Floyd, 2004). In response to this medicalized perspective,
Rothman (1993) notes that prenatal surveillance technologies can influence an
individual’s experiences of pregnancy and create a “tentative pregnancy.” In response, an
individual may feel less inclined to bond with their future child until they have an
assurance that the fetus is “healthy” (Asch & Wasserman, 2005; Rothman, 1993;
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Richardson & Ormond, 2018; Tymstra, 1991; Lippman, 1991; Williams et al., 2005;
Chiang et al., 2007). This detachment is a psychological defense mechanism that can also
help patients cope better if they eventually choose to terminate the pregnancy (Vanstone
et al., 2018; Vanstone, Yacoub, Giacomini, et al., 2015; Lewis et al., 2012b). Providers in
this study discussed how some patients expect a screening test to ensure that their fetus is
“healthy.” As a result, the choice to undergo a screening test may be one to seek
reassurance (den Berg et al., 2005; Götzmann et al., 2002; O’Connor et al., 2003) which
can create unrealistic expectations about the scope of a screening test (Palomaki et al.,
2017).
Although this delayed attachment to pregnancy or “tentative” pregnancy is not a new
experience, participants discussed how NIPT enhances this phenomenon due to a lack of
visual acknowledgement of pregnancy. For example, one participant noted how the
decision to terminate a pregnancy earlier would be emotionally easier for patients based
on the fewer ultrasounds involved compared to other screening and diagnostic testing
methods. Depending on how NIPT is implemented, some pregnant individuals will have
NIPT as their first prenatal genetic screen in their pregnancy. Accordingly, they may no
longer be offered the first-trimester ultrasound included as part of multiple marker
screening. In addition, the early timing of NIPT could also mean results before the
detailed anatomical second trimester ultrasound. For some pregnant individuals,
ultrasound plays an important part in bonding with their future child (Floyd et al., 2016).
Participants also mentioned that as NIPT is performed early, termination can occur before
the individual is visibly pregnant. Studies have found that pregnant women will withhold
the pregnancy announcement (Öhman et al., 2006) as if they’re not pregnant (Aune &
Möller, 2012) in situations where the fetus's health could be in question based on
biomedical information. The timing of NIPT allows patients to have reassurance or
consider additional follow-up testing before they must announce their pregnancy
publicly.
With expanded screening available, NIPT may place the initial conversation of prenatal
screening in a highly medicalized context by providing opportunities for more complex
screening than traditional serum screening early in pregnancy. This context may lead
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individuals to believe that they must choose the most comprehensive panel available to
ensure that their fetus is “healthy.” For these reasons, prenatal care providers may
encounter more patients with unrealistic expectations about NIPT as panels continue to
expand. These expectations are a difficult underlying belief that must be addressed by
prenatal care providers within the confines of an already busy pre-test counselling
session.
These high prospects for NIPT can be especially problematic when counselling patients
who may be unprepared in the event of an unfavourable outcome (Öhman et al., 2006).
and the cognitive bias that leads people to believe that more desirable events, such as a
“healthy” pregnancy, are more likely to occur (Chiang et al., 2007; Ajzen, 1996; Rose et
al., 2016; Seavilleklein, 2009). ACOG and SMFM recommendations state that providers
should counsel patients that a negative test result does not prevent an unaffected
pregnancy (ACOG-SMFM, 2020). However, commercial labs use positive taglines such
as: “For your baby’s health and your peace of mind” (Roche, 2021) and “Get peace of
mind about the health of your baby earlier” (Panorama, 2021) to advertise NIPT. This
vague positive messaging, as noted by Vanstone et al. (2015), describes a broader use for
NIPT and emphasizes reassurance. This is in contrast to professional society documents,
which describe a narrow use to NIPT as a screen for various conditions to decide whether
or not to proceed with invasive diagnostic testing (Vanstone, Yacoub, Winsor, et al.,
2015).
Participants in this study, experts, and other healthcare professionals are concerned that
the understanding that NIPT is diagnostic is an incorrect belief shared widely by both
patients and healthcare professionals (Mozersky et al., 2017; Long & Goldblatt, 2014;
Advani et al., 2017; Stoll, 2013a; Stoll, 2013b; Stoll, 2014; Stoll & Lindh, 2015; Evans et
al., 2016; Hui et al., 2015; Haidar et al., 2020). In addition, participants in the current
study noted that their colleagues might not have time to make sure patients understand
that NIPT is a screening test and is not diagnostic. In a survey of general obstetricsgynecology professionals by Farrell et al. (2016), a few respondents reported that they
“never/rarely” (4%) or only “sometimes” (11%) discuss the differences between
diagnostic and screening tests. Updated guidelines from SOGC-CCMG published in 2017
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emphasize that individuals and their health care providers “need to fully understand that
cfDNA screening is not a substitute for invasive diagnostic testing” (Audibert et al.,
2017, p.810). This misconception can prevent pregnant individuals from making
informed decisions about NIPT due to confusion between diagnostic and screening tests.
Qualitative interviews before and after 2016 revealed that patients have misperceptions
about the differences between a prenatal screen and diagnostic test (Floyd et al., 2016;
Long et al., 2018). Studies have reported individuals terminating pregnancies based on a
positive NIPT result without further verification through diagnostic testing (Dar et al.,
2014; Dobson et al., 2016; Ramdaney et al., 2018). It was unclear what directions they
received from their healthcare providers. As discussed previously, patients can be heavily
influenced by a referring physician's counselling, especially those with a strong, trusting
relationship with this provider (Bensend et al., 2014). Therefore, dispelling the
misperception that NIPT is diagnostic may be a major barrier to counselling for prenatal
care providers if another healthcare professional is also misinformed or has not taken the
time to address the difference between a screening and diagnostic test.
One reason for the misperception that NIPT is diagnostic may be in part due to how
prenatal care providers compare NIPT to other prenatal screening and diagnostic testing
methods. For example, many participants in this study cite that NIPT has increased
accuracy compared to other screening tests and that it’s non-invasive compared to
diagnostic tests like CVS. This comparison could lead to confusion as patients may
erroneously believe this test is diagnostic, especially if the provider does not spend
enough time educating the patient on this critical distinction.
A patient’s impression that NIPT is diagnostic could also be due to the description of the
test. As seen in other disciplines, labels that contextualize available options can affect and
even manipulate a person’s decision-making process (Dolan et al., 2017; Ho et al., 2012;
Morris et al., 2010). Both PanoramaTM and HarmonyTM have labelled their maternal
plasma cfDNA screening test “NIPT” (Harmony, 2021; Natera, 2021a), and educational
materials specific to Ontario also refer to this testing by the same name (PSO, 2020).
Joint SOGC-CCMG clinical practice guidelines acknowledge that this testing is “widely
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referred to as NIPT,” but the preferred nomenclature is maternal plasma cfDNA
screening (Audibert et al., 2017, p.810). Other guidelines also describe this procedure as
cell-free fetal DNA screening (ACOG-SMFM, 2020; Salomon et al., 2014). To further
emphasize that this method is not diagnostic, the American College of Medical Genetics
and Genomics recommends the acronym NIPS, with the “S” representing “screening”
(Gregg et al., 2016). Beyond the naming convention itself, Vanstone, Yacoub, Winsor, et
al. (2015) note how many vendor documents, for both patients and providers, can have
additional ambiguous or vague wording such as “detect,” “evaluate,” or “assess,” which
can imply that the use of NIPT is for diagnostic purposes (Vanstone, Yacoub, Winsor, et
al., 2015). Fisher et al. (2020) found that colloquial and industry-derived terms acted as
sources of decision-making support by providing contextual information about screening
options. The authors concluded that consumer-driven terms create the potential for
patient attachment to industry-driven labels, which in turn could impact a patient’s
decision-making in a clinical setting (Fisher et al., 2020). The impact on naming
conventions is not well studied. Still, findings by Fisher et al. (2020) emphasize the need
for non-biased education materials for both patients and providers that use the preferred
terminology for NIPT to clarify expectations.
In addition, manufacturers marketing materials provided to both patients and providers
are subject to bias and misleading language. For example, NIPT has been advertised by
manufacturers as an assay that will provide “definite, informative results.” (Illumina,
2014, p. 5) (Resta, 2014; Stoll, 2013a; Stoll, 2013b; Stoll, 2014; Lewis et al., 2015). This
confusing language may lead patients into thinking NIPT is diagnostic (Murdoch et al.,
2017); which is especially concerning as patients have reported seeking information
about this testing from these sources (Yi et al., 2013; Floyd et al., 2016; Lewis et al.,
2016a; Daley et al., 2017; van Schendel, Van El, Pajkrt et al., 2017; Lau et al., 2016).
Patients’ and providers’ poor understanding of validation measures may also contribute
to the misconception that NIPT is diagnostic. Participants mentioned that screening tests’
performance data such as false-positive and false-negative rates are difficult for patients
to comprehend. These mathematical concepts underlying screening tests are not ones that
most people encounter during their everyday lives, and this has caused confusion for both
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patients and providers (Advani et al., 2017). For example, patients have
misrepresentations around the accuracy of NIPT compared with that of invasive
diagnostic tests (Floyd et al., 2016; Vanstone, Yacoub, Giacomini, et al., 2015; Vanstone
et al., 2018). Accordingly, patients have reported a greater need for additional, more
trustworthy information about the sensitivity and specificity of NIPT (Lewis et al.,
2016b; Kibel & Vanstone, 2017; Floyd et al., 2016; Piechan et al., 2016; Farrell, Agatisa,
Mercer, et al., 2015), and the implications of false-positive or false-negative results
(Farrell, Agatisa & Nutter, 2014; Floyd et al., 2016; Farrell, Agatisa, Mercer, et al.,
2015). Participants in this study did not say they have difficulties comprehending
performance metrics for NIPT; however, healthcare providers in Lebanon and Quebec
showed concerns regarding providers' lack of knowledge about NIPT’s performance
measures, such as its sensitivity and specificity (Haidar et al., 2020).
Many providers in this current study do not differentiate between the detection rates for
aneuploidies beyond trisomy 21, and very few mentioned any additional validation
measures to their patients. This practice occurred despite guidelines in 2016 stressing the
importance of discussing the potential for PPV and/or false-positive results during pretest counselling (ACOG-SMFM, 2015; Langlois et al., 2013; Wilson et al., 2013).
Without discussing these additional performance metrics, some patients may be led to
believe that NIPT is diagnostic. The European Society of Human Genetics and the
American Society of Human Genetics released a position document in 2015 stressing that
“although 10 times better than the PPV of current first-trimester screening in a similar
population… [these values are] still far below the near 100% required for a diagnosis of
Trisomy 21” (Dondorp et al., 2015, p.1439).
The performance data for different conditions can also become overlooked, combined,
and confused with other metrics, impairing reliable genetic counselling for low-risk
populations and the various conditions that NIPT can screen for (Di Renzo et al., 2019;
Rose et al., 2016; Dondorp et al., 2015; Kliff & Bhatia, 2022). Updated guidelines such
as SOGC-CCMG and ACMG discuss how these different performance values are
essential for healthcare providers and patients to discuss in order to enable more accurate
and informative counselling (Audibert et al., 2017; Gregg et al., 2016). They state that
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laboratories should provide visible and clearly stated detection rates, specificities,
positive predictive values, and negative predictive values for each condition being
screened in pretest marketing materials to support patients and providers in making
decisions. Despite these recommendations, these specific performance metrics are not
always present in marketing materials; PanoramaTM, for example, provides the sensitivity
and false-positive rate only for trisomy 21 screening in marketing materials (LifeLabs,
2018). Confusion with performance metrics and misleading messaging may “blur the
line” between screening and diagnostic testing (Rose et al., 2016, p.10). There is a clear
need for further education of physicians regarding NIPT's technical capabilities and
limitations. Furthermore, consistent guidelines should be developed to guarantee that
tests are validated and robust and that knowledgeable professionals provide appropriate
pre-test counselling.
Clinicians in this current study did not discuss differences in performance measures with
expanded panel testing in 2016 as they may not have been aware of this data at the time.
However, some genetic counsellors from the U.S. emphasize that prenatal care providers
are still not informed about these specifics and emphasize the importance of providing
this education (Kliff & Bhatia, 2022; Agatisa, Mercer, Coleridge, et al., 2018). Pregnant
individuals have also said they would like more detailed information about the
performance measures of NIPT. Additional information includes the sensitivity and
specificity of NIPT (Lewis et al., 2016b; Kibel & Vanstone, 2017; Floyd et al., 2016;
Piechan et al., 2016; Daley et al., 2017; Farrell, Agatisa, Mercer, et al., 2015) and the
implications of a false-positive or false-negative result (Farrell, Agatisa & Nutter, 2014;
Floyd et al., 2016; Farrell, Agatisa, Mercer, et al., 2015).
The confusing performance measurements of NIPT are exacerbated by the microdeletion
syndromes available for testing (Kliff & Bhatia, 2022). Expanded screening provides a
risk assessment about numerous conditions that conventional prenatal screening has not
previously assessed, with associated metrics for each (Suskin et al., 2016; Palomaki et al.,
2017). Due to the low incidence in the general population, the PPVs for the five
microdeletions currently offered are low, and the risk of false positives is high (Bianchi et
al., 2014; Meck et al., 2015; Vora & OʼBrien, 2014). For example, NateraTM recently
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released a new study on the performance of NIPT screening for 22q11.2 and reported a
PPV of 52.6% (n=18,043) (Dar et al., 2022). Consequently, this will increase the number
of invasive procedures performed to verify results, which screening tests like NIPT are
designed to avoid (Audibert et al., 2017; Dondorp et al., 2015).
In addition, there is concern that commercial laboratories have proprietary approaches to
obtaining these validation measures, and this data is often hard to find or is not provided
at all (Skrzypek & Hui, 2017; Shaw et al., 2020; Ye et al., 2021; Harmony, 2019; Kliff &
Bhatia, 2022). HarmonyTM, for example, currently does not give a detection and falsepositive rate for 22q11.2. Instead, a report states that, “limited numbers of 22q11.2 cases
have been evaluated to date” (Harmony, 2019, p.8). Patients were recently interviewed
for a New York Times article investigating the performance of microdeletion panels for
NIPT. These individuals wished they had been informed about these false-positive rates
for microdeletion syndrome before agreeing to test (Kliff & Bhatia, 2022). Indeed,
patients have noted anxiety and uncertainty related to confusion surrounding the
accuracy, false-positive, and false-negative rates of prenatal testing (Lewis et al., 2016a;
Li et al., 2017; Yi et al., 2013; Farrell, Agatisa & Nutter, 2014; Mozersky, 2015; Floyd et
al., 2016; Farrell, Agatisa, Mercer, et al., 2015; Vanstone, Yacoub, Giacomini, et al.,
2015). Others were concerned about how they would cope with the potential outcomes
associated with false-positive and false-negative results of NIPT (Kibel & Vanstone,
2017; Li et al., 2017; Lewis et al., 2013). In addition, systematic reviews suggest
expanded panels have higher false-positive rates than those reported by the manufacturers
(Badeau et al., 2017; Varela-Lema et al., 2018; Iwarsson et al., 2017; Taylor-Phillips et
al., 2016). Other authors suggest that the PPV and NPV rates in marketing materials, and
in some cases, test reports, are inflated as well (Stoll & Lindh, 2015). It is therefore
important that unbiased sources such as Prenatal Screening Ontario update their website
to provide some information on what is known about the performance measures for
microdeletions (PSO, 2019b).
Providers in this study also noted how difficult it would be to counsel for conditions
beyond traditional aneuploidies as they can have variable phenotypes. This variability
also introduces a level of uncertainty to their counselling that they were uncomfortable
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providing. Certainly, SCAs may have a generally mild phenotype, while others are
asymptomatic and never diagnosed (Health Quality Ontario, 2019a; Geeter, 2015; Benn,
2016; Viuff et al., 2015). Similarly, the microdeletions currently available for NIPT
screening present phenotypic variability with very little information available for
assessing their clinical significance (Armour et al., 2018; Agatisa, Mercer, Coleridge, et
al., 2018; Dukhovny & Norton, 2018; Benn, 2016; Gammon et al., 2016; Health Quality
Ontario, 2019a; Samura, 2020). Providers felt the additional uncertainty that comes with
these options only further complicated a patient’s decision-making process, and pre-test
counselling challenges for these expanded disorders would be multiplied exponentially as
screening options grow. Previous studies have indicated how difficult it is to engage
patients in decision-making without a clear understanding of the condition itself (Agatisa
et al., 2015; van Schendel et al., 2014; Gregg et al., 2016; Geeter, 2015). It is also
challenging to discuss these conditions concisely and in a way that is accessible to
patients (Han et al., 2017; Skinner et al., 2016). Therefore, these expanded options for
NIPT screening have several challenges that require extensive pre-test counselling (Bedei
et al., 2021). Guidelines acknowledge these counselling challenges before and after these
interviews (Salomon et al., 2017; Dondorp et al., 2015; Gregg et al., 2016), including
SOGC-CCMG’s updated guidelines, which states that “screening for microdeletions
involves complex issues of pre-test…counselling that is currently unresolved” (Audibert
et al., 2017, p. 812).
The concept of uncertainty is not new to prenatal genetics (Hogan, 2016). Newson et al.
(2016) introduced the idea of genomic uncertainty, which they define as
“…information…obtained from genomic testing that is imperfect or unknown, leading to
uncertainty in clinical diagnosis or management” (p.3). Experiences of genomic
uncertainty may create stress, a reduced sense of coherence, and loss of control (Newson
et al., 2016). In addition, the individuals hope for a “healthy” fetus, and this added
uncertainty may “cast a shadow on [an individual’s] … emotional experience around the
pregnancy” (Di Renzo et al., 2019, p.4). In addition, introducing greater chances for
uncertainty was likely concerning to these prenatal care providers as genetic testing is
meant to reduce this uncertainty (Sankar et al., 2006). Uncertainty is prevalent in
genomic medicine but is often framed negatively; it is usually desired as something that

110

needs to be avoided or eradicated. Individuals can see these uncertainties as a burden as
they now face complex decision-making (Crawford et al., 2013).
Participants noted that this uncertainty is akin to that experienced with prenatal
microarray testing. As prenatal microarrays look at chromosomal abnormalities at a
higher resolution than traditional karyotype analysis, microarray technology can also
detect microdeletions (Lefebvre et al., 2016). Some centers offer a microarray test to all
individuals undergoing invasive testing (Armour et al., 2018). Providers felt that lessons
learned with counselling for prenatal microarray testing could perhaps guide how to
counsel for uncertainty when discussing expanding NIPT’s use.
Newson et al. (2016) suggest healthcare providers directly acknowledge uncertainty
during pre-test discussions when considering complex genomic testing. Instead of
framing genetic testing to eliminate uncertainty, providers should help patients cope with
the inevitable uncertainty of genetic testing. The authors argue that this involves complex
pre-test counselling, where providers discuss uncertainty in a structured and supportive
way, while ensuring that uncertainty becomes constructively incorporated into the
decision-making process (Newson et al., 2016). The ACMG recognizes as well that the
ever-evolving technology of NIPT should include pre-test counselling that explores the
patient’s ability to accept uncertainty concerning possible screening outcomes (Gregg et
al., 2016). To tackle complex concepts in NIPT counselling, such as uncertainty, prenatal
care providers must engage in a genetic counselling model that promotes psychosocial
support (Ferrier et al., 2013). For example, the “counselling model” of genetic
counselling emphasizes the support of patients on an emotional and personal level while
still providing education (Kessler, 1997). Ideal counselling consists of an appropriately
trained professional who understands genetics and provides psychosocial support
(Sequeiros & Ka, 2008).
To counterbalance the complexity of pre-test counselling for conditions with variable
phenotypes, one clinician in this study mentioned the need for two different tiers of
counselling: those individuals who paid privately versus those who undergo public
screening. Despite the increasing complexity of counselling expected of prenatal care
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providers, clinicians are reimbursed for offering and counselling on NIPT at the same rate
as counselling for other prenatal screening tests (Burgess et al., 2020). In addition,
prenatal care providers may feel that private counselling could offer the additional time
and expertise required to counsel on expanded testing, compared to what they could
provide within the confines of their prenatal visit. In response to the growing need for
genetic counselling in general, commercial laboratories employ increasing numbers of
genetic counsellors (Stoll et al., 2017). More specifically, privatized genetic counselling
support has been made available in Canada for select genetic tests after 2016 (Genolife,
2021; LifeLabs, 2021). However, private laboratories' patient education materials and
counselling may not necessarily be neutral, as the company may profit from a patient’s
decision to undergo testing (Stoll et al., 2017; O’Brien & Dugoff, 2018; Vanstone,
Yacoub, Winsor, et al., 2015). Although societies like the NSGC have published a code
of ethics that states genetic counsellors must acknowledge and disclose any conflict of
interest (NSGC, 2021), further regulation is required for this process. The discussion of a
two-tier system for NIPT illustrates a need for policy determining best practices within
the Canadian healthcare system and for the need to discuss private pay testing with
patients. This statement also highlights the prenatal care provider’s desire for a more
overt definition of their role as a prenatal counsellor compared to a genetic specialist,
especially as the options for private pay expand.

5.1.3

Engaging Patients in Decision-making

As the provider who often introduces prenatal screening to their patients, participants
discussed the importance of this initial conversation in order to understand their patients’
values and beliefs and set general screening goals. Providers begin this discussion by
identifying if prenatal testing options will support the patient's values and belief systems.
This preliminary discussion in genetic counselling is known as contracting (Veach et al.,
2018). Contracting is the “…two-way communication process between the genetic
counsellor and the patient/client, which aims to clarify both parties’ expectations and
goals for the session” (Accreditation Council for Genetic Counselling, 2019, p.8).
According to prenatal counselling guidelines, this is a fundamental process to undergo in
genetic counselling (Gregg et al., 2016; Wilson et al., 2013; ACOG-SMFM, 2020) and
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informed decision-making “rests on the practice of contracting with patients” (Case et al.,
2007, p.655). Our findings revealed how prenatal care providers utilized contracting as an
essential first step in the decision-making process for NIPT.
Participants described their role in NIPT pre-test counselling as communicating adequate
information about the test to facilitate informed decision-making and choice. Effective
communication of relevant information is essential for pre-test counselling and informed
decision-making (Ferrier et al., 2013). Relevant information in this context, according to
our results, were the indications for NIPT screening, as well as its advantages and
limitations compared to other prenatal screening and diagnostic options. This information
is analogous to what other providers self-reportedly discuss with their patients and what
is recommended as key discussion points by professional societies and expert groups
(Audibert et al., 2017; Chitayat et al., 2017; Devers et al., 2013; Salomon et al.,
2014;ACOG, 2017; Wilson et al., 2013; Gregg et al., 2016; Sachs et al., 2015; Tognetto
et al., 2019; Rink & Kuller, 2018; ACOG-SMFM, 2020).
Many participants did not counsel on expanded options for NIPT, despite these options
being available for private pay. Some providers did not discuss these options with
patients because they were unaware they existed. In contrast, others may have chosen to
omit this information based on their struggle to perceive the clinical usefulness of
screening for these conditions and the sparse validation data available. These two motives
were also listed among the reasons genetic counsellors do not offer expanded testing at
all in their practice (Flynn, 2018). In addition, these reasons are why guidelines and
expert groups do not recommend NIPT as a first-tier screening test for these conditions
(Gregg et al., 2016; ACOG-SMFM, 2020; Audibert et al., 2017). Providers may have
also been uncomfortable discussing the uncertainty of these disorders with patients.
Guidelines acknowledge these counselling challenges (Salomon et al., 2017; Dondorp et
al., 2015), including SOGC-CCMG, which states that “screening for microdeletions
involves complex issues of pre-test…counselling that is currently unresolved” (Audibert
et al., 2017, p. 812). Rather than withholding this information from patients, additional
support in this area could provide prenatal care providers with the skills to participate in
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more complex pre-test counselling conversations about expanded screening options for
NIPT.

5.2

Support Required

Primary care providers have raised concerns that further genetic responsibilities will be
given to them without sufficient support (Harding et al., 2019). In addition to the implicit
discussion surrounding participants’ need for more guidance and education, participants
in this study expressly spoke about the support they require as they take on a larger role
in prenatal counselling for NIPT. There is also an overall need for bolstering education
and dissemination efforts and updating guidelines and regulations to accommodate the
expanding options of NIPT. This support will ensure prenatal care providers can deliver
adequate counselling in an otherwise busy prenatal session.

5.2.1

Need for Regulations and Directives

Providers indicated they felt pressure from the industry to adopt NIPT quickly in a
practice setting. Industry involvement of this technology has rapidly led to intense
competition between companies for patents, markets and commercial exploitation of
NIPT (Löwy, 2020). Much of the commercialization and innovation of this testing has
occurred in the United States, with Canada experiencing intense pressures of this testing
as a result (Agarwal et al., 2013). Consequently, participants from this study expressed
the need for stricter regulations for ordering NIPT to ensure access for all pregnant
individuals is appropriate and equitable. Some worry that NIPT is not cost-effective in
how it’s currently being used. There is empirical evidence that providers are
inappropriately using public funding for NIPT in Ontario. Bellai-Dessault et al. (2020)
reported in the descriptive cohort study of all pregnant individuals who received NIPT
screening in Ontario between January 2016 to December 2017, that 2.9% of all publicly
funded NIPT tests (N= 11,166) were administered to pregnant individuals who were not
eligible for funding between January 2016 to December 2017. These individuals had
discrepancies between the clinical indication and the data entered into the BORN
registry. For example, of the patients who received funding for the indication of
“increased nuchal translucency measurement,” 17.9% of these individuals did not meet
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this criterion. The authors postulated that misuse of screening resulted from a lack of
awareness of funding guidelines, especially in the first month of public funding for NIPT
screening in Ontario. A clinician from the current study observed other colleagues
purposefully taking advantage of public funding as a means for access to low-risk
patients who may not be able to afford to test. Although funding criteria for Ontario were
eventually codified in 2018 and circulated more widely, providers may still purposefully
misuse public funding criteria to provide patients access to testing. Therefore, it is
essential to develop strategies to monitor and ensure the appropriate utilization of
publicly funded testing of NIPT.
A significant finding from this current study was that participants strongly expressed a
need for guidelines and regulations to be updated to correspond with the current testing
practices. In 2016, guidelines by some expert groups such as SOGC were outdated and
had not yet provided any information about expanded testing (Langlois et al., 2013;
Gregg et al., 2013). Other guidelines available in 2016, as well as current
recommendations, do not recommend routine screening for fetal microdeletions (ACOGSMFM, 2015, 2020; Audibert et al., 2017). However, screening for SCAs is available
through basic NIPT panels and microdeletions as a self-pay option in Ontario (Harmony,
2021; Natera, 2021a). Of all the pregnant individuals who underwent NIPT between
January 2016 to December 2017 in Ontario (N=23,845), 33% chose private pay (BellaiDussault et al., 2020). A recent study of Canadian professionals, including geneticists,
genetic counsellors, and nurses, reported NIPT as the second most frequent private pay
genetic test discussed (Di Gioacchino et al., 2019). More specifically, there is evidence
that many individuals are ordering expanded testing, with NateraTM reporting over
400,000 NIPT screening tests for the 22q11.2 microdeletion in 2020 (Natera, 2021b).
Despite the possibility of individuals choosing to pay for screening for sex selection and
expanded panels using NIPT, very little guidance still exists for pre-test counselling for
SCAs and microdeletions. Providers in this study discussed their discomfort with dealing
with counselling situations where they discussed topics like sex selection. Ultimately this
distress can be positively associated with burnout and negatively associated with job
satisfaction (Bernhardt et al., 2009; Bernhardt et al., 2010; Johnstone et al., 2016). Other
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clinicians have noted the intensive industry-driven marketing aimed at the consumer,
which remains ahead of established clinical practice guidelines (Rink & Kuller, 2018).
Additional attention should be placed on addressing the effects of clinician well-being as
this counselling becomes more complex. Providing this support will help address the
possible occupational distress and burnout that these prenatal care providers may be
experiencing, which has also been reported in prenatal genetic counsellors (Benoit et al.,
2007; Bernhardt et al., 2009; Figley, 2002; Johnstone et al., 2016).
Some professional position statements and guidelines provide conceptual guidance on
using NIPT for non-medical fetal sexing. However, not all resources have been clear or
consistent before and after this study's interviews were completed. For example, some
guidelines have stated that NIPT should not be performed if the indication is only for sex
identification (ACOG-SMFM, 2015) and others have encouraged providers to deter
patients from screening for these purposes (Gregg et al., 2016). The most recent joint
SOGC-CCMG guideline for NIPT directly addresses the ethical conflicts prenatal care
providers feel towards using this testing for non-medical reasons, such as fetal sexing,
stating that it is not indicated “…even with patient autonomy considerations” (Audibert et
al., 2017, p. 813). In contrast, a position statement from the Board of the International
Society for Prenatal Diagnosis (ISPD) in 2015 states that individuals should have the
option to choose sex chromosome analysis for NIPT (Benn et al., 2015). ACOG’s latest
clinical management guidelines for obstetrician-gynaecologists in 2020 does not
explicitly address the use of NIPT for this purpose and only notes that “…if fetal sex
determination is elected, the risk of maternal and fetal sex chromosome aneuploidy
should be discussed as a potential finding” (ACOG-SMFM, 2020, p.e56).
The lack of agreement among these resources makes it difficult for real-life applications.
Certified nurse-midwives from the U.S. noted in the qualitative portion of a survey that a
significant challenge in counselling for NIPT, in general, was the absence of consistent
professional guidelines (Weingarten, 2016). In addition, these guidelines do not directly
address how to counsel patients on sex determination or sex selection. Genetic
counsellors have explained that their discomfort with handling counselling surrounding
non-medical sex selection is due to a lack of training and practical guidance (Orr-
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Ferdinand, 2021; Burke, 1992). Therefore, prenatal care providers in this study might feel
uncomfortable with counselling for non-medical indications based on a lack of tools to
navigate this morally sensitive topic. Guidelines require updating to reflect the possibility
of this testing and provide more standardized guidance on counselling patients interested
in paying for these expanded options.
Many providers emphasized how important it was to regulate what conditions NIPT can
be used to screen, including distinguishing between those that should be publicly and
privately available. This is especially important as companies push to screen for more
conditions, with the eventual goal of mapping the entire fetal genome (Lefkowitz et al.,
2016; Hui & Chiu, 2016; Rojahn, 2013). In Ontario, clinicians are reimbursed for
offering and counselling about NIPT at the same rate as counselling for other prenatal
screening technologies (Vanstone, Yacoub, Giacomini, et al., 2015; MOH, 2021).
However, additional counselling is more complex and takes longer for microdeletions
and SCAs (Health Quality Ontario, 2019a). Therefore, participants in this study were
concerned about spending additional public healthcare resources on counselling patients
for expanded panels that are privately paid for. Ongoing regulation on how this
counselling is reimbursed is crucial as the expansion of this technology is moving at an
unprecedented pace (Swaney et al., 2016; Murdoch et al., 2017; Health Quality Ontario,
2019a; Benn & Chapman, 2016; Agatisa, Mercer, Coleridge, et al., 2018).
In this study, prenatal care providers, genetic counsellors and other healthcare
professionals believe that clinical utility and validity are essential measures of whether a
condition is appropriate to screen for using NIPT (Alexander et al., 2015; Vora &
Wapner, 2018). Several systematic reviews and meta-analyses have been conducted to
investigate these NIPT measures in common aneuploidies and SCAs. However, most
have focused on the high-risk population (Gil et al., 2017; Mersy et al., 2013; Mackie et
al., 2017; Yang et al., 2015; Jin et al., 2017). Only a few reviews exist for the averagerisk or general population, with even less including SCAs (Badeau et al., 2017; VarelaLema et al., 2018; Iwarsson et al., 2017; Taylor-Phillips et al., 2016). Badeau et al., 2017
note that there is a “paucity of data” (p. 2) on the accuracy of NIPT as a first-tier
aneuploidy screening test in a population of low-risk individuals. In reviewing the
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accuracy of NIPT across studies, Health Quality Ontario reported a lower sensitivity and
specificity for NIPT compared to that which was reported by manufacturers. The authors
speculate that this could have been because most of these studies focused on the high-risk
population, which has a higher test sensitivity for trisomies 21, 18 and 13 (Health Quality
Ontario, 2019a).
NIPT screening for microdeletion syndromes have not undergone large-scale studies, and
sparse test performance information is available (Health Quality Ontario, 2019a; Bedei et
al., 2021). Due to the rarity of these syndromes, the determination of sensitivity and
specificity is difficult to obtain based on the large numbers of patients that would need to
be involved in clinical validation studies (Health Quality Ontario, 2019a). Therefore,
additional published data is required to firmly establish performance metrics for NIPT in
the low-risk population and for expanded conditions. Ongoing discussions surrounding
clinical utility and unbiased large-scale validation studies should continue to be
performed on expanded panels in both low and high-risk populations in order to inform
regulations on what conditions NIPT should screen for.
As commercial laboratories are conducting many of these large-scale tests and validating
this technology (Norton et al., 2015; Dan et al., 2012; Chen et al., 2011; Chiu et al.,
2008), there is significant risk of bias in research outcomes. This bias includes a
likelihood that benefits of testing are exaggerated, and their potential harms are
downplayed (Omenn et al., 2012; Roseman et al., 2011; Lumbreras et al., 2009; Bell et
al., 2006; Petersen & Krisjansen, 2015; Fugh-Berman, 2013; Tsilidis et al., 2013;
Lexchin, 2012; Stamatakis et al., 2013). As much of the research is done in private
laboratories, some suggest a lack of independent monitoring and evaluation. This
oversight can lead to bias or proficiency issues (Takoudes & Hamar, 2015). For example,
two meta-analyses on the performance of NIPT noted that many published studies had
low-quality methodologies. Many studies were labelled at high-risk for bias as they used
case-control studies or did not explicitly state how their samples were selected (Gil et al.,
2015; Gil et al., 2019). Similarly, many of the test accuracy studies reviewed for the
Health Technology Assessment of NIPT in Ontario were identified as having a
substantial risk of bias due to the lack of clarity in the method of patient enrolment
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(Health Quality Ontario, 2019a). In addition, the independent confirmation of test
performance and utility can be hindered by a manufacturer’s ownership of a patent,
which can restrict independent access to technologies (Thumm, 2004). Independent
confirmation of test performance is essential, especially as NIPT screens for the number
of conditions expand.
Prenatal care providers discussed their feelings of commercial pressures in the NIPT
industry and the fear that introducing screening for additional conditions could lead down
a slippery slope. Currently, no validation thresholds exist before a certain condition can
be marketed and released for clinical use for NIPT screening. Creating these regulations
could reduce current pressures on prenatal care providers, who struggle with
understanding this performance data, and support them in the subsequent gatekeeping
they must face with these expanded conditions.
Providers in this current study desired more transparency in creating policies and
guidelines. They also thought that they should be directly involved with policy
development. This issue is crucial to address, as prenatal care providers were not directly
involved with NIPT's public health policies in 2014. As these providers are central in
public testing and take on a more prominent role in pre-test counselling, providers in this
study believed it is crucial to involve them in policies directly impacting their practice.
U.K. genetic counsellors in the Alexander et al. (2015) study strongly believed that
professionals trained in this test should have some influence on how the test is offered
and used. Prenatal care providers involved in policy creation is consistent with the
“bottom-up” philosophy of engagement, which involves reviewing and developing
recommendations by those expected to apply them. It starts by analyzing what is
necessary for policy implementation with those closest to the problems (Elmore, 1980;
Sabatier, 1986). After this study was conducted, the provincial prenatal screening
program “Prenatal Screening Ontario” launched in 2018 has created various committees
and working groups which depend on experts’ and advisors' input to certify all elements
of a robust screening program implementation (PSO, 2020). As the expansion of NIPT
continues, it is imperative to keep prenatal care providers informed and engaged within
these working groups.
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Participants also thought it was important to have standardized guidelines surrounding
information and counselling on NIPT. Other clinicians have expressed a desire for more
trustworthy and definitive information and evidence about this testing (Horsting et al.,
2014; Gammon et al., 2016; Filoche et al., 2017; Alexander et al., 2015; Suskin et al.,
2016). The media’s portrayal of NIPT has been framed mostly by industry and therefore
the perception of this testing is predominately positive (Kamenova et al., 2016).
However, recently, the New York Times published an article titled “When They Warn of
Rare Disorders, These Prenatal Tests are Usually Wrong” (Kliff & Bhatia, 2022). This
article questions the performance measures of NIPT for microdeletion syndromes and
acknowledges that these companies are biased in their messaging. Articles like this one,
although criticized for its inflammatory messaging (Matloff, 2022), emphasizes the need
for standardized information that often is seen between advertised test capabilities,
professional recommendations, and actual clinical use (Gammon et al., 2016; Kloza et al.,
2015; Haymon et al., 2014).
Educational resources are still heavily created and disseminated by the companies that
sell NIPT (Vanstone, Yacoub, Winsor, et al., 2015; Kamenova et al., 2016; Panorama,
2021; Natera, 2021a). However, some educational resources, including webinars,
modules and courses, have been developed by independent third parties since this study
ended (ACOG, 2021; Perinatal Quality Foundation, 2022; Genetics Education Canada,
2020). Still, after these interviews were conducted, O’Brien & Dugoff (2018) noted a
high level of variability reported in presenting informational materials for NIPT, both
within and across commercial laboratories. Indeed, Ontario providers still voiced a need
for standardized information from an unbiased, trustworthy source in 2018 (Burgess et
al., 2020).

5.2.2

Education and Dissemination of Information

Participants noted that the dissemination of information surrounding the overall process
of NIPT was suboptimal when it was first rolled out. Publicly funded screening for NIPT
in Ontario was introduced in 2014, with no province-wide education or training strategy
for providers (Bellai-Dussault et al., 2020). The original policy surrounding public
funding was not written or publicized and instead was exclusively shared through word
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of mouth (Burgess et al., 2020). At the time of interviews in 2016, these policies were
distributed more widely. Commercialization of this test through Ontario-based
commercial laboratories also increased awareness of these tests by this time. Providers
mentioned that they learned about NIPT through various methods, including conferences,
meetings, information through their genetics department, continuing medical education,
the Ministry of Health, companies offering the test, specialty organizations such as the
SOGC and word of mouth from other professionals.
Despite a broader distribution of information since its implementation in Ontario,
participants in this study still report a lack of knowledge with NIPT. Many clinicians
report low knowledge and confidence in NIPT (Horsting et al., 2014; Gammon et al.,
2016; Filoche et al., 2017; Alexander et al., 2015; Suskin et al., 2016). A greater need for
education in NIPT has even been identified for genetic counsellors. In 2019, a special
interest group for NSGC conducted a survey to assess genetic counsellors’ current
genomic technologies knowledge. Even for those counsellors who received their degree
in more recent years (2000-2015) (n=171), some (40%) said that they required “some” or
“significant” amount

of additional training in NIPT in order for them to perform their

practice adequately (Hagman et al., 2020).
In addition, specialist providers (e.g., obstetricians, maternal-fetal medicine specialists) in
this current study felt that family physicians’ knowledge of NIPT was inadequate,
considering their involvement in the NIPT's pre-test counselling process. Beyond selfreporting, recent studies have measured a lack of knowledge and understanding of NIPT
in obstetricians from countries such as the United States and New Zealand (Brewer et al.,
2017; Filoche et al., 2017; Mayes et al., 2016). In addition, some patients have reported
that their clinician did not have enough knowledge about NIPT to provide counselling
(Kibel & Vanstone, 2017; Floyd et al., 2016; Lau et al., 2016; van Schendel, KaterKuipers, van Vliet-Lachotzki, et al., 2017). In 2018, prenatal care providers still selfperceived a strong need for more NIPT education in Ontario, based on qualitative
interviews conducted by Burgess et al., 2020. Providers have also discussed a lack of
knowledge of the different companies and labs that offer versions of NIPT in Ontario
(Burgess et al., 2020). This knowledge deficit creates a barrier to counselling and can
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severely impair a provider’s ability to engage their patients in informed decision-making
for NIPT.
Importantly, prenatal care providers in this study conveyed that it is challenging to keep
up to date about expanded panels available for NIPT and potential incidental findings.
For example, many participants were unaware of maternal genomic information that
testing could identify and many also did not know that several companies offer the option
to screen for microdeletions. This lack of knowledge is representative of the educational
delays that prenatal care providers experience with implementing new technology into
their practice setting. Since 2016, expert groups such as SOGC-JOGC have included
information in their guidelines about the possibility of incidental findings including
performance metrics of the microdeletions offered (Gregg et al., 2016; Audibert et al.,
2017). However, surveys still report gaps in knowledge for providers regarding the
availability of NIPT testing for microdeletion syndromes (Brewer et al., 2017; Filoche et
al., 2017; Mayes et al., 2016; Swaney et al., 2016).
Knowledge translation is the dynamic process of bridging the gap between generated
knowledge and practice (Straus et al., 2009; Davis et al., 2003; Landry et al., 2006).
Knowledge translation strategies extend beyond creating more information and focus on
“how” this information is disseminated to participants in practice. Unfortunately,
translating knowledge into clinical practice takes time (Morris et al., 2011) and is one of
the most challenging problems in health care (Khoury et al., 2007). For example, studies
have demonstrated a continued lack of knowledge and confidence in genomic medicine
from prenatal care providers, despite high-quality genomics references and education
materials available (Feero et al., 2016). The process of knowledge translation needs to be
an active, tailored, and targeted distribution of education and training (Chapman et al.,
2020). Even if much-needed updates to professional society's guidelines and policies are
developed, there are challenges to inform health providers of these items. One participant
mentioned that it is helpful when guidelines and policies provide information on
accessing the most up-to-date NIPT information. Prenatal care providers in this study
also stated that they preferred either in-person or electronic formats for ongoing NIPT
education. These informational sources have been mentioned more recently as a way
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prenatal care providers would like to be informed of any updates to this screening
(Benachi et al., 2019; Filoche et al., 2017; Burgess et al., 2020).
One clinician provided Cancer Care Ontario (CCO) as a specific example of an
organization that successfully disseminates information and updates to guidelines. CCO
has a strategy to foster community by publishing a regular newsletter to keep members
updated on learning opportunities and general information in cancer guideline
development (Browman, 2012). CCO represents a programmatic approach that focuses
on knowledge translation; this same approach is necessary when providing ongoing
education of prenatal care providers performing NIPT counselling. In August 2019,
Prenatal Screening Ontario launched its new website, which provides information for
pregnant individuals, families, and healthcare providers
(https://prenatalscreeningontario.ca). Part of PSO’s mandate is to “provide education
supports, information, and transparency needed for health care providers and pregnant
individuals and their families to make informed decisions” (PSO, 2020). This website has
information that addresses the possibility of unexpected fetal or maternal results and
some information about expanded testing for NIPT (PSO, 2020). However, with the
ongoing expansion of NIPT, it is vital to review and augment PSO’s information about
the expanded testing available. These updates include providing easy to access education
regarding the different performance metrics of this testing to prenatal care providers.
Another significant finding of this study was that prenatal care providers specifically
addressed the need for better distribution of information for family physicians. Indeed,
these primary care providers may be challenged by rapidly changing information in this
genomic era of prenatal testing (Huang et al., 2018). Previous research indicates that
primary care providers, including family physicians, mentioned that they do not know
where to find information about genetics or available genetic tests relevant to their
practice (Carroll et al., 2019; Carroll, Makuwaza, Manca, et al., 2016; Haga et al., 2011;
Manolio, 2017; Sebastian, 2020). It is clear from this study that family physicians
specifically require dissemination strategies for new information regarding NIPT that are
accessible to meet their needs as general practitioners. Some participants discussed the
importance of providing accessible education through in-person outreach programs for
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primary care providers or electronic forms of communication. They emphasized that this
information must be accessible to all prenatal care providers who are unwilling or unable
to attend in-person conferences. Indeed, these strategies could be essential for busy
family physicians (Alexander et al., 2015; Adams et al., 2015) in isolated settings with
little access to genetic professionals (McCauley et al., 2017).

5.2.3

Importance of Genetics Professionals

A lack of comfort with pre-test counselling patients for NIPT may explain why some
participants referred patients to genetics when NIPT first became available. It may also
be why some family physicians in this study said they still referred their patients to
genetics for pre-test counselling. Professional societies recommend that if a patient
requests further information about conditions before the screening, it is ideal to refer
them to a qualified provider for a more detailed discussion (Benn et al., 2015; Allen et al.,
2017; Bensend et al., 2014). The ACOG also encourages healthcare providers to refer
patients to a more specialized provider, such as a genetic counsellor, if they do not have
the “… necessary knowledge or expertise in genetics to counsel a patient appropriately”
(ACOG, 2017, p. 693). Indeed, other physicians have noted that feelings of
unpreparedness would discourage them from engaging in any genomic medicine, and
instead, would refer to a genetic counsellor (Christensen et al., 2016).
However, the strategy of referring to genetics becomes problematic if there are not
enough specialists to handle an increasing caseload (O’Brien & Dugoff, 2018; Burgess et
al., 2020). By 2018, Ontario specialists have largely rejected referrals for cases that
primary care physicians could otherwise manage (Burgess et al., 2020). These gaps in
education and awareness emphasize how important it is that prenatal care providers
become knowledgeable and comfortable in NIPT counselling, especially as they take on
more counselling responsibilities in their prenatal role.
Prenatal care providers identify genetic professionals as valuable sources of information
and support for implementing NIPT in their practices. Overall, prenatal care providers
who have incorporated genetics in practice emphasized the importance of genetic
professionals (Qureshi et al., 2004; Hamilton et al., 2014; Carroll, Makuwaza, Manca, et
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al., 2016). Participants mentioned the positive impact of having genetic departments
physically close to where they practice; “hallway consults” were helpful to be kept
informed and up-to-date. Closer relationships may naturally exist between prenatal care
providers and genetics specialists who work in close proximity (Carroll, Makuwaza,
Manca, et al., 2016). Midwives with direct access to genetic counsellors described them
as a helpful resource (Dettwyler et al., 2019). Building relationships between NHGPs and
genetics specialists is critical. The links that naturally exist with other specialists do not
necessarily occur with genetics, as not every hospital has a genetics department (Carroll,
Makuwaza, Manca, et al., 2016).
Genetic counsellors must establish and maintain interdisciplinary professional
relationships and assist prenatal care providers in improving patient care (Ferrier et al.,
2013; Accreditation Council for Genetic Counselling, 2019). Agatisa, Mercer, Coleridge,
et al. (2018) conducted interviews in 2016 with 25 prenatal genetic counsellors in the
U.S. to understand their experience with the continued expansion of NIPT screening.
Counsellors felt a professional obligation to educate obstetricians about prenatal genetic
tests (Agatisa, Mercer, Coleridge, et al., 2018). Although this support has shown to be
essential to prenatal care providers, further investigations are required regarding the exact
responsibilities that genetics professionals and their respective societies have in assuring
prenatal care providers have adequate knowledge and support for this testing in the
future.
Importantly, collaboration between genetic centers and the primary care community
make genetic medicine services more accessible. Strategies such as provider-to-provider
telegenetic consultation have been suggested to pair genetics providers with non-genetic
professionals (Raspa et al., 2021). In a survey conducted in 2011-2012 by Carroll et al.
(2019), many physicians in Ontario (88.8%, n=347) noted that contact information to a
genetics clinic, such as telephone/fax or email, would be useful to achieve this
connection. PSO launched a toll-free prenatal screening information line in 2018 where a
certified genetic counsellor is available 8 am-4 pm Monday to Friday to answer questions
from patients, providers and other stakeholders like lab personnel (BORN Ontario, 2020).
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These services must be made known to those isolated providers in the community and the
genetics services should initiate these connections.

5.3

Conclusion

This grounded theory provides a unique perspective of prenatal care providers in Ontario
and their experience with pre-test counselling for NIPT. These providers play an
increasingly prominent role in NIPT pre-test counselling and continue to face complex
counselling conversations with their patients. However, there are very striking practical,
educational and ethical challenges between current NIPT panel options and prenatal care
providers’ comfort with pre-test counselling for these possibilities. The consequences of
these challenges ultimately affect how prenatal care providers engage patients in
decision-making for NIPT. Ongoing support for these providers is essential to ensure that
patients receive adequate counselling as NIPT options expand (Sahlin et al., 2016;
Piechan et al., 2016).
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Chapter 6

6

Conclusion

Prenatal care providers play an essential role in offering NIPT to pregnant individuals.
This dissertation generated a theoretical model, ‘prenatal care providers’ involvement
with pre-test counselling for NIPT in Ontario,’ explaining how prenatal care providers in
Ontario have implemented NIPT into their prenatal screening practices. Participants
discussed the additional responsibilities they have in providing pre-test counselling for
NIPT. Providers discussed how they struggle to prioritize pre-test counselling for NIPT
in their current practice. They also felt underprepared and uncomfortable using NIPT for
indications other than traditional aneuploidies.
These ethical considerations and difficulties experienced during counselling informed
what additional support prenatal care providers require. They emphasized the need for
ongoing development of regulations and guidelines and the importance of ensuring these
were disseminated efficiently and effectively in the future. Genetics professionals were
highlighted as valuable sources of information regarding education and learning about
any updates to genetic technology.

6.1

Implications for Prenatal Care Providers: An
Increase in Genetics in Practice

This study revealed what it means for prenatal care providers to be providers of frontline
genetic services. These providers were no longer referring to genetic specialists and
counsellors when an individual was interested in NIPT. Instead, participants in this study
discussed taking on the additional responsibilities in providing pre-test counselling for
NIPT based on the limited genetic counsellors available. By 2018, Burgess et al. (2020)
indicated that most community-based clinicians in Ontario who were interviewed
provided pre-test counselling instead of referring to genetic services.
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Participants noted that the quality of pre-test counselling patients about NIPT was
challenged by time constraints and prioritizing what is covered at each prenatal visit.
Clinicians in this current study struggled with prioritizing pre-test counselling for this test
during a busy prenatal visit early in pregnancy and were worried that other prenatal care
providers were not spending enough time to appropriately counsel patients on this
screening option. Notably, family physicians who engage in generalist practice find NIPT
counselling challenging to accommodate within an otherwise hectic prenatal
appointment. This concern contributed to why some providers did not discuss NIPT’s
incidental findings with patients and explains some of their hesitations in discussing
expanded testing. Further investigations are warranted into how prenatal care providers
can incorporate complex information about NIPT into the consent process given the time
restrictions of their practice (Piechan et al., 2016).
In addition, participants stated that the introduction of NIPT augmented difficulties with
establishing realistic expectations about prenatal screening and the scope and limitations
of this testing. Participants discussed how difficult it was to address these
misconceptions, given the poor understanding of concepts such as sensitivity and
specificity in prenatal screening. The findings provide insight into the challenges
providers may face with discussing a technology that further medicalizes pregnancy and
is advertised as a test that will reassure a healthy pregnancy.
As a result of various tensions of offering testing for non-medical indications including
fetal sexing and conditions with variable phenotypes, such as SCAs and microdeletion
syndromes, some participants did not discuss screening for these indications during the
pre-test counselling process. These indications introduced ethical concerns into
providers’ prenatal counselling and made them question the clinical usefulness of
offering NIPT for these additional indications. These concerns for counselling on
complex issues, and differences in values, can contribute to the variation observed by
prenatal care providers in how professionals choose to provide counselling (Arora et al.,
2017).
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6.2

Implications for Policy and Guideline Development

Commercial pressures have rapidly pushed NIPT towards broader applications (Murdoch
et al., 2017); however, providers in this study questioned the boundaries of NIPT use. As
screening has evolved throughout the years, providers have reflected on the goals of
prenatal screening and how these tests impact perinatal outcomes (Dukhovny & Norton,
2018). This study emphasized how the future scope of prenatal screening and NIPT
should involve the perspectives of various stakeholders, such as prenatal care providers,
as guidelines and policies towards expanded testing for NIPT are updated. Indeed,
Prenatal Screening Ontario has developed various committees and working groups to
facilitate stakeholder input and advice on operational areas of prenatal screening in
Ontario, including an advisory committee, genetics expert and education working groups
(PSO, 2020). These groups are interdisciplinary and include family medicine
representatives, ensuring a “bottom-up” engagement model for policy implementation.
Similarly, a health technology assessment of NIPT was performed in Ontario in 2017 to
evaluate the clinical benefits and harms, monetary value, budgetary impact, and patient
preferences related to NIPT in the average-risk population. This evaluation was
conducted by Health Quality Ontario and included a multidisciplinary team including
prenatal care providers who are active in the prenatal screening community. These
assessments and working groups should continue to include prenatal care providers to
help inform the use of NIPT in the future, including the expansion of this testing.
The ethical considerations discussed by participants emphasized the need to enforce
current regulations to ensure the appropriate utilization of this publicly funded test in
Ontario. These considerations also correspond with the importance of policy enforcement
and the creation of new regulations regarding how NIPT is utilized publicly and
privately. They discussed the ethically complex topic of offering expanded testing panels
through private pay. Prenatal care providers are reimbursed for offering and counselling
NIPT at the same rate as counselling for other prenatal screening technology (Vanstone,
Yacoub, Giacomini, et al., 2015; MOH, 2021). From a provider’s perspective, there was
concern that the counselling required for these additional options would burden them
with additional pre-test counselling that they may not have the resources or confidence to
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provide. Currently, no policies separate the type of counselling prenatal care providers
should be responsible for compared to genetic professionals. There is a definite need for
policies to clarify the scope of prenatal care providers' counselling as NIPT options
expand. In addition, with privatized counselling support currently available in Canada
(Genolife, 2021; LifeLabs, 2021), stricter regulations should be enforced to ensure these
companies provide unbiased education materials and counselling. Regulations on this
issue will lead to consistency in patients’ care (Boycott et al., 2015; Toews & Caulfield,
2014).
Participants raised concerns regarding equal access to NIPT, including the discrepancy in
testing availability and affordability across Canada. Indeed, provincial, and territorial
policies regarding the implementation and public coverage of NIPT are diverse and
evolving. In addition to Ontario, NIPT is publicly funded for pregnant individuals who
meet certain requirements in British Columbia, Manitoba, Nova Scotia, Nunavut, Prince
Edward Island, Yukon and Quebec (Ryan, 2018; Impact Ethics, 2019; Hayeems et al.,
2015). Eligibility for public funding in these regions varies widely. For example,
pregnant individuals are eligible for publicly funded NIPT in Novia Scotia if they either
had a previous pregnancy affected with trisomy 13, 18 or 21 or are found to be at an
increased risk for trisomy 21 based results of maternal serum screening (Reproductive
Care Program of Nova Scotia, 2022; IWK Health Centre, 2022). The criteria in Quebec
are similar to Novia Scotia’s criteria, except public funding is also provided to
individuals who will be 40 years or older at the time of delivery (Gouvernement du
Québec, 2022). Access to public funding in these areas are more restrictive than Ontario,
which provides funding for more indications including sex chromosome determination in
individuals at risk of a sex-limited disorder (Dynacare, 2020c; PSO, 2021a). In contrast,
an individual can have NIPT funded in the Yukon for indications that are not available to
individuals in Ontario. This includes public funding for NIPT if an individual is 35 years
or older at the time of delivery, if the pregnancy is a result of IVF (with intracytoplasmic
sperm injection) or if the pregnant person is HIV positive (Dynacare, 2017; Heft, 2019).
Further investigation is required to see what prenatal care providers from differing
regions in Canada feel about barriers to access of public funded NIPT based on these
disparities.
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In addition, participants from this study expressed the need for stricter regulations for
ordering NIPT in Ontario to ensure access for all pregnant individuals is appropriate and
equitable. Some provinces have instituted regulations to control how publicly funded
NIPT is ordered. In Manitoba, results of a positive maternal serum screen must be
attached to the NIPT requisition in order for this test to be publicly funded (Dynacare,
2020e). In British Columbia, patients are required to give an authorization code as proof
of indication for funded NIPT which is provided by a prenatal biochemistry lab or
medical genetics (Provincial Health Services Authority, 2022). It is worth investigating
whether regulations like these could be adopted by MOH to monitor and ensure the
appropriate utilization of public funded testing in Ontario.
In certain regions in Canada, patients need to pay for the test out of pocket or through
private insurance, which may create major issues of equity of access and justice for
providers and patients. For example, Birko et al. (2019) reported the results of three
large-scale Canadian surveys which investigated stakeholders’ perceptions and attitudes
towards NIPT. The study included 184 healthcare professionals, a majority which
practiced in regions where public funding for NIPT was not available at the time (Birko
et al., 2019). These professionals reported that a “lack of coverage of the test” was the
number one barrier to clinical implementation. Although SOGC-CCMG recommends
offering NIPT as a possible screening option to all individuals in Canada (Audibert et al.,
2017), 50% of professionals in the study by Birko et al. (2019) agreed that NIPT’s
coverage would influence their decision to offer NIPT to a specific patient. Such issues
may be abated by public funding for NIPT, however additional studies are required to
investigate stakeholders’ preference regarding the implementation and coverage of this
testing through a public funding model.
Additionally, providers in this current study attributed initial difficulties with pre-test
counselling for NIPT due to suboptimal education of public funding guidelines in 2014.
Other provinces and territories wishing to implement a public funding model for NIPT
can learn from these experiences and invest in resources to disseminate information about
public funding guidelines to the appropriate stakeholders.
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Participants raised the concern that other prenatal care providers have variable quality in
their ability to effectively provide counselling for NIPT, and called for updated
guidelines to support providers with these difficulties. Although there are various expert
policy statements and guidelines regarding the use of NIPT, they are diverse in their pretest counselling recommendations. Sachs et al. (2015) released a standardized framework
that included recommended pre-test counselling points for providers offering NIPT.
However, providers need an updated pre-test counselling framework that is more
representative of the current NIPT climate in Ontario. This framework can address the
difficulties providers experience with pre-test counselling, including the challenge of
communicating this information after patients have been exposed to advertising
materials. Therefore, pre-test counselling points could highlight the importance of pretest counselling patients on the difference between screening and diagnosis testing and
specifying what NIPT does and doesn’t screen for. Emphasis could include how NIPT
does not screen for single-gene disorders, open neural tube defects or late pregnancy
complications or replace routine fetal anatomic screening by ultrasound. Importantly,
providers should emphasize that a negative NIPT result does not ensure a “healthy” baby,
even if expanded screening is performed. In addition, this framework could touch on pretest counselling for a low-risk population and the differences in PPV for the different
aneuploidies in this population. This framework could also discuss pre-test counselling
points for microdeletions, including lower PPVs and the uncertainty associated with these
syndromes. Standardized guidance could give providers a clear direction for what
essential points to address in their pre-test counselling. Standardization could also prevent
prenatal care providers from overloading patients with information during pre-test
counselling, which was another concern raised by prenatal care providers in this study.
Other healthcare providers have suggested that professional societies could work together
to publish joint consensus statements about best practices rather than conflicting ones
(Vora & Wapner, 2018). These consensus statements include guidelines surrounding the
use of NIPT for non-medical fetal sexing (Orr-Ferdinand, 2021). More specifically, the
Ethics Committee of the American Society for Reproductive Medicine encouraged clinics
to create written policies regarding whether, and under what circumstances, nonmedical
sex selection will be available (Ethics Committee of the American Society for
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Reproductive Medicine, 2015). Additional practical guidance in this area could lessen the
emotional distress that prenatal care providers experience when pre-test counselling for
NIPT includes this ethically and morally sensitive topic.
Prenatal care providers also discussed standardizing the education and training of NIPT
for pre-test counselling for this technology. Standardization includes creating unbiased
education sources to prevent ongoing education of NIPT from being shaped by
commercial pressures alone (Agarwal et al., 2013). In addition, minimum standards, or
requirements for certification specific to genetic counselling for NIPT, separate from
overarching training requirements, could ensure that prenatal care providers can provide
higher quality counselling to patients (O’Brien & Dugoff, 2018; Piechan et al., 2016;
Gammon et al., 2016; Murdoch et al., 2017). These requirements are critical if NIPT
continues to be offered to a broader, larger population of individuals.
Participants also need additional counselling guidelines for NIPT and its expanding
options as these providers are increasingly entrenched in the pre-test counselling process.
For example, providers were uncomfortable counselling about indications beyond
common aneuploidies due to ethical concerns and the complexity of pre-test counselling
involved. Current guidelines, such as SOGC-CCMG and ACMG acknowledge the
complexity of counselling required for these expanded testing options and do not
recommend offering screening for these indications to low-risk individuals at this present
time (Audibert et al., 2017; Gregg et al., 2016); however, these expanded panels are
available privately through Ontario laboratories. Therefore, this study revealed a gap in
what prenatal care providers are comfortable discussing and what is currently offered.
With more patients becoming aware of these options (Burgess et al., 2020), prenatal care
providers may have to provide pre-test counselling for these expanded screening
possibilities. Therefore, guidelines on providing pre-testing counselling for indications
beyond the traditional aneuploidies are required (Farrell et al., 2016).
Participants mentioned that screening tests’ validation measures are difficult for patients
to comprehend, and NIPT is often thought of as a diagnostic test. Confusion with these
metrics leads to patient uncertainty, stress, and anxiety (Lewis et al., 2016a; Li et al.,
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2017; Yi et al., 2013; Farrell, Agatisa & Nutter, 2014; Mozersky, 2015; Floyd et al.,
2016; Farrell, Agatisa, Mercer, et al., 2015; Vanstone, Yacoub, Giacomini, et al., 2015).
This confusion is further muddled by the fact that laboratories in Ontario have validation
measures for NIPT that are misleading, hard to find, or not present (Mercer et al., 2014;
Health Quality Ontario, 2019a). These counselling considerations coincide with the
necessary creation of new policies to regulate what performance data each commercial
lab offering NIPT should make available. Optimally, data such as sensitivity, specificity,
PPVs, and cut-off levels, including expected false-negative and false-positive rates,
should be accessible to prenatal care providers. Ensuring these metrics are present could
clarify misconceptions surrounding NIPT’s performance for those aneuploidies beyond
trisomy 21.
Lastly, NSGC professional practice guidelines state that pre-test counselling for NIPT
should be performed by “qualified providers” (Devers et al., 2013, p. 291). However, it is
unclear what constitutes a “qualified” provider and what education, background and
credentials are required to provide adequate pre-test counselling for NIPT (Liehr, 2021).
For example, although midwives are independent prenatal clinicians in Ontario who
provide care for low-risk pregnant individuals, provincial policies prevent them from
ordering NIPT. Instead, they are required to refer their patients to a physician for
counselling and follow-up (PSO, 2021a). This process has been described as frustrating
for both types of clinicians, as it creates an unnecessary time and cost burden within the
time-sensitive practice of prenatal testing (Burgess et al., 2020). It is important to
investigate why midwives are excluded from offering NIPT given their involvement in
pregnancy and informed choice conversations. Overall, it is crucial to explore what
constitutes a provider qualified to perform pre-test counselling for NIPT and what
additional standardized activities or requirements may be necessary beyond their facility
level of education and training (O’Brien & Dugoff, 2018). Core competencies in genetics
for health professionals in medicine have been developed (Skirton et al., 2010; Korf et
al., 2014); however, this is not specific to Ontario prenatal care providers or NIPT.
Creating standards and requirements will be essential as the complexity of counselling
increases and NIPT counselling is performed by additional healthcare providers such as
nurses or medical assistants (Farrell et al., 2016).
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6.3

Implications for Dissemination of Information and
Education

When publicly funded screening for NIPT was introduced in Ontario, there was no
priority to providing education or training for health providers (Bellai-Dussault et al.,
2020). This study identified the existing gaps in knowledge and confidence that prenatal
care providers hold in pre-test counselling for NIPT as well as their lack of awareness of
updates to this rapidly expanding test. Canadian health care providers still expressed
these concerns in qualitative studies conducted in 2018 and 2020, with a perceived need
for greater education and awareness among clinicians (Burgess et al., 2020; Haidar et al.,
2020).
Ongoing dissemination of updates to NIPT was a crucial proactive strategy identified by
prenatal care providers in this study. With such a rapidly developing test, providers were
concerned that they would encounter the same educational delays they experienced with
implementing this technology. Importantly, there is still an identified need for NIPT
educational materials by providers in Canada (Burgess et al., 2020; Haidar et al., 2020),
despite the development of educational resources that occurred after this study took place
(Perinatal Quality Foundation, 2022; Genetics Education Canada, 2020). Although
genetic resources exist, prenatal care providers lack the awareness and time to find,
identify and use them (Carroll, Grad, Allanson, et al., 2016; Haga et al., 2011). There
should be a streamlined process to distribute educational materials about NIPT and NIPT
developments to all prenatal care providers delivering pre-test counselling (Ngan, 2018).
In this study, providers suggested in-person and electronic educational strategies. It is
recommended to implement these educational resources as an effective way to access upto-date medical information (Agius & Bagnall, 1998; Ruiz et al., 2006). In the past, the
outcomes of online interventions in genetics have been shown to improve knowledge,
confidence, and skills and can indicate when to appropriately refer to genetic
professionals (Bell et al., 2015; Carroll, Grad, Allanson, et al., 2016; Paneque et al.,
2017; Telner et al., 2017). In addition, PCPs exist in large numbers, and therefore

135

targeted, effective education can affect thousands of providers and, consequently, affect
patients (Dougherty et al., 2016).
Importantly, prenatal care providers highlight family physicians as a group with a
concerning divide between education, awareness, and practice. Updating isolated prenatal
care providers in the community is considered especially important as they may not have
the luxury of having a genetics department nearby. As per the suggestions of prenatal
care providers in this study, outreach programs could inform family physicians of any
updates to policies or guidelines. Outreach could include in-person or electronic
workshops and educational materials created by third-party genetic specialists (Paneque
et al., 2016).

6.4

Opportunity for Different Models of Genetic
Counselling and Service Delivery

This study underlines how the continued expansion and extension of NIPTs use
necessitates new approaches and techniques to pre-test counselling (Agatisa, Mercer,
Coleridge, et al., 2018). For example, as NIPT expands into the average-risk population,
more providers are faced with the difficult task of providing NIPT counselling to every
individual considering prenatal screening (Parham et al., 2017). Respondents in this study
were concerned about the lack of time spent educating patients about the complexities of
this test in a prenatal session. This concern is rooted in the assumption that, if given more
time, patients could receive sufficient information to allow for informed consent (Gabriel
& Diskin, 2018). This belief aligns with the “teaching” approach to genetic counselling
practice. Initially described by Kessler in 1997, the primary purpose of the teaching
model in genetic counselling is to communicate information to patients. This thinking is
abstracted in the informed consent literature as the “conduit/container” model, or
“professional monologue,” where information transfers from one person to the other
(Kessler, 1997). However, more information shared by a provider is not always
equivalent to more information understood and integrated by a patient (Gabriel & Diskin,
2018). Informed consent and reproductive autonomy may not be enhanced when more
information is given, and an excessive amount of medical-technical information could
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overload patients and hinder reproductive autonomy (Dondorp et al., 2016; Gabriel &
Diskin, 2018). Indeed, participants from this current study were also concerned about
overloading patients with information during NIPT's pre-test counselling session.
In contrast, other counselling models have been proposed that do not solely focus on the
knowledge component of pre-test counselling. For example, Kessler (1997) also
described the “counselling” model as another primary professional approach to genetic
counselling practice. This framework is grounded in psychology and based on the belief
that individuals seek genetic counselling not only for information but also for alleviating
psychological distress, promoting autonomy, and gaining a greater sense of control of a
situation. This model emphasizes the support of patients on an emotional and personal
level while still providing education (Kessler, 1997). The counselling model is associated
with increased knowledge retention, reduced anxiety, and higher satisfaction with
decision-related outcomes as compared to teaching-based models (Roter et al., 2006;
Dijkstra et al., 2013).
Despite this, prenatal care providers and genetic counsellors often use the teaching model
in modern practice for pre-test counselling (Lerner et al., 2014; Meiser et al., 2008; Roter
et al., 2006; Martin et al., 2014; Walser et al., 2017). Many professional practice
guidelines available in 2016 and onward emphasize objective information in pre-test
counselling (Audibert et al., 2017). For example, a main point of pretest counselling in
ACOG’s clinical management guidelines is that it should be done “…in a clear,
objective, and non-directive fashion, which allows patients sufficient time to understand
information and make informed decisions regarding testing…” (ACOG-SMFM, 2020,
p.e56).
In contrast, the emphasis in pre-test genetic counselling should involve clinicians
addressing the psychological nuances that prenatal care providers in this study have
acknowledged. For example, participants discussed how NIPT screening for additional
conditions such as SCAs and microdeletions introduces new levels of uncertainty in their
pre-test counselling process that they may be uncomfortable counselling on. Indeed, after
these interviews were conducted, ACMG’s policy statement addressed how the ever-
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evolving technology of NIPT should include pre-test counselling which explores the
patient’s ability to accept uncertainty concerning possible screening outcomes (Gregg et
al., 2016). To tackle complex concepts such as uncertainty, prenatal care providers must
engage in a genetic counselling model that promotes psychosocial support (Ferrier et al.,
2013). Therefore, future guidelines, education, and prenatal care provider training should
incorporate and emphasize psychological counselling into the pre-test communication
process for NIPT.
The teaching model may also be used by prenatal care providers based on time
constraints and the high volume of patients (Brunger & Lippman, 1995). Further
investigations and strategies are required as to how prenatal care providers can
incorporate this complex information within a time-limited visit (Piechan et al., 2016).
Educating patients about NIPT through alternative techniques including telemedicine,
educational pamphlets, videos, or decision aids are all options that may facilitate the
information provision part of the pre-test counselling session while allowing more time
for psychosocial support (Gammon et al., 2016; Metcalfe, 2018; Gammon et al., 2018;
Kim et al., 2018; Raspa et al., 2021). These additional educational methods have shown
to be equivalent to, or better than, in-person genetic counselling in promoting knowledge
and achieving long-term comfort with choices made (Glazier et al., 1997; Hilgart et al.,
2012; Kuppermann et al., 2014; Yee et al., 2014). Another option includes group
information sessions about NIPT, coupled with abbreviated counselling. An alternative
counselling model such as this one has been shown to have significant positive effects on
patients’ knowledge of NIPT and other prenatal testing options and their decisional
confidence and sense of preparation (Gammon et al., 2018). These alternative service
delivery models and counselling aids could reduce the burden of prenatal care providers
delivering information and allow them to integrate psychosocial aspects in their
counselling. In addition, these delivery models could standardize counselling and add a
quality control component, which some providers have concerns about regarding NIPT
counselling. Developing educational tools and decision support tools to enhance a
patient’s understanding is critical for ongoing research and work by professional societies
(O’Brien & Dugoff, 2018).
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6.5

Responsibilities of Genetic Professionals and
Professional Societies

This study confirms that genetic services and genetic counsellors play an essential role in
providing education and support to prenatal care providers. With genetics becoming
increasingly prominent in primary care providers’ practice (Joseph, 2018; Patch &
Middleton, 2018; Battista et al., 2011), genetic services need to take on a more supportive
role for these professionals during the pre-test counselling process. For example,
participants noted the importance of having interdisciplinary professional relationships
with genetic departments and genetic counsellors for this support. Genetic counsellors
must continue to maintain interdisciplinary professional relationships and assist prenatal
care providers in improving patient care (Carroll et al., 2019; Agatisa, Mercer, Coleridge,
et al., 2018).
In addition, interdisciplinary medical education can improve learning outcomes and
increase the confidence and comfort of prenatal care providers who provide NIPT
counselling (Dougherty et al., 2016). Focusing on interprofessional education and
collaboration may also help address the lack of transparency prenatal care providers felt
with genetics policy development. Practical options include developing interprofessional
coursework for prenatal care providers and genetic counsellors, joint panel presentations
at conferences, completion of observational rotations, offering continuing education,
teamwork training, and interdisciplinary rounds (Mann et al., 2014; Oxenford et al.,
2017; Cernat et al., 2019). It is also crucial to investigate what role educational and
certifying organizations, such as the Canadian Association of Genetic counsellors, play in
supporting these additional education and training initiatives (Gabriel & Diskin, 2018).

6.6

Future Directions and Research

More research is required regarding the effect of providing NIPT pre-test counselling to
patients at such an early time in their pregnancy. Little is known about the added stress
and anxiety that NIPT may place on patients who are still adjusting to the news of a
pregnancy. The patient’s overall reception of NIPT and how this affects their broader
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pregnancy experience is an area of research that has not been widely explored (Alexander
et al., 2015). Future research could include exploring the specific experiences of both
patients and providers who have discussed NIPT at the first prenatal visit. Examining
how NIPT relates to the medicalization of pregnancy could provide insight into how
NIPT shapes an individual’s early experience of pregnancy. An in-depth understanding of
individuals’ pre-natal counselling experiences could, in turn, inform pre-test counselling
for providers who must discuss screening at such an early time in pregnancy.
Further research is also needed to explore prenatal care providers’ experience with pretest counselling for the ever-expanding screening options available for NIPT. This area of
research is crucial to study in a timely fashion as NIPT screening is expanding rapidly.
For example, laboratories in Ontario are now offering screening for more microdeletions
and aneuploidies than previously available when this study was conducted in 2016
(Dynacare, 2020b). In addition, many expect that NIPT for single-gene disorders and
whole-genome sequencing will eventually be introduced into clinical practice (Shaw et
al., 2020). With this expanded testing comes a broader range of possible outcomes that
requires more complex pre-test counselling (Dondorp et al., 2015). Future research
should explore how these ever-expanding options will impact prenatal care providers’
practice, such as the complexity of the required counselling or their perspectives of
offering to screen for these additional conditions. This research should also explore
providers’ and patient perspectives on the ethical concerns associated with the ongoing
expansion of NIPT, including on informed consent, reproductive autonomy, and equity of
access to testing for an increasingly larger panel of conditions. In addition, more research
is necessary to explore what educational resources are essential for pre-test counselling
for this range of conditions (Botkin et al., 2015; Richardson & Ormond, 2018).
Importantly, this research has implications for other areas where non-genetic
professionals are involved with genomics in medicine in both the public and private
sectors. For example, oncology-based/rapid genetic testing is a process where genetic
testing is offered to a patient by their breast cancer specialist rather than a genetic
specialist, which is meant to provide a more streamlined and efficient experience for the
patient. This practice, otherwise known as “mainstreaming,” is clinically useful when the
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impact of the genetic test result has treatment implications (Beard et al., 2021).
Mainstreaming is an emerging area of practice in Ontario that has just been initiated in
September 2021 as part of Cancer Care Ontario’s initiative to provide equitable access to
hereditary cancer services across the province (Cancer Care Ontario, 2021). This method
allows cancer patients to access genetic testing at one of their routine cancer clinic
appointments, eliminating the need to be first referred to a genetic counsellor. However,
very little is known about how oncologists experience mainstreaming and their
challenges when providing pre-test cancer genetic counselling within an otherwise
routine oncology appointment.
Direct-to-consumer testing (DTC) is a genetic test that is more directly accessible to
consumers than those offered through existing health services. With DTC, the consumer
pays the company directly, and it is possible to order testing without the involvement of a
health professional (Eng & Sharp, 2010). However, many companies now require a
referral from the consumer’s healthcare provider (Borry et al., 2010). This requirement
means non-genetic providers should know how to advise on these additional genetic tests
that may offer testing for many conditions. For example, Myriad genetics© offers a
carrier screening test that examines over 100 genes associated with severe and prevalent
inherited conditions (Myriad, 2021). However, healthcare providers report low awareness
and experience with DTC (Bernhardt et al., 2012; Ram et al., 2012; Goldsmith et al.,
2012; Powell et al., 2012a; Powell et al., 2012b). In addition, primary care providers from
Ontario and Alberta have described direct-to-consumer testing as “scary” territory they
do not know much about (Carroll, Makuwaza, Manca, et al., 2016, p. 629). Very little is
known about the effect of having these tests available for consumers and the
consequential challenges that this may cause prenatal care providers in their practice.
Comparing the results of this current study to future studies in the contexts of non-genetic
specialists offering genetic testing may illuminate common challenges and support
required for prenatal care providers who are offering genetic testing in their practice.
Pharmacogenetics (PGx) is the study of interactions between genetic factors and drug
response. PGx testing can help predict therapeutic response and minimize adverse events
by detecting variants in genes that influence drug response (Spear et al., 2001; Lee et al.,
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2014). This type of genetic testing is expected to define the future of medical and
pharmaceutical practice in terms of prescriptions, treatment and management of patients
(Green et al., 2010). Health Canada has approved the placement of PGx biomarker
information on labels of over 100 drugs (PharmGKB, 2018). Primary care providers,
including physicians and pharmacists, will play an essential role in offering PGx during
routine clinical care (Obeng et al., 2018). However, there has been a slow uptake of PGx
testing in clinics (Singh, 2007). Reasons for this slow uptake mirror that of NIPT and
other emerging healthcare technologies, including unfamiliarity of health care providers
with PGx, time constraints, absence of clear clinical guidelines, inconclusive clinical
utility and other ethical considerations (Drozda & Pacanowski, 2017; Hall, 2003;
Rothstein, 2003). Therefore, it is important to understand the perceptions of primary care
providers and pharmacists on the implementation of PGx testing in clinical practice.
Therefore, additional research is required to understand the limitations faced by these
providers and further define their role in the implementation of PGx testing to support
these non-genetic specialists who offer genetic testing.
Future research should also involve the evaluation of educational interventions for NIPT.
Since 2016, third-party resources on NIPT have become available for patients and
providers, such as the information found on Prenatal Screening Ontario’s website
(https://prenatalscreeningontario.ca). After exploring the various information needs of
prenatal care providers in this study, further steps should be taken to evaluate the
effectiveness of these resources, including measuring knowledge outcomes for prenatal
care providers. Similarly, alternative techniques of providing NIPT education to patients,
such as telemedicine, pamphlets or decision aids, should be evaluated for their
effectiveness compared to in-person genetic counselling in terms of knowledge and longterm comfort with choices made.
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6.7
6.7.1

Strengths and Limitations
Study Limitations

There are limitations to this study needing mention. To begin, all participants were selfselected volunteers and so perhaps more interested than average in research or about the
topic of NIPT. Participants who would volunteer for this research may be experiencing
more extreme barriers to counselling than other prenatal care providers who provide
prenatal counselling. The study findings and interpretation must be considered within the
context of the research design and methodology. The results represent Ontario providers
in an urban setting. Therefore, they do not reflect the more extensive experiences and
attitudes of a wider group of prenatal care providers. However, by using in-depth
interviews of the participants, I was able to get a thorough understanding of these
prenatal care providers’ experiences with NIPT. The experiences of prenatal care
providers interviewed for this study may have changed since these interviews were
conducted in 2016. However, additional literature was sourced for this analysis which
explored the experiences of prenatal care providers after 2016, including Ontario
providers (Burgess et al., 2020). Further analysis of this new data confirmed the model
generated from this study was still relevant and emphasized that prenatal care providers
still required additional support to provide adequate pre-test counselling for NIPT.
Another potential limitation of this study is based on the process of coding, which can
remove context and narrative flow and thus fragment results (Coffey & Atkinson, 1996).
I attempted to limit this by writing field notes and memoing throughout the entire data
collection phase. Memos are written records of a researcher’s thinking during the entirety
of the research process and they allowed me to become actively engaged in the material,
develop ideas, fine-tune subsequent data gathering and engage in critical reflexivity
(Charmaz, 2014). Lastly, some of the interviews were conducted by telephone, which can
lead to less interaction between the interviewer and participant compared to face-to-face
interviews (Shuy, 2002; Trochim and Donnelly, 2007; Weiss, 1994). Consequently, there
may be a lack of rapport and loss of the natural conversation, which makes participants
feel less comfortable during an interview (Shuy, 2002). For interviews conducted over
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the phone, I tried to engage in small talk before the recording occurred in order to build
this rapport (Glogowska et al., 2011). In addition, participants may be reluctant to
elaborate on their responses over the phone, which compromises the richness and quality
of the collected information (Hermanowicz, 2002). I practiced intensive interview
techniques as per Charmaz (2014), which included asking the participant to elaborate,
clarify, or give examples of responses (Charmaz source). In addition, the interview script
communicated the purpose of the study and emphasized the importance of the participant
contribution, which also promotes an in-depth telephone interview (Glogowska et al.,
2011; Musselwhite et al., 2007; Smith, 2005). Another disadvantage of conducting
phone interviews was the inability to observe or respond to visual cues during
conversation (Nagy et al., 2010). However, I recorded any vocal cues as field notes such
as pauses and inflections in speech to provide additional contextual information.

6.7.2

Strengths of Study

While there has been some research on genetic professionals’ experience with
counselling on NIPT, an exploration of how NIPT has affected counselling for prenatal
care providers is lacking. Therefore, qualitative inquiry effectively discovered and
documented aspects of the prenatal care providers’ experience with pre-test counselling
for NIPT, which may be unknown or unexpected. The use of constructivist grounded
theory helped provide a clear and nuanced picture of the experience of pre-test
counselling for prenatal care providers. The creation of this model identified what
challenges and concerns these providers experience in their practice and informed the
practical support required as they take on a more prominent role in pre-test counselling
for NIPT. In addition, this is one of the few studies which probes how these providers
feel about using NIPT for indications beyond traditional aneuploidies.
In addition, this research has overarching use in other areas of medicine where nongenetic professionals are becoming increasingly entrenched with offering genetic testing.
Like NIPT, DTC genetic testing, including pharmacogenetics, is heavily commercialized
(Borry et al., 2010). Additional research studies could utilize methodologies and methods
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from this current study to explore the experiences of non-genetic professionals, such as
oncologists, pharmacists and physicians, and their increasing role in providing pre-test
counselling for genetic tests. Understanding how these non-genetic specialists navigate
this pre-test counselling within their practice could identify barriers and subsequently
inform what further support is required for these clinicians to provide the highest quality
of care possible. Support could include improvements to practice guidelines and can
inform policies in order to clarify how these genetic tests should be used in practice.

6.8

Conclusion

The model “Prenatal care providers’ involvement with pre-test counselling for NIPT in
Ontario” explains what is involved in these providers' pre-test counselling process,
including important challenges that NIPT places on the clinical infrastructures of prenatal
care providers. These burdens contribute to a significant risk that individuals will not
make informed decisions surrounding NIPT. Prenatal care providers, especially family
physicians, who are taking on a more prominent role in NIPT’s pre-test counselling
process, need better guidance and support to provide quality pre-test counselling. Support
is important to ensure that NIPT will be used effectively and ethically as testing increases
into a more extensive and diverse set of genetic variants and uses among the low-risk
obstetric population. This research suggests that NIPT’s implementation and ongoing
expansion within prenatal care providers' clinical practice is complex and dynamic.
Recognizing the needs of these providers is essential to ensure quality counselling for
patients undergoing decision-making for NIPT. In addition, to ensure the continuous
ethical implementation of this prenatal screening and avoid a downslide towards
eugenics, it is important to include prenatal care providers in discussions surrounding the
expansion of this testing.
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Appendices
Appendix A: Ministry of Health Criteria
CATEGORY I
Can be ordered by any physician or nurse practitioner
For investigation of trisomy 21, 18 or 13 ONLY
Any of the following:
□ Maternal multiple marker screening result positive for aneuploidy
□ Individual of advanced maternal age, defined as ≥40 years of age at expected time of
delivery. In the context of in vitro fertilization, the maternal age is guided by the age at
egg retrieval (whether own or donor egg)
□ Ongoing twin pregnancy (both twins must demonstrate fetal activity by ultrasound)
□ Nuchal translucency (NT) ≥3.5mm
□ Previous pregnancy or child with trisomy 21, 18 or 13
CATEGORY II
Funding for these indications must be submitted by a genetics or maternal fetal medicine
(MFM) specialist
Risk indicators:
A)
□ Fetal congenital anomalies identified on ultrasound, which are suggestive of trisomy
21, 18 or 13
OR
B)
□ Risk of aneuploidy for trisomy 21, 18 or 13 is greater than that of a positive maternal
multiple marker screen.
• Individuals <40 years of age at expected date of delivery must have at least one
other risk factor
• Risk of aneuploidy can be calculated by including any combination of risk
indicators including soft markers*, biochemistry, maternal age, etc.
OR
C)
□ NIPT for sex chromosome determination (at least one of the following):
□ Risk of a sex-limited disorder
□ Ultrasound findings suggestive of a sex chromosome aneuploidy
□ Ultrasound findings suggestive of a disorder of sex determination (DSD)

Note. Ministry of Health Criteria for eligibility (Dynacare, 2020c; PSO, 2021a)
*Soft markers include absent nasal bone, choroid plexus cysts, clinodactyly, cystic hygroma,
hyperechogenic bowel, hypoplastic nasal bone, increased nuchal fold/edema, increased nuchal
translucency, intracardiac echogenic focus/foci, short femur, short humerus, ventriculomegaly.
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Appendix B: Email Script-Clinicians
Dear [Name],
I'm involved with a qualitative research study and I wonder if you might consider
participating in an interview or focus group. The study is looking for health care
provider opinions of non-invasive prenatal testing (NIPT) to potentially inform future
policy decisions about public funding of NIPT. The interview or focus group will last
approximately one hour, and can be scheduled at a time and location of your choosing.
The interview will be audio-recorded with your permission and transcribed for
analysis.
If you are willing to participate or would like more information, please contact our
research assistant Leichelle Little or the Local Principal Investigators, Drs. Barbra de
Vrijer and Marilyn Evans at [email omitted from published thesis]. I've also attached
our official letter of information about the study.
Thank you for considering this request.

Sincerely, [Research Team Member Name]
on behalf of Barbra de Vrijer, MD, Dept Obstetrics & Gynaecology, Schulich School
of Medicine & Dentistry, Western University, [email omitted from published thesis]
(Local Principal Investigator)
Marilyn Evans, RN, PhD, Associate Professor, Arthur Labatt Family School of
Nursing, Western University (Local Principal Investigator)
Meredith Vanstone, PhD, Assistant Professor, Department of Clinical Epidemiology
and Biostatistics, McMaster University, [contact information omitted from published
thesis] (Principal Investigator)

208

Appendix C: Letter of Information and Consent
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Contact information omitted from published thesis

Contact information omitted from published thesis
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Contact information omitted from published thesis
Contact information
omitted from published thesis
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Appendix D: Interview Guide-Clinicians
The purpose of this study is to examine how NIPT is currently being used in Ontario,
and how the practice of prenatal testing might have changed since the introduction of
public funding for NIPT in early 2014. We have conducted interviews with women
who've had personal experiences with this technology and we are now speaking with
prenatal care providers about the ways in which it is used in their practices, and how
their practices have changed in response to this new technology.
1. To start, could you tell me a bit about your prenatal care practice. For instance,
what kind of practitioner are you, do you generally see low or high-risk women,
what kind of settings do you work in?
2. How do you typically encounter NIPT in clinical practice?
•

How frequently do you encounter NIPT?

•

Tell me about any difficulties that you may have faced since
implementing this new test?

•

By the time you discuss NIPT with a patient, what point are they at in
the decision-making process [testing pathway?]?

3. Let's pretend for a moment that I'm a woman to whom you are offering NIPT.
Please explain this technology to me in the language you would use with
women.
•

How do you explain the limitations of this technology? Confidence in
test accuracy?

•

How do you explain the relationship to other prenatal tests?

•

What resources on NIPT do you provide to your patients?
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4. What has influenced the way that you use and offer NIPT?
•

How confident and comfortable are you with this source of information?
Is it easy to find information about this technology?

•

What is the preferred way in which you would like to be informed about
changes to NIPT?

•

With all the other things you must keep up to date on, where does this
fit in?

•

How informed do you think prenatal care providers in the community
are informed about this test? How much information would be
reasonable to expect them to have?

5. In addition to fetal sex, NIPT results may screen for sex chromosome
aneuploidies such as Turner syndrome (monosomy X) or Kleinfelter syndrome
(XXY). There is a wide variety in the severity and expression of features
among individuals with the same sex chromosome aneuploidy, and many
individuals may go undiagnosed in the general population. What are your
thoughts on the utility of this application to your current clinical practice?
•

Were you aware that these results were possible with NIPT?

•

What are your thoughts about offering testing for fetal sex chromosome
aneuploidy to everyone who obtains NIPT? What are you concerned
about?

•

How comfortable are you explaining the results of this test to your
patients?

6. In rare cases, NIPT may also raise suspicion for unexpected secondary
chromosomal abnormalities for fetal or maternal conditions that were not
initially targeted by NIPT. Reported incidental findings have included maternal
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chromosome differences, such as sex chromosome aneuploidies, maternal
cancers (imbalances in the number of copies of chromosomes have flagged the
presence of a tumour), and also fetal or placental chromosome differences such
as placental mosaicism and smaller duplications/deletions to fetal DNA other
than the aneuploidies for which the test is being performed.
•

Were you aware of these secondary findings that were possible with
NIPT?

•

What are your thoughts on utility of this application to your current
clinical practice?

•

How comfortable are you explaining the potential for these results to
your patients?

•

How should secondary findings be handled in pre-test counselling? Do
you have any concerns about discussing these potential findings with
your patients?

•

Using the same language you would with a patient, how do you discuss
the potential for secondary findings?

7. In addition to testing for trisomy 21, 18 and 13 and sex chromosomes, NIPT is
currently being offered with an expanded panel that includes testing for two
aneuploidies associated with nonviable pregnancies (trisomy 16 and 22) as well
as rare microdeletion/microduplication syndromes (22q11 deletion syndrome
[DiGeorge syndrome], cri-du-chat [5p minus], Prader Willi/Angelman
syndrome and 1p36 deletion syndrome). These syndromes may result in
physical and/or intellectual impairments that can be more severe than whole
chromosome abnormalities. A clinically relevant
microdeletion/microduplication occurs in 1% of all pregnancies, and is
independent of maternal age.
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Is this application of NIPT part of your clinical practice? Tell me about how
you work with the expanded panel testing.
•

Were you aware of the additional testing available with NIPT?

•

What are your thoughts about offering an NIPT screen which
tests for a larger number of microdeletion/microduplication
syndromes?

•

Who do you think should be offered this expanded testing? - Do
you have any concerns about offering this expanded testing?

•

What are you concerned about?

•

How likely are you to discuss this expanded testing with a
patient? If not likely, is someone else having this conversation?

•

What are your thoughts on utility of this application to your
current clinical practice?

•

How comfortable are you explaining potential microdeletion
NIPT results to your patients?

•

Using the same language you would with a patient, how do you
discuss the potential results of this additional panel?

8. We’ve been discussing expanded testing options for NIPT. The number of
conditions NIPT can be used to detect will likely continue to expand, including
detecting the presence of monogenic disorders, such as cystic fibrosis,
Huntington’s disease and achondroplasia, allowing for recognition of these
conditions in a fetus early in pregnancy. Some people are concerned that
expanding this test to screen for additional genetic abnormalities may cause
uncertainty for some women, potentially inundating them with too much
information and unquantifiable risks. However, others recognize the woman’s
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right to know this personal health information about her pregnancy, and worry
about who is restricting access to this information. {Additional information:
monogenetic disorders are caused by mutations in a specific gene}. We are
interested in understanding your opinion about policy and regulation which
could guide the future use of NIPT.
What is your opinion?
•

What guidance would you offer to policy-makers tasked with
deciding these limits?

•

If there should be limits, what type of people should be involved
in making this type of policy? What issues should they consider?

•

Do you have a different opinion on the conditions that should be
included in NIPT testing, if the patient pays out of pocket vs. if
the test is publicly funded?

9. What excites you about this technology? What good might it do?
10. What worries you about this technology? What harm might it do?
11. Is there anything else you think we should know about your thoughts or
opinions about this technology?
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Appendix E: Example of how Subcategory “Difficulties Experienced with
Counselling” was Generated

Category

Subcategory Initial Code (Gerund)

Supporting Quote

Counselling

Difficulties

Facing Difficulties with “I think the whole idea of

Considerations

experienced

educating patients

with

about prenatal testing in negatives…for the average

counselling

general

false-positives, false-

person out there who has
not really heard those terms
before, I think that’s more
difficult than most people
think to actually get around.
And the idea of a screening
versus a diagnostic test, I
think not all people
understand the difference.”
[FP: 016]
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